<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000100.pub3" GROUP_ID="LIVER" ID="327999082511234944" MERGED_FROM="" MODIFIED="2008-10-16 19:22:36 +0200" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:17:10 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" REVIEW_NO="07" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-10-16 18:17:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Vaccines for preventing hepatitis B in health-care workers</TITLE>
<CONTACT>
<PERSON ID="13987" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Wendong</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX>MD. Ph.D candidate</SUFFIX>
<POSITION/>
<EMAIL_1>wdchen@uhnres.utoronto.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Departments of Health Policy Management and Evaluation, and Pharmacy</DEPARTMENT>
<ORGANISATION>Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto</ORGANISATION>
<ADDRESS_1>Room 679, 6th floor, Leslie L. Dan Pharmacy Building</ADDRESS_1>
<ADDRESS_2>144 College Street</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M5S 3M2</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1-416-946-3696</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-10-16 18:17:54 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="13987" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Wendong</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX>MD. Ph.D candidate</SUFFIX>
<POSITION/>
<EMAIL_1>wdchen@uhnres.utoronto.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Departments of Health Policy Management and Evaluation, and Pharmacy</DEPARTMENT>
<ORGANISATION>Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto</ORGANISATION>
<ADDRESS_1>Room 679, 6th floor, Leslie L. Dan Pharmacy Building</ADDRESS_1>
<ADDRESS_2>144 College Street</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M5S 3M2</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1-416-946-3696</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6439" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D, Dr. Med. Sci.</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>cgluud@ctu.rh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+ 45 3545 7175</PHONE_1>
<PHONE_2/>
<FAX_1>+ 45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-16 18:17:54 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Minor update: 22/08/05&lt;/p&gt;&lt;p&gt;New studies sought but none found: 01/02/03&lt;/p&gt;&lt;p&gt;Reformatted: 19/03/03&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:17:54 +0100" NOTES_MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="15" MONTH="8" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="2" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="12" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-16 18:09:49 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>The Copenhagen Trial Unit</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Danish Medical Research Council Grant on Getting Research into Practice (GRIP)</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY>
<TITLE>Hepatitis B vaccine prevents hepatitis B infection in health-care workers</TITLE>
<SUMMARY_BODY>
<P>Plasma-derived vaccine significantly prevents hepatitis B events in health-care workers. Recombinant vaccine does not significantly differ from plasma-derived vaccine in eliciting protective hepatitis B surface antibody levels. Both vaccines are well tolerated. The intramuscular route causes significantly more systemic adverse events, and the intradermal route causes significantly more local adverse events. The deltoid injection seems more effective than the gluteal injection in eliciting antibodies. The standard vaccination schedule (0, 1, and 6 months) elicits a better antibody response than a rapid vaccination schedule (0, 1, and 2 months). It is unknown whether hepatitis B vaccine protects health-care workers from infection of mutated hepatitis B virus. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Hepatitis B virus (HBV) causes acute and chronic liver diseases. Hepatitis B vaccination is recommended for health-care workers.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the beneficial and harmful effects of hepatitis B vaccination in health-care workers.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the trial registers of <I>The Cochrane Hepato-Biliary Group</I>, <I>The Cochrane Library</I>, <I>MEDLINE</I>, and <I>EMBASE</I> to February 2003. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing any dose, injection route, injection site, or schedule of hepatitis B plasma-derived vaccines (PDV) or recombinant vaccines (RV) versus placebo, no intervention, or another hepatitis B vaccine in health-care workers. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers extracted the data independently. The reviewers assessed the methodological quality of the trials regarding generation of the allocation sequence, allocation concealment, double blinding, and follow-up. The results were presented as relative risk (RR) with 95% confidence intervals (CI). </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We identified 21 randomised trials, all with one or more methodological weaknesses. Four trials demonstrated that PDV versus placebo significantly decreased hepatitis B events at maximum follow-up (RR 0.51, 95% CI 0.35 to 0.73). RV did not differ significantly from PDV in eliciting a protective hepatitis B surface antibody (anti-HBs) level in two trials. Both vaccines were well tolerated. Low-dose vaccine (1 or 2 µg) by the intradermal route resulted in significantly more participants without protective anti-HBs level compared with high-dose (10 or 20 µg) by the intramuscular route (RR 1.41, 95% CI 1.13 to 1.76). The intradermal route caused significantly more local adverse events, while the intramuscular route caused significantly more systemic adverse events. The gluteal injection produced significantly more participants without protective anti-HBs level than the deltoid injection. The prevalence of anti-HBs seroconversion by rapid vaccination (0, 1, and 2 months) was significantly lower than that by standard vaccination (0, 1, and 6 months). Booster vaccinations with different RV doses (2.5, 5, 10, 20, or 40 µg) produced similar prevalence of anti-HBs seroconversion in three trials assessing participants who did not respond to previous HBV vaccination. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>PDV significantly prevents hepatitis B events. RV seems to be able to elicit similar protective anti-HBs levels. The intramuscular route with 20 µg RV was significantly more effective compared with the intradermal route with 2 µg RV as was the standard schedule compared with a rapid schedule and deltoid intramuscular injection compared with the gluteal intramuscular injection. It is unclear if booster vaccination of non-responders offers higher anti-HBs seroconversion and hepatitis B vaccine prevents the infection of hepatitis B mutants in health-care workers. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND MODIFIED="2008-10-16 18:14:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Hepatitis B is a global acute and chronic communicable disease being carcinogenic and causing major hepatic diseases, with an estimated 300 million HBV carriers (<LINK REF="REF-Maynard-1990" TYPE="REFERENCE">Maynard 1990</LINK>). Health-care workers face high risk of HBV infection because of patients' blood or other biological materials containing HBV. In the United States, every year 12,000 to 15,000 health-care workers take the risk of HBV infection and 12 to 15 health-care workers die of acute hepatitis, 40 die of hepatoma, and about 200 die of chronic liver diseases and liver cirrhosis. Furthermore, 500 to 1200 become carriers of hepatitis B surface antigen (HBsAg) and they may infect others (<LINK REF="REF-Harris-1991" TYPE="REFERENCE">Harris 1991</LINK>). The U.S. Centers for Disease Control (CDC) recommends HBV vaccine as the best strategy to prevent HBV infection in health-care workers (<LINK REF="REF-CDC-1987" TYPE="REFERENCE">CDC 1987</LINK>). When used routinely and massively, HBV vaccine is supposed to substantially reduce the incidence of clinical and subclinical hepatitis B infection among health-care workers and the need for post-exposure prophylaxis with hepatitis B immune globulin.</P>
<P>The first HBV vaccine, derived from the plasma of HBsAg carriers by a sequence of physical and chemical procedures (pepsin digestion, treatment with 8-molar urea, and treatment with formaldehyde) (<LINK REF="REF-Tabor-1983" TYPE="REFERENCE">Tabor 1983</LINK>), was approved by the U.S. Food and Drug Administration in November 1981 (<LINK REF="REF-Stephenne-1988" TYPE="REFERENCE">Stephenne 1988</LINK>). The chemicals used during the production of plasma-derived vaccine (PDV) destroy all known life forms including human immunodeficiency virus and the vaccine is safe to use in humans (<LINK REF="REF-Francis-1986" TYPE="REFERENCE">Francis 1986</LINK>). HBV PDV containing S antigen segment of HBsAg is effective to elicit host immune response to HBV and used widely in preventing HBV infection among health-care workers. Shortly after the launch of HBV PDV, recombinant HBV vaccine (CRV) was developed by recombinant expression vectors (yeast or mammalian cells) because of the difficulty to obtain plasma from HBsAg carriers, the high cost of producing PDV, the public fear of infectious diseases transmitted by plasma, and the practicable DNA recombinant technology. The main difference between PDV and RV is that S-antigen in RV is nonglycosylated, while 25% of S-antigen in PDV is glycosylated (<LINK REF="REF-Emini-1986" TYPE="REFERENCE">Emini 1986</LINK>). The two types of vaccines have been proven safe and effective in eliciting protective anti-HBs level in randomised trials conducted in populations with high risk of HBV infection, such as homosexual men (<LINK REF="REF-Szmuness-1981" TYPE="REFERENCE">Szmuness 1981</LINK>; <LINK REF="REF-Odaka-1988" TYPE="REFERENCE">Odaka 1988</LINK>), patients who receive dialysis treatment (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>), and health-care workers (<LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>). However, approximately 5% to 12% of the health-care workers failed to develop protective anti-HBs levels after the recommended three-dose intramuscular series (<LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK>; <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK>). Current evidence demonstrates that people who do not develop protective anti-HBs levels are still at risk of becoming infected with hepatitis B, and indeed some of them developed acute, symptomatic hepatitis B (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>). Even though PDV has been disregarded in high-income countries, basic research and some clinical trials have reported the advantages of PDV in terms of the anti-HBs characteristics and immunogenicity (<LINK REF="REF-Odaka-1988" TYPE="REFERENCE">Odaka 1988</LINK>; <LINK REF="REF-Stephenne-1988" TYPE="REFERENCE">Stephenne 1988</LINK>; <LINK REF="REF-Heijtink-2000" TYPE="REFERENCE">Heijtink 2000</LINK>).</P>
<P>HBV vaccination via the intramuscular route is costly (around 23 US dollars per dose) (<LINK REF="REF-CDC-2003" TYPE="REFERENCE">CDC 2003</LINK>). This has motivated researchers to look for a dose-saving route to reduce vaccination cost (<LINK REF="REF-Bryan-1992" TYPE="REFERENCE">Bryan 1992</LINK>). Compared with the intramuscular route that can give a fast introduction of large amounts of antigen by the formation of soluble immune complexes in the body (<LINK REF="REF-Carmeli-1993" TYPE="REFERENCE">Carmeli 1993</LINK>), the intradermal route allows a more progressive diffusion of antigen and prolong the action time of vaccine. However, low diffusion of aluminium hydroxide, vaccine adjuvant to enhance anti-HBs response (<LINK REF="REF-Pineau-1992" TYPE="REFERENCE">Pineau 1992</LINK>), commonly causes a granuloma at the site of injection after vaccination by the intradermal route. The arguments regarding vaccination route remain ongoing. Some randomised trials using PDV (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="REF-Fessard-1988" TYPE="REFERENCE">Fessard 1988</LINK>) or RV (<LINK REF="REF-Egemen-1998" TYPE="REFERENCE">Egemen 1998</LINK>; <LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>) in healthy people observed similar anti-HBs seroconversion rates after vaccination by the two routes, while one randomised trial suggests that the intramuscular route may be preferable (<LINK REF="REF-Fessard-1988" TYPE="REFERENCE">Fessard 1988</LINK>).</P>
<P>Building on a previous Cochrane review (<LINK REF="REF-Jefferson-1997" TYPE="REFERENCE">Jefferson 1997</LINK>), the present systematic review expanded inclusion criteria aiming to conduct comprehensive assessment of HBV vaccines in health-care workers regarding benefits and harms.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the beneficial and harmful effects of all types of preventive hepatitis B vaccines in health-care workers based on randomised trials.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-16 18:14:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2008-10-16 18:14:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES>
<P>We included randomised trials irrespective of blinding, publication status, or language. We excluded quasi-randomised trials and observational studies. However, for the evaluation of rare, serious adverse events we considered large cohort studies and previous meta-analyses/systematic reviews, as such events are rarely captured in randomised trials due to their sample size.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included healthy health-care workers who were in contact with blood or blood products, blood contaminated instruments, stained body fluids, or tissues. Health-care workers who were non- or low-responders to previous hepatitis B vaccination (anti-HBs level less than 10 IU/litre) in the trials assessing the effects of booster vaccination were also included. We excluded health-care workers who had previous hepatitis B infection, positive serum hepatitis B markers including HBsAg, HBsAb (antibodies) and/or HBcAb, or received hepatitis B vaccination as part of a post-exposure treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We assessed the following comparisons:<BR/>
</P>
<UL>
<LI>Hepatitis B vaccine versus placebo or no intervention.</LI>
<LI>One dose, type, or regimen of hepatitis B vaccine versus another dose, type, or regimen of hepatitis B vaccine (similar or different).</LI>
<LI>Hepatitis B vaccination via the intradermal route versus the intramuscular route.</LI>
<LI>Hepatitis B vaccination via gluteal intramuscular injection versus deltoid intramuscular injection.</LI>
<LI>Hepatitis B booster vaccination versus no booster vaccination or another booster vaccination schedule.</LI>
</UL>
<P>
<BR/>We allowed co-interventions in the trials if received by both arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-16 18:14:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The primary outcome measure was:<BR/>(1) Hepatitis B events at maximum follow-up. A hepatitis B event was considered to have occurred in a participant if two or more consecutive blood specimens were HBsAg and/or HBcAb positive.</P>
<P>The secondary outcome measures were:<BR/>(2) Number of health-care workers without protective anti-HBs level (less than 10 IU/litre), which is considered insufficient to prevent HBV infection (<LINK REF="REF-Szmuness-1981" TYPE="REFERENCE">Szmuness 1981</LINK>; <LINK REF="REF-Hadler-1986" TYPE="REFERENCE">Hadler 1986</LINK>), one or two months after the last injection of vaccine and/or at maximum follow-up.<BR/>(3) Anti-HBs antibody titre, either expressed as geometric mean titre (GMT) and/or mean titre.<BR/>(4) Local adverse events: adverse events such as pain, redness, swelling, and/or myalgia at the site of the inoculation after each injection of vaccine.<BR/>(5) Systemic adverse events: adverse events such as malaise, nausea, fever, arthralgia, rash, and/or headache after each injection of vaccine.<BR/>(6) Any adverse events: adverse events including local adverse events and/or systemic adverse events. The adverse events were divided into severe adverse events according to the International Committee on Harmonization guidelines (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>) as any event that would increase mortality; is life-threatening; requires inpatient hospitalisation; results in a persistent or significant disability; or any important medical event, which may jeopardise the patient or require intervention to prevent it. All other adverse events were considered non-severe.<BR/>(7) Quality of life.<BR/>(8) Cost-effectiveness.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-16 18:12:01 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register </I>(February 2003) and <I>The Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library </I>(Issue 1, 2003) by combining the words 'vaccine' with one of the words (anaesthesiologists, dental, doctor, emergency, employee, haemodialysis, hospital, nurse, obstetrical, occupational, periodontal, personnel, physician, professional, staff, student, surgeon, and worker) related to the notion of health-care workers. We also searched <I>MEDLINE</I> (from January 1966 to February 2003) and <I>EMBASE</I> (from January 1980 to February 2003) using the same strategy mentioned above (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>We contacted the principal authors of the included trials and the main pharmaceutical companies (SmithKline Beecham and Merck Sharp &amp; Dohme (MSD)) producing hepatitis B vaccines for missing information and additional published or unpublished randomised trials on the topic.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-16 18:14:26 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The meta-analysis was conducted following the recommendations given in the Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
<P>
<B>Trial identification</B>
<BR/>WC and CG independently identified the trials and evaluated whether the trials fulfilled the inclusion criteria. We listed excluded trials with the reasons for exclusion.</P>
<P>
<B>Assessment of methodological quality</B>
<BR/>Methodological quality was defined as the confidence that the design and report restrict bias in the intervention comparison (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). We assessed the methodological quality using four separate components (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>) as defined by Kjaergard et al (<LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>):<BR/>
</P>
<UL>
<LI>generation of the allocation sequence: adequate (computer generated random numbers or similar) or inadequate (other methods or not described);</LI>
<LI>allocation concealment: adequate (central independent unit, sealed envelopes, or similar) or inadequate (not described or open table of random numbers or similar);</LI>
<LI>double-blinding: adequate (identical placebo or similar) or inadequate (not performed);</LI>
<LI>follow-up: adequate (number and reasons for dropouts and withdrawals described) or inadequate (number or reasons for dropouts and withdrawals not described).</LI>
</UL>
<P>
<BR/>Further, we registered whether the randomised trials reported to have used intention-to-treat analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>) and sample size calculation.</P>
<P>
<B>Data extraction</B>
<BR/>We extracted the following characteristics from each randomised trial: primary author, number of health-care workers randomised, participant inclusion and exclusion criteria, methodological quality, sample size calculation, intention-to-treat, intervention regimens, doses and types of vaccine, routes for vaccine injection, vaccination schedules, mean age, proportion of males, smoking, mean body weight, duration of follow-up, outcome measures, and number and type of adverse events in the intervention and the control group.</P>
<P>
<B>Statistical methods</B>
<BR/>We performed the analyses in Review Manager 4.2. The analyses for binary outcomes included all patients irrespective of compliance or follow-up (intention-to-treat) using the last reported observed response ('carry forward'). We analysed the data by both a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). If results produced by the two models did not differ, we only reported the results of the fixed-effect model, otherwise we reported the results by the two models. We planned to explore evidence of publication biases and other biases by funnel plot analyses (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We presented binary outcome measures as relative risks (RR) with 95% confidence intervals (CI).</P>
<P>We planned to do the following subgroup analyses:<BR/>
</P>
<UL>
<LI>methodological quality. We planned to divide the trials into high-quality trials (ie, trials with low risk of bias) and low-quality trials (ie, trials with higher risk of bias) based on the adequacy of generation of the allocation sequence, allocation concealment, double-blinding, and follow-up</LI>
<LI>risk of hepatitis B infection;</LI>
<LI>schedule of vaccination;</LI>
<LI>dose of vaccination;</LI>
<LI>type of vaccine;</LI>
<LI>age;</LI>
<LI>weight;</LI>
<LI>smoking;</LI>
<LI>hepatitis B events in relation to duration of follow-up;</LI>
<LI>number of health-care workers without protective anti-HBs level in relation to follow-up.</LI>
</UL>
<P>
<BR/>We tested for differences between estimates of intervention effects with best interaction (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
<P>The changes in the present protocol compared to the original version (<LINK REF="REF-Jefferson-1997" TYPE="REFERENCE">Jefferson 1997</LINK>) are listed in 'Published notes'.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDY_DESCRIPTION MODIFIED="2008-10-16 18:14:27 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Our electronic searches found 367 publications. After reading the titles and abstracts, we excluded 336 of these publications because they were duplicates, non-clinical studies, or had study objectives different from this review. We retrieved the remaining 31 publications for further assessment. Of these, we excluded five publications because they did not meet the inclusion criteria. We list the reasons for exclusion in the table 'Characteristics of excluded studies'.</P>
<P>The remaining 26 publications were on 21 randomised trials that reported the random allocation of health-care workers to hepatitis B vaccination. We list these trials in the table 'Characteristics of included studies'. Twenty trials were published in English and one trial in Italian.</P>
<P>
<B>PDV versus placebo</B>
<BR/>Four trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK> from France; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK> from the Netherlands; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK> and <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK> from the United States) compared PDV versus placebo in health-care workers. The participants in three trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) were from dialysis units with high risk of HBV infection. Low dose of PDV was applied by the intradermal route (5 µg PDV in <LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>) or the intramuscular route (3 µg PDV in <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) three times at monthly intervals. <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK> and <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK> vaccinated health-care workers with three intramuscular injections of 20 µg PDV at 0, 1, and 6 months. All four trials had at least one year follow-up (range from 12 to 24 months), which allowed the investigation on hepatitis B events in both arms.</P>
<P>
<B>Gluteal intramuscular injection versus deltoid intramuscular injection</B>
<BR/>One trial (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK> from Italy) compared three gluteal injections of 20 µg PDV versus three deltoid injections of 20 µg PDV by the intramuscular route at 0, 1, and 6 months in hospital workers.</P>
<P>
<B>Different doses of PDV</B>
<BR/>One trial (<LINK REF="STD-Chan-1992" TYPE="STUDY">Chan 1992</LINK> from Taiwan, China) compared different doses of PDV (1, 2, or 5 µg) by four intramuscular injections in the deltoid muscle at 0, 1, 2, and 12 months in hospital personnel.</P>
<P>
<B>PDV produced in different countries</B>
<BR/>Another trial (<LINK REF="STD-Pennie-1992" TYPE="STUDY">Pennie 1992</LINK> from Canada) compared different brands of PDV (Korean PDV versus American PDV). The healthy medical students were vaccinated with the two vaccines at the same dose (20 µg), route (intramuscular), and schedule (0, 1, and 6 months). The Korean Green Cross produced the Korean vaccine and Merck Sharp &amp; Dohme produced the American vaccine.</P>
<P>
<B>RV versus placebo or no intervention</B>
<BR/>We were not able to identify any randomised trials that compared RV versus placebo or no intervention.</P>
<P>
<B>RV versus PDV</B>
<BR/>Two trials (<LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> from Canada and <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK> from Turkey) compared RV versus PDV. The <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> trial vaccinated health-care workers with 20 µg of RV (mammalian cell-derived) or PDV by the intramuscular route at 0, 1, and 6 months, while the <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK> trial used 2 µg of RV (yeast-derived) or PDV to vaccinate medical students by the intradermal route at 0, 1, and 6 months.</P>
<P>
<B>Different brands of RV</B>
<BR/>One trial (<LINK REF="STD-Averhoff-1998" TYPE="STUDY">Averhoff 1998</LINK> from the United States) compared two main brands of RV launched in high-income countries. The trial compared the licensed dose of Recombivax-HB (10 µg) versus the licensed dose of Engerix-B (20 µg) by the intramuscular route at 0, 1, and 6 months in health-care workers.</P>
<P>
<B>Intradermal route versus intramuscular route</B>
<BR/>Eight trials (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK> from Italy; <LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK> from the Netherlands; <LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK> from Spain; <LINK REF="STD-Coleman-1991" TYPE="STUDY">Coleman 1991</LINK> and <LINK REF="STD-Parish-1991" TYPE="STUDY">Parish 1991</LINK> from the United States; <LINK REF="STD-Oliveira-1995" TYPE="STUDY">Oliveira 1995</LINK> and <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK> from Brazil; <LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK> from Canada) compared the intradermal route versus the intramuscular route. The <LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK> trial vaccinated the health-care workers with 2 µg PDV by both routes at 0, 1, 2, and 6 months. The <LINK REF="STD-Coleman-1991" TYPE="STUDY">Coleman 1991</LINK> trial and the <LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK> trial used 2 µg PDV by the intradermal route versus 20 µg PDV by the intramuscular route at 0, 1, and 6 months. The <LINK REF="STD-Parish-1991" TYPE="STUDY">Parish 1991</LINK> trial compared 1 µg RV intradermal with 20 µg RV intramuscular at 0, 1, and 6 months. The remaining four trials (<LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK>; <LINK REF="STD-Oliveira-1995" TYPE="STUDY">Oliveira 1995</LINK>; <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>; <LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>) compared 2 µg RV intradermal versus 20 µg RV intramuscular at 0, 1, and 6 months, except that the last injection in the intradermal group of the <LINK REF="STD-Oliveira-1995" TYPE="STUDY">Oliveira 1995</LINK> trial was administrated by the intramuscular route with 20 µg vaccine. The follow-up time in these seven trials ranged from seven months to two years after the first injection.</P>
<P>
<B>Rapid vaccination schedule versus standard vaccination schedule</B>
<BR/>Two trials (<LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK> from Italy; <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK> from United Kingdom) compared a rapid vaccination schedule (0, 1, and 2 months) versus the standard vaccination schedule (0, 1, and 6 months) of intramuscular injections of 20 µg RV.</P>
<P>
<B>Booster vaccinations</B>
<BR/>Two trials (<LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK> from United Kingdom; <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK> from the United States) investigated the effects of booster vaccination with RV in health-care workers who did not respond satisfactorily to the primary vaccination. The <LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK> trial compared different doses of RV (5, 10, 20, or 40 µg) for booster vaccination by two intramuscular injections two months apart, and the <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK> trial compared 2.5 µg RV versus 10 µg RV for booster vaccination by one intramuscular injection.</P>
<P>The RVs used in the <LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK> trial and the <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> trial were derived from a continuous mammalian cell line and contained pre-S1, pre-S2, and S antigenic components of HBsAg. The RV used by the other trials included in this review were derived from yeast and only contained the S component of HBsAg.<BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-16 18:14:29 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Overall we found one or more methodological weaknesses in all the included trials. Accordingly, all trials were considered to be of low methodological quality.</P>
<P>
<B>PDV versus placebo</B>
<BR/>None of the four trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK>) in this comparison reported adequate generation of allocation sequence; two trials (<LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) reported adequate allocation concealment; all trials reported adequate double blinding and adequate follow-up. Accordingly, these four trials were considered of low methodological quality. Two trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK>) reported sample size calculation. None of the four trials performed intention-to-treat analysis.</P>
<P>
<B>Gluteal intramuscular injection versus deltoid intramuscular injection</B>
<BR/>The trial (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK>l) included in this comparison did not report adequate generation of the allocation sequence, allocation concealment, and double blinding, but adequate follow-up. This trial did not perform sample size calculation and intention-to-treat. Accordingly, this trial was considered of low methodological quality.</P>
<P>
<B>Different doses of PDV </B>
<BR/>The only one trial (<LINK REF="STD-Chan-1992" TYPE="STUDY">Chan 1992</LINK>) included in this comparison did not report adequate generation of the allocation sequence, allocation concealment, double blinding, and follow-up. Accordingly, this trial was considered of low methodological quality. This trial did not perform sample size calculation and intention-to-treat analysis either.</P>
<P>
<B>PDV produced in different countries</B>
<BR/>The only trial (<LINK REF="STD-Pennie-1992" TYPE="STUDY">Pennie 1992</LINK>) included in this comparison did not report adequate generation of allocation sequence and allocation concealment, but reported adequate double blinding and follow-up. Accordingly, this trial was considered of low methodological quality. This trial did not report sample size calculation and intention-to-treat analysis was not performed.</P>
<P>
<B>RV versus PDV </B>
<BR/>None of the two trials (<LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK>; <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK>) included in this comparison reported adequate generation of allocation sequence. One trial (<LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK>) reported adequate allocation concealment by using coded boxes, and adequate double blinding. Both trials had adequate follow-up because of no dropouts. Accordingly, the two trials were considered of low methodological quality. None of the two trials reported sample size calculation. Both trials performed intention-to-treat analysis.</P>
<P>
<B>Different brands of RV</B>
<BR/>The only trial (<LINK REF="STD-Averhoff-1998" TYPE="STUDY">Averhoff 1998</LINK>) included in this comparison did not report adequate generation of allocation sequence, allocation concealment, and double blinding (only the participants were blinded), but adequate follow-up. Accordingly, this trial was considered of low methodological quality. The trial did not report sample size calculation and intention-to-treat analysis was not performed.</P>
<P>
<B>Intradermal route versus intramuscular route </B>
<BR/>None of the eight trials (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK>; <LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK>; <LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK>; <LINK REF="STD-Coleman-1991" TYPE="STUDY">Coleman 1991</LINK>; <LINK REF="STD-Parish-1991" TYPE="STUDY">Parish 1991</LINK>; <LINK REF="STD-Oliveira-1995" TYPE="STUDY">Oliveira 1995</LINK>; <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>; <LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>) included in this comparison reported adequate generation of allocation sequence and adequate allocation concealment. One trial (<LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>) reported single blinding for the anti-HBs assessment, the other trails did not perform blinding. Only one trial (<LINK REF="STD-Coleman-1991" TYPE="STUDY">Coleman 1991</LINK>) did not report adequate follow-up. Only the <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK> trial reported sample size calculation. Three trials (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK>; <LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK>; <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>) performed intention-to-treat analysis. Accordingly, none of the eight trials were considered to have high methodological quality.</P>
<P>
<B>Rapid vaccination schedule versus standard vaccination schedule </B>
<BR/>None of the two trials (<LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK>; <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK>) included in this comparison reported adequate generation of allocation sequence, adequate allocation concealment, and adequate double blinding. Both trials reported adequate follow-up. Accordingly, both trials were considered of low methodological quality. Sample size calculation was not reported in these two trials. The <LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK> trial performed intention-to-treat analysis.</P>
<P>
<B>Booster vaccination </B>
<BR/>Two trials (<LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK>; <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK>) were included in this comparison. One (<LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK>) of the trials reported adequate generation of allocation sequence. No trials reported adequate allocation concealment. One trial (<LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK>) reported adequate double blinding. The <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK> trial reported single blinding for anti-HBs assessment. Accordingly, none of the two trials was considered of high methodological quality. The <LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK> trial reported sample size calculation and stated and performed intention-to-treat analysis. The <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK> trial performed intention-to-treat analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>
<B>PDV versus placebo<BR/>
</B>
<BR/>
<B>
<I>Hepatitis B events<BR/>
</I>
</B>Four trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>; <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK>) compared PDV versus placebo. PDV significantly decreased the number of hepatitis B events (38/1365 (2.8%) versus 71/1332 (5.3%); RR 0.51, 95% CI 0.35 to 0.73) at the maximum follow-up. There was no significant heterogeneity.</P>
<P>Three trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) showed that PDV significantly decreased the number of hepatitis B events in health-care workers with high risk of infection in dialysis units (37/699 (5.3%) versus 66/668 (9.9%); RR 0.53, 95% CI 0.36 to 0.77), while one trial (<LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK>) did not show significant effects of PDV on hepatitis B events in normal hospital staff with low risk of infection (1/666 (0.2%) versus 5/664 (0.8%); RR 0.20, 95% CI 0.02 to 1.70) (Comparison 01-01). The difference is not significant (test of interaction z = -0.85, NS).</P>
<P>The doses of PDV used in these four randomised trials differed. We therefore made post hoc subgroup analyses regarding the doses. <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK> and <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK> compared 20 µg PDV versus placebo. The occurrence of hepatitis B events was significantly decreased in the PDV group (10/1108 (1.0%) versus 30/1087 (2.8%); RR 0.32, 95% CI 0.16 to 0.65). The two other trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK>) using 3 µg or 5 µg PDV also showed significant reduction of hepatitis B events (28/257 (10.9%) versus 41/245 (16.7%); RR 0.64, 95% CI 0.41 to 0.99) (Comparison 01-02).</P>
<P>
<B>
<I>Number without protective anti-HBs levels<BR/>
</I>
</B>We were not able to find any data of the placebo groups of the four trials regarding the number of health-care workers without protective anti-HBs levels after completion of the vaccination. Therefore, we were only able to list the result in the PDV group in each trial. The <LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK> trial reported 9/157 participants (5.7%), the <LINK REF="STD-Szmuness-1982" TYPE="STUDY">Szmuness 1982</LINK> trial reported 15/337 participants (4.5%), the <LINK REF="STD-Desmyter-1983" TYPE="STUDY">Desmyter 1983</LINK> trial reported 4/73 participants (5.5%), and the <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK> trial reported 32/645 participants (5.0%) without protective anti-HBs levels after completion of the vaccination. This corresponds to 5.0% (95% CI 3.8 to 6.3%).</P>
<P>
<B>
<I>Anti-HBs level<BR/>
</I>
</B>Only two trials (<LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK>; <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK>) reported anti-HBs response in health-care workers who received PDV. We were not able to pool data for meta-analyses due to the lack of the data in placebo group. The <LINK REF="STD-Crosnier-1981" TYPE="STUDY">Crosnier 1981</LINK> trial reported the mean titre +/- 2 standard errors (SE) of anti-HBs in 148 responders as 904 +/- 231 IU/litre at 12 months follow-up. The <LINK REF="STD-Dienstag-1984" TYPE="STUDY">Dienstag 1984</LINK> trial reported the peak GMT +/- SE of anti-HBs as 26,718 +/- 2234 IU/litre.</P>
<P>
<B>
<I>Adverse events<BR/>
</I>
</B>There were no significant differences regarding adverse events, including local adverse events and systemic adverse events, between PDV and placebo after each injection (Comparison 01-03, 01-04, and 01-05).</P>
<P>We also searched the databases for studies about post-marketing surveillance of adverse events occurring with PDV. One study (<LINK REF="REF-McMahon-1992" TYPE="REFERENCE">McMahon 1992</LINK>) found 39 adverse event reports out of 43,618 persons who received 101,360 doses of PDV. The most frequent adverse events were myalgia/arthralgia, skin rashes, and dizziness. No serious adverse events attributable to PDV were reported by this study.</P>
<P>
<B>Gluteal intramuscular injection versus deltoid intramuscular injection<BR/>
</B>
<BR/>One trial (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK> ) compared the different sites of injection regarding the vaccination effects. The number of health-care workers without protective anti-HBs level was significantly higher in the gluteal injection group than in the deltoid group (20/71 (28.2%) versus 1/75 (1.3%); RR 21.13, 95% CI 2.91 to 153.32) (Comparison 02-01). The mean titre of anti-HBs in the gluteal group was also significantly lower than that in the deltoid group (WMD -241 IU/litre, 95% CI -242 to -240 IU/litre) (Comparison 02-02). No adverse events were reported.</P>
<P>
<B>Different doses of PDV<BR/>
</B>
<BR/>One trial (<LINK REF="STD-Chan-1992" TYPE="STUDY">Chan 1992</LINK>) including 300 health-care workers compared different doses (1, 2, or 5 µg) of PDV by the intramuscular route at 0, 1, 2, and 12 months. Hepatitis B events were not reported in this trial. There were no significant difference in the number of health-care workers without protective anti-HBs level in the comparisons of 2 µg versus 1 µg (RR 1.47, 95% CI 0.88 to 2.46) and 5 µg versus 1 µg (RR 0.84, 95% CI 0.46 to 1.54) (Comparison 02-01). However, the difference in the comparison of 5 µg versus 2 µg reached statistical significance (RR 0.57, 95% CI 0.33 to 0.99) (Comparison 03-01).</P>
<P>
<B>PDV produced in different countries</B>
</P>
<P>One trial (<LINK REF="STD-Pennie-1992" TYPE="STUDY">Pennie 1992</LINK>) enrolled 693 health-care workers in order to compare PDV produced in Korea with the one in America. Hepatitis B events were not reported in this trial. There was no significant difference in the proportion of participants without protective anti-HBs level (58/349 (16.6%) versus 45/344 (13.1%); RR 1.27, 95% CI 0.89 to 1.82) (Comparison 04-01).</P>
<P>
<B>RV versus placebo or no intervention</B>
</P>
<P>We did not identify randomised trials comparing RV versus placebo or no intervention in health-care workers.</P>
<P>
<B>RV versus PDV</B>
</P>
<P>
<LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> included 800 health-care workers and compared the two types of vaccines by the intramuscular route. <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK> included 45 health-care workers and compared two types of vaccines by the intradermal route. The vaccination schedules were 0, 1, and 6 months for both trials.</P>
<P>
<B>
<I>Hepatitis B events</I>
</B>
<BR/>None of the trials reported the outcome measure of the number of hepatitis B events.<BR/>
<BR/>
<B>
<I>Number without protective anti-HBs levels<BR/>
</I>
</B>The analysis did not demonstrate significant differences between the number without protective anti-HBs level regardless the vaccination routes (Comparison 05-01). We found a significant heterogeneity in this comparison (Chi-square = 2.77, df = 1, P = 0.096).</P>
<P>
<B>
<I>Anti-HBs level<BR/>
</I>
</B>The two trials reported the GMT of anti-HBs level after the completion of vaccination program. However, we were not able to pool the data for meta-analyses because the standard deviations of anti-HBs level were not reported. The <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> trial reported a GMT of anti-HBs 3018 IU/litre in the RV group, which was much lower than the GMT of 9469 IU/litre in the PDV group. However, in the <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK> trial, the GMT of anti-HBs was 1390 IU/litre in the RV group which was much higher compared than the GMT of 329 IU/litre in the PDV group.<BR/>
<BR/>
<B>
<I>Adverse events<BR/>
</I>
</B>The <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> trial reported the adverse events after each injection by the intramuscular route at 0, 1, and 6 months.</P>
<P>Adverse events after the first injection of vaccine encompassed significantly more pain (96/594 (16.2%) versus 54/199 (27.1%); RR 0.60, 95% CI 0.44 to 0.80), redness (35/594 (5.9%) versus 25/199 (12.6%); RR 0.47, 95% CI 0.29 to 0.76), and myalgia (55/594 (9.3%) versus 38/199 (19.1%); RR 0.48, 95% CI 0.33 to 0.71) in the PDV vaccinated than in the RV vaccinated (Comparison 05-02). Adverse events after the second injection of vaccine encompassed no significant difference in adverse events between RV and PDV (Comparison 05-03). Adverse events after the third injection of vaccine encompassed significantly more redness (33/566 (5.8%) versus 22/192 (11.5%); RR 0.51, 95% CI 0.30 to 0.85) in health-care workers vaccinated with PDV than with RV (Comparison 05-04).</P>
<P>We also searched the databases for studies about postmarketing surveillance of adverse events occurring in the vaccination with RV. One study (<LINK REF="REF-Grotto-1998" TYPE="REFERENCE">Grotto 1998</LINK>) reviewed the postmarketing surveillance literature (4.5 million doses) and found that the incidence of adverse events was one out of 15,500 doses and the incidence of local adverse events was one out of 85,000 doses. No serious or severe adverse events attributable to RV were reported.<BR/>
<BR/>A postmarketing surveillance reported 19,931 adverse events out of 500 million doses of RV (yeast-derived). The main adverse events include nausea (1:296,000), rash (1: 250,000), headache (1:326,000), fever (1:254,000), and injection site reaction (1:203,000) (<LINK REF="REF-Assad-1999" TYPE="REFERENCE">Assad 1999</LINK>). No serious adverse events attributable to RV were reported.</P>
<P>
<B>Comparison between different brands of RV<BR/>
</B>
<BR/>The <LINK REF="STD-Averhoff-1998" TYPE="STUDY">Averhoff 1998</LINK> trial including 1765 health-care workers compared 10 µg Recombivax-HB versus 20 µg Engerix-B by the intramuscular route at 0, 1, and 6 months. Hepatitis B events were not reported in this trial. There were significantly more health-care workers without protective anti-HBs level in the low-dose Recombivax-HB group versus the high-dose Engerix-B group (128/891 (14.4%) versus 96/874 (11.0%); RR 1.31, 95% CI 1.02 to 1.68) (Comparison 06-01). We were not able to extract the original data regarding the GMT of anti-HBs in each arm. However, the publication reported significantly higher GMT of anti-HBs in the Engerix-B group (&lt; 40 years of age: 1047 IU/litre versus 2138 IU/litre, P&lt; 0.001; <U>&gt;</U> 40 years of age: 288 versus 1000 IU/litre, P&lt; 0.001). No adverse events were reported in this trial.<BR/>
<BR/>
<B>Intradermal route versus intramuscular route<BR/>
</B>
<BR/>
<B>
<I>Hepatitis B events</I>
</B>
<BR/>None of the trials included in this comparison reported the outcome measure of the number of hepatitis B events.</P>
<P>
<B>
<I>Number without protective anti-HBs levels<BR/>
</I>
</B>One trial (<LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK>) including 165 health-care workers compared the intradermal route with 2 µg PDV versus the intramuscular route with 2 µg PDV at 0, 1, and 6 months. There was no significant difference between the two routes regarding the number without protective anti-HBs level after vaccination (5/82 (6.1%) versus 8/83 (9.6%); RR 0.63, 95% CI 0.22 to 1.85) (Comparison 07-01).</P>
<P>Two trials (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK>; <LINK REF="STD-Coleman-1991" TYPE="STUDY">Coleman 1991</LINK>) including 576 participants showed significantly more participants without protective anti-HBs level following 2 µg PDV by the intradermal route compared with 20 µg PDV by the intramuscular route (52/285 (18.2%) versus 23/291 (7.9%); RR 2.33, 95% CI 1.47 to 3.68) (Comparison 07-01).</P>
<P>Four trials (<LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK>; <LINK REF="STD-Parish-1991" TYPE="STUDY">Parish 1991</LINK>; <LINK REF="STD-Oliveira-1995" TYPE="STUDY">Oliveira 1995</LINK>; <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>; <LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>) compared 2 µg RV by the intradermal route versus 20 µg RV by the intramuscular route. One trial compared 1 µg RV by the intradermal route versus 10 µg RV by the intramuscular route. The low-dose intradermal RV did not elicit the same anti-HBs seroconversion as the high/dose intramuscular dose (123/383 (32.1%) versus 89/400 (22.3%); RR 1.41, 95% CI 1.13 to 1.76) (Comparison 07-01).</P>
<P>We conducted subgroup analyses regarding the follow-up time (less than eight months after the first injection of the vaccine, one year after the first injection of the vaccine, and two years after the first injection of the vaccine). The higher-dose intramuscular vaccination was significantly superior to the lower-dose intradermal vaccination irrespective of duration of follow-up (Comparison 07-02). Tests of interaction did not show significant differences (short versus long follow-up test of interaction z = -0.11, NS).</P>
<P>
<B>
<I>Anti-HBs level<BR/>
</I>
</B>The <LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK> trial demonstrated that the GMT of anti-HBs following 2 µg intradermal PDV was significantly lower than following 20 µg intramuscular PDV (WMD -346 IU/litre, 95% CI -347 to -345 IU/litre) (Comparison 07-03).<BR/>
<BR/>Six trials included in this comparison reported the GMT of anti-HBs without giving standard deviation or error after the completion of vaccination programme. Therefore, we were not able to pool data for meta-analyses. The GMT of anti-HBs tended to be higher in high-dose intramuscular PDV than in low-dose intradermal PDV (median 432 IU/litre versus 1463 IU/litre) (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>
<B>
<I>Adverse events<BR/>
</I>
</B>One trial (<LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>) including 180 health-care workers did not identify a significant difference in the occurrence of total adverse events (local and/or systemic adverse events) during the vaccination between the two routes (Comparison 07-03).</P>
<P>Two trials (<LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK>; <LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>) including 373 health-care workers showed significantly more local adverse events such as pain, redness, and swelling by the intradermal route compared with the intramuscular route (89/131 (67.9%) versus 19/242 (7.8%); RR 6.86, 95% CI 4.63 to 10.17) (Comparison 07-04), while significantly less systemic adverse events (fever) occurred in the health-care workers vaccinated by the intradermal route versus the intramuscular route (4/131 (3.1%) versus 17/242 (7.0%); RR 0.31, 95% CI 0.12 to 0.82) (Comparison 07-05).<BR/>
<BR/>
<B>Rapid schedule (0, 1, and 2 months) versus standard schedule (0, 1, and 6 months)<BR/>
</B>
<BR/>Two trials (<LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK>; <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK>) including 230 health-care workers compared a rapid vaccination schedule versus standard vaccination schedule (both by the intramuscular route with 20 µg RV). Hepatitis B events were not reported by these trials. The rapid schedule elicited significantly more without protective anti-HBs level (12/109 (11.0%) versus 6/121 (5.0%); RR 3.45, 95% CI 1.47 to 8.07) (Comparison 08-01). The <LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK> trial reported a GMT of anti-HBs of 383 IU/litre in the rapid schedule group, which was significantly less than the 704 IU/litre in the standard schedule group.</P>
<P>In the <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK> trial, the number without protective anti-HBs level were reported separately for non-smokers and smokers. We pooled the data for two vaccination schedules and made a comparison between non-smokers and smokers. The number without protective anti-HBs level did not differ significantly (8/78 (10.3%) versus 8/37 (21.6%); RR 0.47, 95% CI 0.19 to 1.16).</P>
<P>
<B>Booster vaccination of non-responders<BR/>
</B>
<BR/>Two trials (<LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK>; <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK>) including 128 health-care workers who were non-responders to a primary hepatitis B vaccination evaluated the effects of booster vaccination. Hepatitis B events were not reported by these trials. There were no significant differences in the number without protective anti-HBs after booster vaccination in the comparisons between different doses of RV (2.5 µg or 5 µg RV versus 10 µg RV, 5 µg RV versus 20 µg RV, 5 µg RV versus 40 µg RV, 10 µg RV versus 20 µg RV, and 20 µg RV versus 40 µg RV (Comparison 09-01). The anti-HBs seroconversion rate ranged from 30% to 68%.</P>
<P>The <LINK REF="STD-Williams-2001" TYPE="STUDY">Williams 2001</LINK> trial reported the GMT of anti-HBs at one year follow-up and found that there was no significant difference between two doses (2.5 µg versus 10 µg: 17 IU/litre, 95% CI 10 to 30 IU/litre versus 33 IU/litre, 95% CI 7 to 153 IU/litre). Neither did the <LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK> trial find any significant difference in GMT of anti-HBs between four different doses of booster vaccination (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>
<B>Quality of life and cost-effectiveness<BR/>
</B>
<BR/>We were not able to extract data regarding quality of life.<BR/>
<BR/>Regarding cost-effectiveness, only one trial (<LINK REF="STD-Pennie-1992" TYPE="STUDY">Pennie 1992</LINK>) mentioned that there was no significant difference in vaccination effect between PDV produced in Korea and America, while the price of the former was nine times less than the latter.</P>
<P>
<B>Sensitivity/subgroup analyses and funnel plot analyses<BR/>
</B>
<BR/>Due to the limited number of the trials in each comparison group and the low methodological quality of the trials, we were not able to perform sensitivity/subgroup analyses and funnel plot analyses as planned in the protocol for this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Our review, compared to the first Cochrane review on this topic, expanded the inclusion criteria (<LINK REF="REF-Jefferson-1997" TYPE="REFERENCE">Jefferson 1997</LINK>). Accordingly, we identified 16 new trials and were able to cover more aspects of hepatitis B vaccination of health-care workers. None of the 21 randomised trials had high methodological quality regarding all components for the assessment of methodological quality. Therefore, the data may be influenced by bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>). Accordingly, our findings should be cautiously interpreted. In spite of this reservation, we are quite confident to conclude that PDV seems to decrease the number of hepatitis B infections, and that RV seems to produce an anti-HBs response, which is not significantly different from PDV.</P>
<P>Four randomised clinical trials published during the 1980s compared PDV versus placebo in health-care workers (<LINK REF="REF-Jefferson-1997" TYPE="REFERENCE">Jefferson 1997</LINK>; the present review). PDV significantly decreased the hepatitis B events. Although these four trials had low methodological quality, we think the evidence is reliable because large randomised trials found similar effects of PDV in homosexual men, who also have high risk of hepatitis B infection (<LINK REF="REF-Szmuness-1981" TYPE="REFERENCE">Szmuness 1981</LINK>; <LINK REF="REF-Hadler-1986" TYPE="REFERENCE">Hadler 1986</LINK>). Further, other Cochrane reviews have demonstrated beneficial effects of hepatitis B infection in dialysis patients (<LINK REF="REF-Schroth-2004" TYPE="REFERENCE">Schroth 2004</LINK>) and new-borns of HBsAg-positive mothers (<LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK>). In the four trials we were able to include, the maximum follow-up time was two years and we noticed that the anti-HBs level and seroconversion rate decreased with the duration of follow-up. Some studies have demonstrated that the anti-HBs seroconversion rate drops following the primary PDV vaccination in healthy populations (<LINK REF="REF-Wainwright-1997" TYPE="REFERENCE">Wainwright 1997</LINK>; <LINK REF="REF-Xia-2002" TYPE="REFERENCE">Xia 2002</LINK>). However, anti-HBs level monitoring may not be necessary and booster vaccination may not be beneficial in health-care workers who lose protective anti-HBs level, years after the primary vaccination (<LINK REF="REF-Banatvala-2003" TYPE="REFERENCE">Banatvala 2003</LINK>). Immunocompetence may mount an anamnestic anti-HBs response even if anti-HBs levels drop below 10 IU/L (<LINK REF="REF-Banatvala-2003" TYPE="REFERENCE">Banatvala 2003</LINK>).</P>
<P>We only identified one trial (<LINK REF="STD-de-Lalla-1988" TYPE="STUDY">de Lalla 1988</LINK>) that compared gluteal versus deltoid vaccination. This trial found significantly higher anti-HBs seroconversion rate and GMT of anti-HBs in the deltoid group. In 1985 the U.S. CDC conducted a survey in 57 haemodialysis units across U.S.A. to compared the anti-HBs responses to hepatitis B vaccine given by gluteal or deltoid injection (<LINK REF="REF-CDC-1985" TYPE="REFERENCE">CDC 1985</LINK>). This study indicated that the gluteal injection was not able to elicit the same level of anti-HBs response as the deltoid injection. Another similar study (<LINK REF="REF-Ukena-1985" TYPE="REFERENCE">Ukena 1985</LINK>) also reached the same conclusion that gluteal fat with less blood perfusion was responsible for the low response. One study (<LINK REF="REF-Cockshott-1982" TYPE="REFERENCE">Cockshott 1982</LINK>) estimated the size of gluteal fat of vaccinated persons by computed tomography scanning. It found that less than 5% of women and 15% of men received an intramuscular injection into the gluteal muscle. It also noticed calcified nodules within the fat but not within the muscle from previous injections. Therefore, vaccination by gluteal injection should not be encouraged.</P>
<P>One trial (<LINK REF="STD-Chan-1992" TYPE="STUDY">Chan 1992</LINK>), which compared the immunogenicity of different doses of PDV (1, 2, or 5 µg), showed that high dose seemed to have stronger immunogenicity. This could be important in the generation of antibody-forming memory B cells and maintenance of protective anti-HBs levels (<LINK REF="REF-Banatvala-2001" TYPE="REFERENCE">Banatvala 2001</LINK>). We were not able to find any PDV dose-finding trials in health-care workers apart from those reviewed. The U.S. CDC recommends that 20 µg PDV administrated via the intramuscular route at 0, 1, and 6 months leads to the maximum anti-HBs response (<LINK REF="REF-CDC-1987" TYPE="REFERENCE">CDC 1987</LINK>).</P>
<P>We were not able to identify any randomised trials that compared RV versus placebo or no intervention in health-care workers. By searching the main medical databases, we were also unable to identify randomised trials in other adult populations that compare RV versus placebo or no intervention. <LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK> identified one randomised trial that compared RV versus no intervention in infants of HBsAg-positive mothers. The trial reported a significant beneficial effect of RV on occurrence of hepatitis B events. <LINK REF="REF-Lee-2005" TYPE="REFERENCE">Lee 2005</LINK> also reviewed randomised trials that compared RV versus PDV, observing no significant difference regarding hepatitis B events of infants of HBsAg-positive mothers, but significantly better antibody responses. Two trials included in the present review found no significant difference between the two vaccines in the number of health-care workers without protective anti-HBs level. However, in this comparison we found significant heterogeneity. This might be due to the high risk of random error in the <LINK REF="STD-Soyletir-1992" TYPE="STUDY">Soyletir 1992</LINK> trial, which had a small sample size (45 participants) compared to the <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK> trial with 800 participants. We found four trials comparing RV versus PDV on anti-HBs responses in different populations (<LINK REF="REF-Just-1987" TYPE="REFERENCE">Just 1987</LINK>; <LINK REF="REF-Odaka-1988" TYPE="REFERENCE">Odaka 1988</LINK>; <LINK REF="REF-Scheiermann-1990" TYPE="REFERENCE">Scheiermann 1990</LINK>; <LINK REF="REF-Panda-1991" TYPE="REFERENCE">Panda 1991</LINK>). The RV elicited much lower anti-HBs level than PDV in these trials. The difference in eliciting anti-HBs level might result in the difference in chemical and physical characteristics of the two antigens contained in the two types of vaccines. Although the HBsAg segment produced by recombinant technology has the same amino acid sequence as HBsAg derived from plasma (<LINK REF="REF-Emini-1986" TYPE="REFERENCE">Emini 1986</LINK>), human monoclonal and polyclonal antibodies have different affinities for RV and PDV. It has been suggested that some epitopes may have been changed in RV when compared to PDV due to differences in glycosylation and the lipid contents (<LINK REF="REF-Heijtink-2002" TYPE="REFERENCE">Heijtink 2002</LINK>). Antibodies elicited by the two vaccines are also different in chemistry and physics. Accordingly, antibodies may have different affinity in different tests (<LINK REF="REF-Heijtink-2000" TYPE="REFERENCE">Heijtink 2000</LINK>).</P>
<P>Currently, only RVs are available in high-income countries. This is due to the public fear of human immunodeficiency virus and other infections transmitted by plasma-derived products. However, the procedures used to produce plasma-derived hepatitis B vaccine is believed to destroy all live matters. We have been unable to identify any reports that PDV causes infections. However, blood-related transmission of Creutzfeldt-Jacob disease is possible (<LINK REF="REF-Brown-2004" TYPE="REFERENCE">Brown 2004</LINK>). Although several small randomised trials (<LINK REF="REF-Odaka-1988" TYPE="REFERENCE">Odaka 1988</LINK>; <LINK REF="REF-Seaworth-1988" TYPE="REFERENCE">Seaworth 1988</LINK>) have shown a possible advantage of PDV in human immunodeficiency virus carriers and dialysis patients, the fear of disease transmission may dampen the enthusiasm for doing more randomised trials comparing PDV versus RV.</P>
<P>Two RVs are most often used in high-income countries. SmithKline Beecham recommends 20 µg of Engerix-B intramuscularly for adults and children over 12 years. Recombivax-HB manufactured by Merck Sharp &amp; Dohme has 10 µg as licensed dose for adults over 20 years. One included trial (<LINK REF="STD-Averhoff-1998" TYPE="STUDY">Averhoff 1998</LINK>) compared Recombivax-HB versus Engerix-B at their recommended dosages and found significantly more health-care workers with protective anti-HBs level and higher GMT of anti-HBs following vaccination with 20 µg Engerix-B. Other trials (<LINK REF="REF-Dahl_x002d_Hansen-1990" TYPE="REFERENCE">Dahl-Hansen 1990</LINK>; <LINK REF="REF-Hammond-1991" TYPE="REFERENCE">Hammond 1991</LINK>; <LINK REF="REF-Greenberg-1996" TYPE="REFERENCE">Greenberg 1996</LINK>; <LINK REF="REF-Leroux_x002d_Roels-2000" TYPE="REFERENCE">Leroux-Roels 2000</LINK>) with other populations confirm that the licensed dosage of Engerix-B is able to elicit higher anti-HBs responses than the licensed dosage of Recombivax-HB. One randomised trial (<LINK REF="REF-Bryan-1995" TYPE="REFERENCE">Bryan 1995</LINK>) compared two vaccines at the same two dosages (5 µg and 10 µg) and demonstrated that Engerix-B seemed to be less immunogenic than Recombivax-HB in 268 healthy adults. However, the dosages used in this trial was below the recommended dosage (20 µg) by the U.S. CDC. We may need randomised trials comparing the two vaccines at different dosages to clarify this issue.</P>
<P>The cost of hepatitis B vaccine has hampered vaccination of all health-care workers, especially in low-income countries. One way to reduce cost is to reduce the vaccine dose required. The recommended hepatitis B vaccination program by the U.S. CDC involves three intramuscular injections of 20 µg vaccine (<LINK REF="REF-CDC-1987" TYPE="REFERENCE">CDC 1987</LINK>). We identified seven randomised trials that compared the intradermal route versus the intramuscular route in regard to anti-HBs seroconversion. The intradermal route with 2 µg vaccine was not able to reach the comparable seroconversion rate elicited by the intramuscular route with 20 µg vaccine. However, it may be worth to keep on exploring the intradermal route with low-dose vaccine as we have seen that the doses used by the two routes differed 10 times, while the seroconversion rates differed less than two times. Arguments against widespread use of the intradermal route encompass difficulty of technique and the risk of local adverse events (<LINK REF="REF-Bryan-1992" TYPE="REFERENCE">Bryan 1992</LINK>). Hepatitis B vaccines contain an aluminium adjuvant enhancing antibody response. The aluminium adjuvant may produce granuloma after intradermal injection and the granuloma may undergo necrotic breakdown. In our review, the intradermal route did cause significantly more local adverse events than the intramuscular route. Therefore, the selection of vaccination route should concern not only the effect and the cost of vaccination, but also the potential adverse events and the acceptability for the recipients.</P>
<P>The rapid vaccination schedule (0, 1, and 2 months) is appealing because it may increase participant compliance and provide earlier protection for people who have high risk of hepatitis B infection. However, the rapid vaccination schedule has not been widely used because of the concern that the anti-HBs seroconversion rate and the duration of protection may be inferior to that achieved by the standard vaccination schedule (0, 1, and 6 months). The two trials (<LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK>; <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK>) included in our review and other randomised trials (<LINK REF="REF-Bruguera-1987" TYPE="REFERENCE">Bruguera 1987</LINK>; <LINK REF="REF-Marsano-1996" TYPE="REFERENCE">Marsano 1996</LINK>) in other populations have shown that the rapid vaccination schedule was not able to elicit the same anti-HBs seroconversion rate and GMT as the standard vaccination schedule. In order to achieve the same anti-HBs seroconversion rate elicited by the standard vaccination schedule, the participants in the rapid vaccination schedule group had to receive one additional dose of vaccine one year after the first vaccine injection (<LINK REF="STD-Ricciardi-1990" TYPE="STUDY">Ricciardi 1990</LINK>; <LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK>), which means more costs and poorer compliance.</P>
<P>Although PDV significantly decrease the hepatitis B events in health-care workers, hepatitis B events in the vaccinated health-care workers were not completely avoided. Some studies included in the present Review demonstrated that more than 10% of the health-care workers vaccinated by the standard vaccination program recommended by the U.S. CDC did not develop protective anti-HBs level (<LINK REF="STD-Pennie-1992" TYPE="STUDY">Pennie 1992</LINK>; <LINK REF="STD-Halliday-1990" TYPE="STUDY">Halliday 1990</LINK>). Some studies also demonstrated that people without protective anti-HBs after the recommended vaccination programme still face the risk of hepatitis B infection (<LINK REF="REF-Szmuness-1981" TYPE="REFERENCE">Szmuness 1981</LINK>; <LINK REF="REF-Hadler-1986" TYPE="REFERENCE">Hadler 1986</LINK>). Until now, several factors, such as age above 40 years, smoking, and obesity have been found to contribute to the non-response to hepatitis B vaccine (<LINK REF="REF-Roome-1993" TYPE="REFERENCE">Roome 1993</LINK>; <LINK REF="REF-Wood-1993" TYPE="REFERENCE">Wood 1993</LINK>). We were not able to find enough evidence to explore the relationship between those factors and non-response to hepatitis B vaccination. There was only one study (<LINK REF="STD-Winter-1994" TYPE="STUDY">Winter 1994</LINK>) showing that more non-smokers acquired protective anti-HBs level after vaccination when compared to smokers. How to handle the non-responders is definitely a big issue. Most studies attempted to seroconvert non-responders by giving two additional intramuscular booster doses of vaccine. However, at least 50% of non-responders might not be able to acquire protective anti-HBs level (<LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK>; <LINK REF="STD-Averhoff-1998" TYPE="STUDY">Averhoff 1998</LINK>). Assumptions that mammalian cell-derived vaccines containing two or three hepatitis B surface proteins (pre-S1, pre-S2, and S-protein) would be more immunogenic have also been evaluated. However, no studies have demonstrated that the addition of pre-S antigen is able to improve the antibody response so far (<LINK REF="REF-Pillot-1995" TYPE="REFERENCE">Pillot 1995</LINK>; <LINK REF="REF-Bertino-1997" TYPE="REFERENCE">Bertino 1997</LINK>; <LINK REF="STD-Zuckerman-1997" TYPE="STUDY">Zuckerman 1997</LINK>; <LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>).</P>
<P>Another strategy to enhance the immunogenicity of hepatitis B vaccine is to combine the antigen with a more powerful adjuvant. All the licensed hepatitis B vaccines use aluminium salts as adjuvants. Aluminium is a safe adjuvant, but it is relatively weak in enhancing the immunogenicity of vaccine, particularly when used with subunit antigens (<LINK REF="REF-Gupta-1995" TYPE="REFERENCE">Gupta 1995</LINK>). A new adjuvant MF59, which is thought to be stronger than aluminium, is under development. MF59 is an oil-in-water emulsion, which consists of the metabolisable oil, squalene, and surfactants, which form small, stable, uniform droplets when microfluidised (<LINK REF="REF-Ott-1995" TYPE="REFERENCE">Ott 1995</LINK>). MF59 augments the antigen-specific humoral and T-cell responses to subunit vaccine antigens better than aluminium (<LINK REF="REF-Traquina-1996" TYPE="REFERENCE">Traquina 1996</LINK>). Further, MF59 has been used as adjuvant for several other vaccines (including human immunodeficiency virus, herpes simplex virus, cytomegalovirus, and influenza) and the experience on 30,000 participants have shown that MF59 is safe and well tolerated in humans (<LINK REF="REF-Singh-1999" TYPE="REFERENCE">Singh 1999</LINK>). We have traced the progress of MF59 for hepatitis B vaccine and found one randomised trial showing that MF59 adjuvant enhanced the immunogenicity of HBsAg by up to 100-fold with a local and systemic safety profile comparable with that of a licensed hepatitis B vaccine, which contains aluminium adjuvant (<LINK REF="REF-Heineman-1999" TYPE="REFERENCE">Heineman 1999</LINK>). 'Natural' hepatitis B infection is able to elicit a lifelong detectable anti-HBs level. However, less than 50% of vaccinated persons can maintain protective anti-HBs level 10 or 15 years after the primary vaccination (<LINK REF="REF-Banatvala-2003" TYPE="REFERENCE">Banatvala 2003</LINK>). Research also found that the persistence of anti-HBs is dependent upon the peak of anti-HBs level after the full vaccination (<LINK REF="REF-Jilg-1988" TYPE="REFERENCE">Jilg 1988</LINK>). One study observed an annual six-fold decrease of anti-HBs in the first 17 months reducing to an annual 1.1 fold decrease after five to seven years after a vaccination schedule (0, 1, 2, and 11 months) in healthy adults (<LINK REF="REF-Gesemann-1995" TYPE="REFERENCE">Gesemann 1995</LINK>). Therefore, it is estimated that the aluminium-adjuvant vaccine may maintain the protective anti-HBs level for 15 years. In the <LINK REF="REF-Heineman-1999" TYPE="REFERENCE">Heineman 1999</LINK> trial, the vaccine with MF59 produced the highest peak GMT of anti-HBs of 265,848 IU/litre after three-dose schedule (0, 1, and 6 months). Based on the model to calculate the persistence of protective anti-HBs level, MF59 would be able to elicit a protective anti-HBs level, which can last a human lifetime. We do need more randomised trials with large sample size and high methodological quality that evaluate adjuvant MF59. Such trials should monitor the decline of anti-HBs level and predict the duration of protective anti-HBs levels as well as monitor the risk of hepatitis B infection.</P>
<P>With the selection pressure associated with massive vaccination programme in HBV-endemic countries and wide use of nucleoside analogue in patients with chronic HBV, the emergence of variants of HBV has raised concern. A study from Taiwan (<LINK REF="REF-Hsu-1999" TYPE="REFERENCE">Hsu 1999</LINK>) demonstrated the increase of the prevalence of mutants of the alpha determinant of HBV in vaccinated children over a period of 10 years. Hepatitis B therapy is entering a new era with a number of new antiviral drugs, including lamivudine and adefovir. During lamivudine monotherapy, 24% of patients develop drug resistance per year and this can increase to approximately 67% in mono-infected individuals and 90% in HIV/HBV co-infected patients after four years (<LINK REF="REF-Lai-1998" TYPE="REFERENCE">Lai 1998</LINK>; <LINK REF="REF-Benhamou-1999" TYPE="REFERENCE">Benhamou 1999</LINK>; <LINK REF="REF-Leung-2002" TYPE="REFERENCE">Leung 2002</LINK>). This drug-selected HBV mutant may act as vaccine escape virus with the potential to infect the HBV vaccinated population. The increasing prevalence of HBV mutants due to massive vaccination and antiviral therapy might lead to rebound of HBV infections among health-care workers in the near future. No randomised clinical trials have assessed hepatitis B vaccine in protecting health-care workers from the infection with HBV mutants.</P>
<P>The objective of our review was to validate the effects of hepatitis B vaccination in health-care workers in preventing hepatitis B. However, hepatitis B vaccination may also be a relevant post-exposure intervention among health-care workers. Historically controlled trials (<LINK REF="REF-Mitsui-1989" TYPE="REFERENCE">Mitsui 1989</LINK>) and controlled trials (<LINK REF="REF-Palmovic-1987" TYPE="REFERENCE">Palmovic 1987</LINK>) suggest that hepatitis B vaccination with an accelerated schedule (0, 1, 2, and 12 months) is recommended for previously unvaccinated health-care workers. In previously vaccinated health-care workers, the strategy is dependent on the anti-HBs level. If the anti-HBs level is at or above 10 IU/litre, re-vaccination is not recommended. Otherwise, the full four doses post-exposure vaccination is recommended (<LINK REF="REF-U.S.-PHS-2001" TYPE="REFERENCE">U.S. PHS 2001</LINK>). Some randomised trials also recommend the additional use of hepatitis B immune globulin for post-exposure prophylactics (<LINK REF="REF-Iwarson-1977" TYPE="REFERENCE">Iwarson 1977</LINK>; <LINK REF="REF-Grady-1978" TYPE="REFERENCE">Grady 1978</LINK>).<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>- PDV significantly decreased the hepatitis B events without severe adverse events. <BR/>- There was no evidence to support or dispute the effects of RV to decrease hepatitis B events. <BR/>- RV seems to elicit protective anti-HBs level in health-care workers comparable to PDV. <BR/>- The intradermal route with 2 µg vaccine was not able to elicit the same anti-HBs response as the intramuscular route with 20 µg vaccine. <BR/>- The gluteal intramuscular injection was not able to elicit the same anti-HBs response as the deltoid intramuscular injection.<BR/>- The rapid vaccination schedule (0, 1, and 2 months) was not able to elicit the same anti-HBs response as the standard vaccination schedule (0, 1, and 6 months).<BR/>- Booster vaccination with high dose vaccine did not work well in non-responders and the proportion with anti-HBs seroconversion was not significantly associated with the vaccine dose.<BR/>- The same type of vaccines produced by different companies or in different countries did not differ significantly regarding anti-HBs seroconversion.<BR/>- Vaccinated health-care workers might still face the risk of HBV mutant infection.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>- No randomised trials have compared RV versus PDV for the prevention of hepatitis B events in long-term follow-up.<BR/>- Long-term persistence of anti-HBs elicited by RV and PDV needs to be assessed. <BR/>- No randomised trials have assessed the intradermal route with a relative higher dose of vaccine, eg, 5 µg. <BR/>- A new type of vaccine (with the new adjuvant MF59) needs to be studied in naive as well as non-responding health-care workers.<BR/>- The current HBV vaccines need to be evaluated in preventing HBV mutant infection among health-care workers. <BR/>- We found relatively poor standards of trial reporting. Initiatives to improve reporting, such as CONSORT (www.consort-statement.org), should be followed in the reporting of future trials. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We want to thank all the health-care workers and clinical researchers who were involved in the trials included in the review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Wengdong Chen reformulated the protocol and the review, performed new searches for trials as well as data extraction, and conducted the statistical analyses. Christian Gluud revised the reformulated protocol and the review, and validated the data extraction and statistical analyses.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Compared to the original version (<LINK REF="REF-Jefferson-1997" TYPE="REFERENCE">Jefferson 1997</LINK>), the present protocol includes the following changes:</P>
<P>(1) Types of intervention<BR/>- We included not only plasma-derived vaccine and yeast-derived vaccines, but also mammalian cell-derived vaccines. Therefore, we used 'recombinant vaccine' for yeast-derived vaccine and mammalian cell-derived vaccine. The detailed information about production of vaccines can be found in 'Table of included studies'.<BR/>- We compared recombinant vaccine versus plasma-derived vaccine.<BR/>- We compared different vaccination routes (intradermal route versus intramuscular route).<BR/>- We compared different injection sites (e.g., gluteal injection versus deltoid injection).<BR/>- We compared the same type of vaccines produced in different countries or by different companies.<BR/>- We compared the different methods for booster vaccination in non-responders.<BR/>- We also considered large cohort studies and previous meta-analyses/systematic reviews to rare adverse events, which might not be captured in randomised trials due to their sample size.</P>
<P>
<BR/>(2) Types of outcome measures<BR/>We added one more outcome measure: number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre).</P>
<P>(3) Search strategy for identification of studies<BR/>The searches were updated until February 2003.</P>
<P>(4) Assessment of methodological quality<BR/>The methodological quality of the included trials was assessed by four components, including generation of the allocation sequence, allocation concealment, double-blinding, and follow-up. High methodological quality was reached if these four components were adequate. Further, we also registered whether 'intention-to-treat' and sample size calculation were performed in trial.</P>
<P>(5) Statistical methods<BR/>- We presented the binary outcome measures as relative risk with 95% confidence intervals.<BR/>- 'Intention-to-treat' was used for data analyses in this Review.<BR/>- The data was analysed by fixed-effect model and random-effects model. We only reported the results of fixed effect model if there was no difference in results analysed by the two models.</P>
<P>
<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-16 18:17:10 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Averhoff-1998" NAME="Averhoff 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H</AU>
<TI>Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9651632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1992" NAME="Chan 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan CY, Lee SD, Tsai YT, Lo KJ</AU>
<TI>Long-term follow-up of hepatitis B vaccination in susceptible hospital personnel</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>3</NO>
<PG>266-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1535229"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coleman-1991" NAME="Coleman 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coleman PJ, Shaw FE Jr, Serovich J, Hadler SC, Margolis HS</AU>
<TI>Intradermal hepatitis B vaccination in a large hospital employee population</TI>
<SO>Vaccine</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>10</NO>
<PG>723-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1836918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosnier-1981" NAME="Crosnier 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al</AU>
<TI>Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8218</NO>
<PG>455-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6110088"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al</AU>
<TI>[Efficacy of a French hepatitis B vaccine. Results of a multicenter clinical trial, using a placebo, with double-blind randomized administration]</TI>
<TO>Efficacite d'un vaccin francais contre l'hepatite B Resultats d'un essai clinique, multicentrique, utilisant un placebo, avec administration des traitements en double insu, apres tirage au sort</TO>
<SO>Bulletin de l'Academie Nationale de Medecine</SO>
<YR>1980</YR>
<VL>164</VL>
<NO>8</NO>
<PG>764-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7011486"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crosnier J</AU>
<TI>Hepatitis B in haemodialysis: vaccination against HBs antigen</TI>
<SO>Proceedings of the European Dialysis and Transplant Association</SO>
<YR>1981</YR>
<VL>18</VL>
<PG>231-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7036150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Guesry P, Jungers P, Courouce AM, Laplanche A, Benhamou E, Dagos F, et al</AU>
<TI>Double blind randomised clinical trial of Pasteur hepatitis B vaccine in high risk haemodialysis units staff</TI>
<SO>Hepatitis B vaccine</SO>
<YR>1981</YR>
<PG>133-47</PG>
<ED>Maupas P, Guesry P</ED>
<PB>Elsevier Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Lalla-1988" NAME="de Lalla 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Lalla F, Rinaldi E, Santoro D, Pravettoni G</AU>
<TI>Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study</TI>
<SO>European Journal of Epidemiology</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>2</NO>
<PG>256-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2969825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desmyter-1983" NAME="Desmyter 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desmyter J, Colaert J, DeGroote G, Reynders M, Reerink-Brongers EE, Lelie PN, et al</AU>
<TI>Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>2</VL>
<NO>8363</NO>
<PG>1323-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6139668"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dienstag-1984" NAME="Dienstag 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, et al</AU>
<TI>Hepatitis B vaccine in health care personnel: safety, immunogenicity and indicators of efficacy</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1984</YR>
<VL>101</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6233921"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-1990" NAME="Gonzalez 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez ML, Usandizaga M, Alomar P, Salva F, Martin F, Erroz MJ, et al</AU>
<TI>Intradermal and intramuscular route for vaccination against hepatitis B</TI>
<SO>Vaccine</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>4</NO>
<PG>402-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2144391"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halliday-1990" NAME="Halliday 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halliday ML, Rankin JG, Bristow NJ, Coates RA, Corey PN, Strickler AC</AU>
<TI>A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1990</YR>
<VL>150</VL>
<NO>6</NO>
<PG>1195-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2141247"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heijtink-1989" NAME="Heijtink 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijtink RA, Knol RM, Schalm SW</AU>
<TI>Low-dose (2 micrograms) hepatitis B vaccination in medical students: comparable immunogenicity for intramuscular and intradermal routes</TI>
<SO>Journal of Medical Virology</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>2</NO>
<PG>151-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2522147"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henderson-2000" NAME="Henderson 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A</AU>
<TI>Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>4</NO>
<PG>264-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10782589"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliveira-1995" NAME="Oliveira 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz ML, de Oliveira PM, Figueiredo VM, Kemp VL, Castelo Filho A, Silva AE</AU>
<TI>The optimization of the use of economic resources for vaccination against hepatitis B in professionals in the health area</TI>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>1995</YR>
<VL>28</VL>
<NO>4</NO>
<PG>393-403</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8668841"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oliveira PMC, Silva AE, Kemp VL, Juliano Y, Ferraz ML</AU>
<TI>Comparison of three different schedules of vaccination against hepatitis B in health care workers</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>9</NO>
<PG>791-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7483798"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parish-1991" NAME="Parish 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parish DC, Muecke HW, Joiner TA, Pope WT, Hadler SC</AU>
<TI>Immunogenicity of low-dose intradermal recombinant DNA hepatitis B vaccine</TI>
<SO>Southern Medical Journal</SO>
<YR>1991</YR>
<VL>84</VL>
<NO>4</NO>
<PG>426-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1826567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pennie-1992" NAME="Pennie 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pennie RA, O'Connor AM, Dulberg CS, Bottiglia A, Manga P, Kang CY</AU>
<TI>Low-cost hepatitis B vaccine improves uptake among self-paying health-care students</TI>
<SO>Journal of Medical Virology</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>1</NO>
<PG>48-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1535653"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ricciardi-1990" NAME="Ricciardi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ricciardi G, Graziano G</AU>
<TI>Safety and immunogenicity of an anti-hepatitis-B vaccine obtained using the recombinant DNA technique: results of a longitudinal study in hospital personnel</TI>
<TO>Sicurezza ed immunogenicita di un vaccino anti-epatite B ottenuto con la tecnica del DNA-ricombinante: risultati di un'indagine longitudinale su personale ospedaliero</TO>
<SO>Bollettino dell'Istituto Sieroterapico Milanese</SO>
<YR>1990</YR>
<VL>69</VL>
<NO>2</NO>
<PG>385-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2152297"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soyletir-1992" NAME="Soyletir 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soyletir G, Bahceci E, Akoglu E, Soyogul U, Lawrance RA</AU>
<TI>Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines</TI>
<SO>Vaccine</SO>
<YR>1992</YR>
<VL>10</VL>
<NO>5</NO>
<PG>301-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1533478"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szmuness-1982" NAME="Szmuness 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al</AU>
<TI>Hepatitis B vaccine in medical staff of haemodialysis units: efficacy and subtype cross-protection</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>24</NO>
<PG>1481-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6755247"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turchi-1997" NAME="Turchi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turchi MD, Martelli CM, Ferraz ML, Silva AE, Cardoso DD, Martelli P, et al</AU>
<TI>Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine</TI>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>1997</YR>
<VL>39</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9394531"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-2001" NAME="Williams 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams JL, Christensen CJ, McMahon BJ, Bulkow LR, Cagle HH, Mayers JS, et al</AU>
<TI>Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers</TI>
<SO>Vaccine</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>28-29</NO>
<PG>4081-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11427285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winter-1994" NAME="Winter 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS</AU>
<TI>Influence of smoking on immunological responses to hepatitis B vaccine</TI>
<SO>Vaccine</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>9</NO>
<PG>771-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7975854"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckerman-1997" NAME="Zuckerman 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ</AU>
<TI>Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<NO>7077</NO>
<PG>329-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9040320"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckerman JN</AU>
<TI>Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>Suppl 2</NO>
<PG>13-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9857355"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Levitz-1995" NAME="Levitz 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levitz RE, Cooper BW, Regan HC</AU>
<TI>Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>2</NO>
<PG>88-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7759824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Playford-2002" NAME="Playford 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, et al</AU>
<TI>Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>2</NO>
<PG>87-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11894838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trivello-1995" NAME="Trivello 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trivello R, Chiaramonte M, Ngatchu T, Baldo V, Majori S, Moschen ME, et al</AU>
<TI>Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>2</NO>
<PG>139-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7625106"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weissman-1988" NAME="Weissman 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB</AU>
<TI>Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>260</VL>
<NO>12</NO>
<PG>1734-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2970557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagura-1999" NAME="Yagura 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagura M, Kamitsukasa H, Harada H</AU>
<TI>Comparative studies on immunogenicity of Chinese hamster ovary cell drived HB vaccine and plasma drived HB vaccine</TI>
<SO>Nippon Shokakibyo Gakkai Zasshi</SO>
<YR>1999</YR>
<VL>96</VL>
<NO>1</NO>
<PG>21-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10047688"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-16 18:17:10 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-16 18:17:10 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Assad-1999" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Assad 1999" TYPE="JOURNAL_ARTICLE">
<AU>Assad S, Francis A</AU>
<TI>Over a decade of experience with a yeast recombinant hepatitis B vaccine</TI>
<SO>Vaccine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>1-2</NO>
<PG>57-67</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10501235"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Banatvala-2001" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Banatvala 2001" TYPE="JOURNAL_ARTICLE">
<AU>Banatvala J, Van Damme P, Oehen S</AU>
<TI>Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory</TI>
<SO>Vaccine</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>7-8</NO>
<PG>877-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11115711"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Banatvala-2003" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Banatvala 2003" TYPE="JOURNAL_ARTICLE">
<AU>Banatvala JE, Van Damme P</AU>
<TI>Hepatitis B vaccine - do we need boosters?</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12558904"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benhamou-1999" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Benhamou 1999" TYPE="JOURNAL_ARTICLE">
<AU>Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al</AU>
<TI>Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1302-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertino-1997" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bertino 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bertino JS Jr, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, et al</AU>
<TI>A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>175</VL>
<NO>3</NO>
<PG>678-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9041342"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Brown 2004" NOTES="&lt;p&gt;315    of 16  Next   &lt;/p&gt;&lt;p&gt;1:  Brown P, Cervenakova L. Related Articles, Links  &lt;br&gt; The modern landscape of transfusion-related iatrogenic Creutzfeldt-Jakob disease and blood screening tests.&lt;br&gt;Curr Opin Hematol. 2004 Sep;11(5):351-6. &lt;/p&gt;&lt;p&gt;315    of 16  Next   &lt;/p&gt;&lt;p&gt;Brown P, Cervenakova L.  &lt;br&gt; The modern landscape of transfusion-related iatrogenic Creutzfeldt-Jakob disease and blood screening tests.&lt;br&gt;Curr Opin Hematol. 2004 Sep;11(5):351-6. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:14:30 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Brown P, Cervenakova L</AU>
<TI>The modern landscape of transfusion-related iatrogenic Creutzfeldt-Jakob disease and blood screening tests</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>5</NO>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruguera-1987" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bruguera 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bruguera M, Cremades M, Mayor A, Sanchez Tapias JM, Rodes J</AU>
<TI>Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>Suppl 2</NO>
<PG>155-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3317354"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bryan-1992" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bryan 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bryan JP, Sjogren MH, Perine PL, Legters LJ</AU>
<TI>Low-dose intradermal and intramuscular vaccination against hepatitis B</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>3</NO>
<PG>697-707</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1532914"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bryan-1995" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bryan 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bryan JP, Craig PG, Reyes L, Hakre S, Jaramillo R, Harlan H, et al</AU>
<TI>Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>11</NO>
<PG>978-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8525691"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carmeli-1993" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Carmeli 1993" TYPE="JOURNAL_ARTICLE">
<AU>Carmeli Y, De-Medina T</AU>
<TI>Serious hepatitis B vaccine adverse reactions, are they immune-mediated?</TI>
<SO>Vaccine</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>13</NO>
<PG>1358-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8296488"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDC-1985" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="CDC 1985" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control</AU>
<TI>Epidemiologic notes and reports: Suboptimal response to hepatitis B vaccine given by injection into buttock</TI>
<SO>CDC Surveillance Summaries: Morbidity and Mortality Weekly Report</SO>
<YR>1985</YR>
<VL>34</VL>
<PG>105-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3155822"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CDC-1987" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="CDC 1987" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control</AU>
<TI>Recommendations of the immunization practices advisory committee update on hepatitis B prevention</TI>
<SO>CDC Surveillance Summaries: Morbidity and Mortality Weekly Report</SO>
<YR>1987</YR>
<VL>36</VL>
<NO>23</NO>
<PG>353-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2003" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="CDC 2003" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>CDC vaccine price list (price last updated: May 13, 2003)</TI>
<SO>www.cdc.gov/nip/vfc/cdc_vac_price_list.htm (accessed on May 27, 2003)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cockshott-1982" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Cockshott 1982" TYPE="JOURNAL_ARTICLE">
<AU>Cockshott WP, Thompson GT, Howlett LJ, Seeley ET</AU>
<TI>Intramuscular or intralipomatous injections?</TI>
<SO>New England Journal of Medicine</SO>
<YR>1982</YR>
<VL>307</VL>
<NO>6</NO>
<PG>356-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7088101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crosnier-1981" NAME="Crosnier 1981" TYPE="JOURNAL_ARTICLE">
<AU>Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al</AU>
<TI>Randomised placebo-controlled trial of hepatitis B surface Ag vaccine in French haemodialysis units: I, medical staff</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8218</NO>
<PG>455-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6110088"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dahl_x002d_Hansen-1990" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Dahl-Hansen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Dahl-Hansen E, Siebke JC, Froland SS, Degre M</AU>
<TI>Immunogenicity of yeast-derived hepatitis B vaccine from two different producers</TI>
<SO>Epidemiology and Infection</SO>
<YR>1990</YR>
<VL>104</VL>
<NO>1</NO>
<PG>143-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2137785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3616287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3802833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egemen-1998" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Egemen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Egemen A, Aksit S, Kurugol Z, Erensoy S, Bilgic A, Akilli M</AU>
<TI>Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>16</NO>
<PG>1511-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9711797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Emini-1986" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Emini 1986" TYPE="JOURNAL_ARTICLE">
<AU>Emini EA, Ellis RW, Miller WJ, McAleer WJ, Scolnick EM, Gerety RJ</AU>
<TI>Production and immunological analysis of recombinant hepatitis B vaccine</TI>
<SO>The Journal of Infection</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>Suppl A</NO>
<PG>3-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2427590"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fessard-1988" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Fessard 1988" TYPE="JOURNAL_ARTICLE">
<AU>Fessard C, Riche O, Cohen JHM</AU>
<TI>Intramuscular versus subcutaneous injection for hepatitis B vaccine</TI>
<SO>Vaccine</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>6</NO>
<PG>469</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2977459"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Francis-1986" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Francis 1986" TYPE="JOURNAL_ARTICLE">
<AU>Francis DP, Feorino PM, McDougal S, Warfield D, Getchell J, Cabradilla C, et al</AU>
<TI>The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture</TI>
<SO>JAMA</SO>
<YR>1986</YR>
<VL>256</VL>
<NO>7</NO>
<PG>869-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3016352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gesemann-1995" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gesemann 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gesemann M, Scheiermann N</AU>
<TI>Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>5</NO>
<PG>443-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7639012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gluud 2001" TYPE="BOOK_SECTION">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>Falk Symposium 121</SO>
<YR>2001</YR>
<PG>322-42</PG>
<ED>Leuschner U, James OFW, Dancygier H</ED>
<PB>Kluwer Academic Publisher</PB>
<CY>Lancaster</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grady-1978" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Grady 1978" TYPE="JOURNAL_ARTICLE">
<AU>Grady GF, Lee VA, Prince AM, Gitnick GL, Fawaz KA, Vyas GN, et al</AU>
<TI>Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1978</YR>
<VL>138</VL>
<NO>5</NO>
<PG>625-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="361899"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-1996" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Greenberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg DP, Vadheim CM, Wong VK, Marcy SM, Partridge S, Greene T, et al</AU>
<TI>Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>7</NO>
<PG>590-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8823852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Grotto-1998" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Grotto 1998" TYPE="JOURNAL_ARTICLE">
<AU>Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J</AU>
<TI>Major adverse reactions to yeast-derived hepatitis B vaccines--a review</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>329-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9607051"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1995" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gupta 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gupta RK, Siber GR</AU>
<TI>Adjuvants for human vaccines--current status, problems and future prospects</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>14</NO>
<PG>1263-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8585280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hadler-1986" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hadler 1986" TYPE="JOURNAL_ARTICLE">
<AU>Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al</AU>
<TI>Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>315</VL>
<NO>4</NO>
<PG>209-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2941687"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hammond-1991" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hammond 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hammond GW, Parker J, Mimms L, Tate R, Sekla L, Minuk G</AU>
<TI>Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines</TI>
<SO>Vaccine</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>2</NO>
<PG>97-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1829306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harris-1991" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Harris 1991" TYPE="JOURNAL_ARTICLE">
<AU>Harris AA, Daly-Gawenda D, Hudson EK</AU>
<TI>Vaccine choice and program participation rates when two hepatitis B vaccines are offered</TI>
<SO>Journal of Occupational Medicine</SO>
<YR>1991</YR>
<VL>33</VL>
<NO>7</NO>
<PG>804-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1832443"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heijtink-2000" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Heijtink 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heijtink RA, van Bergen P, Paulij WP, de Man RA, Osterhaus AD</AU>
<TI>Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>15</NO>
<PG>1531-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10618551"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heijtink-2002" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Heijtink 2002" TYPE="JOURNAL_ARTICLE">
<AU>Heijtink RA, Kruining J, van Bergen P, de Rave S, van Hattum J, Schutten M, et al</AU>
<TI>Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine</TI>
<SO>Journal of Medical Virology</SO>
<YR>2002</YR>
<VL>66</VL>
<NO>3</NO>
<PG>304-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11793381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heineman-1999" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Heineman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heineman TC, Clements-Mann ML, Poland GA, Jacobson RM, Izu AE, Sakamoto D, et al</AU>
<TI>A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant</TI>
<SO>Vaccine</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>22</NO>
<PG>2769-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10438046"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm [accessed 16th August 2005]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-1999" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hsu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL</AU>
<TI>Abstract Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>5</NO>
<PG>1312-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>Code of Federal Regulations &amp; International Conference on Harmonization Guidelines</SO>
<YR>1997</YR>
<PB>Parexel Barnett</PB>
<CY>Media</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iwarson-1977" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Iwarson 1977" TYPE="JOURNAL_ARTICLE">
<AU>Iwarson S, Ahlmen J, Eriksson E, Hermodsson S, Kjellman H, Ljunggren C, et al</AU>
<TI>Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1977</YR>
<VL>135</VL>
<NO>3</NO>
<PG>473-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="321704"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-1997" MODIFIED="2008-10-16 18:16:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Jefferson 1997" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M</AU>
<TI>Vaccines for preventing hepatitis B in health-care workers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-16 18:16:31 +0100" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-10-16 18:16:31 +0100" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD000100.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jilg-1988" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Jilg 1988" TYPE="JOURNAL_ARTICLE">
<AU>Jilg W, Schmidt M, Deinhardt F</AU>
<TI>Persistence of specific antibodies after hepatitis B vaccination</TI>
<SO>Journal of Hepatology</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>2</NO>
<PG>201-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2970501"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Just-1987" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Just 1987" TYPE="JOURNAL_ARTICLE">
<AU>Just M, Berger R, Just V</AU>
<TI>Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>Suppl 2</NO>
<PG>121-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3317346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11730399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lai-1998" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lai 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al</AU>
<TI>A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>2</NO>
<PG>61-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2005" MODIFIED="2008-10-16 18:16:13 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lee 2005" TYPE="COCHRANE_REVIEW">
<AU>Lee C, Gong Y, Brok J, Boxall EH, Gluud C</AU>
<TI>Hepatitis B prophylaxis for newborns of hepatitis B surface antigen-positive mothers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-16 18:15:59 +0100" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-10-16 18:15:59 +0100" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD004790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leroux_x002d_Roels-2000" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Leroux-Roels 2000" TYPE="JOURNAL_ARTICLE">
<AU>Leroux-Roels G, Abraham B, Fourneau M, De Clercq N, Safary A</AU>
<TI>A comparison of two commercial recombinant vaccines for hepatitis B in adolescents</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>7-8</NO>
<PG>937-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11115719"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leung-2002" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Leung 2002" TYPE="JOURNAL_ARTICLE">
<AU>Leung N</AU>
<TI>Clinical experience with lamivudine</TI>
<SO>Seminars in Liver Disease</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marsano-1996" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Marsano 1996" TYPE="JOURNAL_ARTICLE">
<AU>Marsano LS, Greenberg RN, Kirkpatrick RB, Zetterman RK, Christiansen A, Smith DJ, et al</AU>
<TI>Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>1</NO>
<PG>111-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8561109"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maynard-1990" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Maynard 1990" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:14:30 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Maynard JE</AU>
<TI>Hepatitis B: global importance and need for control</TI>
<SO>Vaccine</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>Suppl</NO>
<PG>S18-S20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2139281"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McMahon-1992" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="McMahon 1992" TYPE="JOURNAL_ARTICLE">
<AU>McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K</AU>
<TI>Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons</TI>
<SO>American Journal of Medicine</SO>
<YR>1992</YR>
<VL>92</VL>
<NO>3</NO>
<PG>254-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1532114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitsui-1989" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Mitsui 1989" TYPE="JOURNAL_ARTICLE">
<AU>Mitsui T, Iwano K, Suzuki S, Yamazaki C, Masuko K, Tsuda F, et al</AU>
<TI>Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls</TI>
<SO>Hepatology</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>3</NO>
<PG>324-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2527191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9746022"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Odaka-1988" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Odaka 1988" TYPE="JOURNAL_ARTICLE">
<AU>Odaka N, Eldred L, Cohn S, Munoz A, Fields HA, Fox R, et al</AU>
<TI>Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>260</VL>
<NO>24</NO>
<PG>3635-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2973531"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ott-1995" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Ott 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G</AU>
<TI>MF59. Design and evaluation of a safe and potent adjuvant for human vaccines</TI>
<SO>Pharmaceutical Biotechnology</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>277-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7551221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmovic-1987" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Palmovic 1987" TYPE="JOURNAL_ARTICLE">
<AU>Palmovic D</AU>
<TI>Prevention of hepatitis B infection in health care workers after accidental exposure</TI>
<SO>The Journal of Infection</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>3</NO>
<PG>221-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2961815"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Panda-1991" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Panda 1991" TYPE="JOURNAL_ARTICLE">
<AU>Panda SK, Ramesh R, Rao KV, Gupta A, Zuckerman AJ, Nayak NC</AU>
<TI>Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants</TI>
<SO>Journal of Medical Virology</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>4</NO>
<PG>297-302</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1802958"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pillot-1995" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Pillot 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M, et al</AU>
<TI>Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>3</NO>
<PG>289-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7631515"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pineau-1992" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Pineau 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pineau A, Durand C, Guillard O, Bureau B, Stalder JF</AU>
<TI>Role of aluminium in skin reactions after diphtheria-tetanus-pertussis-poliomyelitis vaccination: an experimental study in rabbits</TI>
<SO>Toxicology</SO>
<YR>1992</YR>
<VL>73</VL>
<NO>1</NO>
<PG>117-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1589878"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roome-1993" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Roome 1993" TYPE="JOURNAL_ARTICLE">
<AU>Roome AJ, Walsh SJ, Cartter ML, Hadler JL</AU>
<TI>Hepatitis B vaccine responsiveness in Connecticut public safety personnel</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<NO>24</NO>
<PG>2931-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8254852"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scheiermann-1990" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Scheiermann 1990" TYPE="JOURNAL_ARTICLE">
<AU>Scheiermann N, Gesemann M, Maurer C, Just M, Berger R</AU>
<TI>Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules</TI>
<SO>Vaccine</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>Suppl</NO>
<PG>S44-S46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2139282"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schroth-2004" MODIFIED="2008-10-16 18:17:10 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schroth 2004" NOTES="&lt;p&gt;Schroth RJ, Hitchon CA, Uhanova J, Noreddin A, Taback SP, Moffatt MEK, Zacharias JM. Hepatitis B vaccination for patients with chronic renal failure. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003775.pub2. DOI: 10.1002/14651858.CD003775.pub2.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:17:10 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="COCHRANE_REVIEW">
<AU>Schroth RJ, Hitchon CA, Uhanova J, Noreddin A, Taback SP, Moffatt MEK, et al</AU>
<TI>Hepatitis B vaccination for patients with chronic renal failure</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3 10.1002/14651858.CD003775.pub2</NO>
<IDENTIFIERS MODIFIED="2008-10-16 18:17:03 +0100" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-10-16 18:17:03 +0100" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD003775.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 18:14:30 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seaworth-1988" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Seaworth 1988" TYPE="JOURNAL_ARTICLE">
<AU>Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J</AU>
<TI>Hepatitis B vaccines in patients with chronic renal failure before dialysis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>157</VL>
<NO>2</NO>
<PG>332-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2961818"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-1999" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Singh 1999" TYPE="JOURNAL_ARTICLE">
<AU>Singh M, O'Hagan D</AU>
<TI>Advances in vaccine adjuvants</TI>
<SO>Nature Biotechnology</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1075-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10545912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stephenne-1988" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Stephenne 1988" TYPE="JOURNAL_ARTICLE">
<AU>Stephenne J</AU>
<TI>Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness</TI>
<SO>Vaccine</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>4</NO>
<PG>299-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2973187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Szmuness-1981" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Szmuness 1981" TYPE="JOURNAL_ARTICLE">
<AU>Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner AA</AU>
<TI>A controlled clinical trial of the efficacy of the hepatitis B vaccine: a final report</TI>
<SO>Hepatology</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>5</NO>
<PG>377-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7030902"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tabor-1983" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Tabor 1983" TYPE="JOURNAL_ARTICLE">
<AU>Tabor E, Buynak E, Smallwood LA, Snoy P, Hilleman M, Gerety RJ</AU>
<TI>Inactivation of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin</TI>
<SO>Journal of Medical Virology</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6403664"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Traquina-1996" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Traquina 1996" TYPE="JOURNAL_ARTICLE">
<AU>Traquina P, Morandi M, Contorni M, Van Nest G</AU>
<TI>MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>6</NO>
<PG>1168-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8940205"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-U.S.-PHS-2001" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="U.S. PHS 2001" TYPE="JOURNAL_ARTICLE">
<AU>U.S. Public Health Service</AU>
<TI>Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis</TI>
<SO>Recommendations and Reports: Morbidity and Mortality Weekly Report</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>RR-11</NO>
<PG>1-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11442229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukena-1985" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Ukena 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ukena T, Esber H, Bessette R, Parks T, Crocker B, Shaw FE Jr</AU>
<TI>Site of injection and response to hepatitis B vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1985</YR>
<VL>313</VL>
<NO>9</NO>
<PG>579-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3160952"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wainwright-1997" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Wainwright 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ</AU>
<TI>Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>175</VL>
<NO>3</NO>
<PG>674-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9041341"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-1993" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Wood 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT</AU>
<TI>Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers</TI>
<SO>JAMA</SO>
<YR>1993</YR>
<VL>270</VL>
<NO>24</NO>
<PG>2935-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8254853"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xia-2002" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Xia 2002" TYPE="JOURNAL_ARTICLE">
<AU>Xia G, Jia Z, Yan T, Li R, Liu H, Xu Z, et al</AU>
<TI>Long-term efficacy and persistence of Chinese infants after receiving only active plasma-derived hepatitis B vaccine</TI>
<SO>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>2</NO>
<PG>146-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12196826"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-2001" MODIFIED="2008-10-16 18:14:31 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Young 2001" TYPE="JOURNAL_ARTICLE">
<AU>Young MD, Rosenthal MH, Dickson B, Du W, Maddrey WC</AU>
<TI>A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine</TI>
<SO>Vaccine</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>25-26</NO>
<PG>3437-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11348708"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Averhoff-1998">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (single blinding of participants only).<BR/>Withdrawal: seven participants in the Recombinvax HB group and four participants in the Engerix B group.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>health-care workers with no prior history of hepatitis B vaccination.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) Recombinvax HB group (n = 891)<BR/>Mean age (years): 41.9.<BR/>Male/female: 223/668.<BR/>Race (%): Black 41%, White 57%, Other 2%.<BR/>Positive smoking status (%): 30%.<BR/>Presence of chronic disease (%): 13%.<BR/>Obesity (%): 29%.<BR/>(2) Engerix B group (n = 874)<BR/>Mean age (years): 41.2.<BR/>Male/female: 201/673.<BR/>Race (%): Black 46%, White 53%, Other 1%.<BR/>Positive smoking status (%): 30%.<BR/>Presence of chronic disease (%): 14%.<BR/>Obesity (%): 32%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Recombinvax HB group:<BR/>Three injections of 10 µg Recombivax HB (yeast-derived vaccine) in the deltoid muscle at 0, 1, and 6 months.</P>
<P>Engerix B group:<BR/>Three injections of 20 µg Engerix B (yeast-derived vaccine) in the deltoid muscle at 0, 1, and 6 months.</P>
<P>Booster vaccination<BR/>Participants who did not acquire protective anti-HBs level after completion of the primary series were offered one additional dose of vaccine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level after the completion of vaccination.<BR/>Number of non-responders with protective anti-HBs level after booster vaccination.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: nine months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chan-1992">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: nine participants in Group I, 20 participants in Group II, and 12 participants in Group III.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Taiwan, China.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) seronegative for antibody to hepatitis B core antigen;<BR/>(2) hospital personnel.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants<BR/>(1) Group I (n = 100)<BR/>no further information.<BR/>(2) Group II (n = 100)<BR/>no further information.<BR/>(3) Group III (n = 100)<BR/>no further information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group I:<BR/>Four injections of 5 µg PDV administered intramuscularly in the deltoid muscle at 0, 1, 2, and 12 months.</P>
<P>Group II:<BR/>Four injections of 2 µg PDV administered intramuscularly in the deltoid muscle at 0, 1, 2, and 12 months.</P>
<P>Group III:<BR/>Four injections of 1 µg PDV administered intramuscularly in the deltoid muscle at 0, 1, 2, and 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level during four years follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: four years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Coleman-1991">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: inadequate (no information).<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) employee staff of the North Arundel Hospital; (2) paramedics, dentists, dental assistants, and physical therapists from community health-care groups.</P>
<P>Exclusion criteria:<BR/>(1) immunosuppressive illnesses or taking immunosuppressive medications (including daily non-steroidal anti-inflammatory drugs or corticosteroids);<BR/>(2) pregnancy;<BR/>(3) previous hepatitis B vaccine or hepatitis B immune globulin;<BR/>(4) serum positive with anti-HBc or anti-HBs.</P>
<P>Participants:<BR/>(1) Intradermal group (n = 216)<BR/>Male/female: 75/141.<BR/>Mean age (years +/- standard deviation): 37 +/- 10.1.</P>
<P>(2) Intramuscular group (n = 209)<BR/>Male/female: 63/146.<BR/>Mean age (years +/- standard deviation): 36 +/- 11.0.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 2 µg PDV administered intradermally in the upper arm at 0, 1, and 6 months.</P>
<P>Intramuscular group:<BR/>Three injections of 20 µg PDV administered intramuscularly in the forearm at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at two years follow-up.<BR/>Adverse events after each vaccine injection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: two years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Crosnier-1981">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: adequate (mentioned in publication).<BR/>Withdrawal: twenty participants in the PDV group and 16 participants in the placebo group.<BR/>Sample size calculation: minimum of 61 health-care workers per group would be necessary to demonstrate a reduction of the incidence rate of HBV infections from 15% to 1% during a period of 12 months, with type I error 5% and type II error 5%.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: France.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>the permanent staff of dialysis, transplant, and nephrology units exposed to the risk of hepatitis B virus infections.</P>
<P>Exclusion criteria:<BR/>(1) previous hepatitis B virus infection;<BR/>(2) positive initial blood specimen for HBsAg and/or anti-HBc and/or anti-HBs, and/or aminotransferase activities above 50 IU/liter;<BR/>(3) injection of hepatitis immune globulin in the past four months; <BR/>(4) likely follow-up of less than 12 months; <BR/>(5) contraindications to vaccinations, including pregnancy.</P>
<P>Participants:<BR/>(1) PDV group (n = 184)<BR/>Mean age (year +/- standard deviation): 29.8 +/- 9.5.<BR/>Male/female: 59/125.<BR/>Staff category (%): Nurses 31%, Physician 19%, Nurses' aids 24%, Laboratory personnel 22%, Other 4%.<BR/>Personnel exposed to the risk for less than two years (%): 70%.<BR/>Other vaccination in the past three months (%): 15%.</P>
<P>(2) Placebo group (n = 170)<BR/>Mean age (year +/- standard deviation): 28.5 +/- 7.4.<BR/>Male/female: 46/124.<BR/>Staff category (%): Nurses 37%, Physician 17%, Nurses' aids 22%, Laboratory personnel 22%, Other 2%.<BR/>Personnel exposed to the risk for less than two years (%): 69%.<BR/>Other vaccination in the past three months (%): 14%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PDV group:<BR/>Three injections of 5 µg PDV subcutaneously at monthly intervals.</P>
<P>Placebo group:<BR/>Three injection of placebo (aluminium hydroxide in buffered solution) subcutaneously at monthly intervals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of hepatitis B events at follow-up.<BR/>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: one year.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-de-Lalla-1988">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) hospital workers; <BR/>(2) negative for all hepatitis B serological markers.</P>
<P>Exclusion criteria:<BR/>(1) no information.</P>
<P>Participants:<BR/>(1) Intradermal group (n = 76)<BR/>Male/female: 10/66.<BR/>Mean age (years +/- standard deviation): 26.3 +/- 6.8.</P>
<P>(2) Intramuscular group (gluteal) (n = 71)<BR/>Male/female: 7/64.<BR/>Mean age (years +/- standard deviation): 26.8 +/- 6.6.</P>
<P>(3) Intramuscular group (deltoid) (n = 75)<BR/>Male/female: 8/67.<BR/>Mean age (years +/- standard deviation): 26.7 +/- 6.6.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 2 µg PDV administered intradermally in the upper arm at 0, 1, and 6 months.</P>
<P>Intramuscular (gluteal) group:<BR/>Three injections of 20 µg PDV administered intramuscularly in the buttock at 0, 1, and 6 months.</P>
<P>Intramuscular (deltoid) group:<BR/>Three injections of 20 µg PDV administered intramuscularly in the upper arm at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.<BR/>Anti-HBs level at follow-up.<BR/>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: one year.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Desmyter-1983">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: adequate (coded vials).<BR/>Double blinding: adequate (placebo used).<BR/>Withdrawal: five participants in the PDV group and 10 participants in the placebo group.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) staff in 18 Belgian dialysis units that collaborated in a transplantation program;<BR/>(2) absence of acute illness or pregnancy;<BR/>(3) absence, one or two months before randomisation, of markers of present or past hepatitis B infection, i.e., HBsAg, antibody against HBc antigen, serum alanine aminotransferase &lt; 50 IU/liter; <BR/>(4) ability and willingness to give written informed consent.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) PDV group (n = 76)<BR/>Mean male age (years +/- standard deviation): 32 +/- 8.<BR/>Male/female: 24/49.<BR/>Mean day injection 2: 30 +/-3.<BR/>Mean day injection 3: 63 +/-6.<BR/>HBIG &lt; or = six months before day 0: 13.<BR/>Transfusion &lt; or = six months before day 0: 0.<BR/>Low, passive anti-HBs day 0: 12.<BR/>Loss to follow-up: 2.<BR/>Death: 0.<BR/>HBIG given: 5.<BR/>Transfusion given: 0.</P>
<P>(2) Placebo group (n = 76)<BR/>Mean male age (years +/- standard deviation): 33 +/- 8.<BR/>Male/female: 25/50.<BR/>Mean day injection 2: 31 +/-3.<BR/>Mean day injection 3: 64 +/-6.<BR/>HBIG &lt; or = six months before day 0: 14.<BR/>Transfusion &lt; or = six months before day 0: 0.<BR/>Low, passive anti-HBs day 0: 14.<BR/>Loss to follow-up: 9.<BR/>Death: 0.<BR/>HBIG given: 7.<BR/>Transfusion given: 0.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PDV group: <BR/>Three intramuscular injections of 3 µg PDV at 0, 1, and 2 months.</P>
<P>Placebo group<BR/>Three intramuscular injections of placebo at 0, 1, and 2 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of hepatitis B events at maximum follow-up. <BR/>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: 14 to 16 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dienstag-1984">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: adequate (placebo used).<BR/>Withdrawal: 13 participants in the PDV group and 11 participants in the placebo group.<BR/>Sample size calculation: minimum sample size of 500 vaccine recepients and 500 placebo recipients would be required to show the efficacy of hepatitis B vaccine during 18 months' follow-up with a power of 0.8 and a level of significance of less than 0.05.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) frequent, intimate exposure to patients' blood and blood-contaminated instruments;<BR/>(2) no history of hepatitis B or chronic liver disease;<BR/>(3) no serologic markers of current or past hepatitis B virus infection (HBsAg, anti-HBs, or anti-HBc);<BR/>(4) an alanine aminotransferase level less than 45 IU/liter in a serum sample obtained within two weeks before entry into the trial.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) PDV group (n = 666)<BR/>Mean age (years +/- standard deviation): 31.3 +/- 8.4.<BR/>Male/female: 317/349.<BR/>Time in occupation (months +/- standard deviation): 76.5 +/- 90.2.<BR/>Recent hepatitis B exposure (%): 32.7%.<BR/>Recent transfusion (%): 5.4%.</P>
<P>(2) Placebo group (n = 664)<BR/>Mean age (years +/- standard deviation): 31.2 +/- 8.2.<BR/>Male/female: 315/349.<BR/>Time in occupation (months +/- standard deviation): 78.0 +/- 88.3.<BR/>Recent hepatitis B exposure (%): 35.4%.<BR/>Recent transfusion (%): 4.5%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PDV group:<BR/>Three intramuscular injections with 20 µg PDV at 0, 1, and 6 months.</P>
<P>Placebo group:<BR/>Three intramuscular injections with placebo at 0, 1, and 6 months.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of hepatitis B events at maximum follow-up. <BR/>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: 13.2 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gonzalez-1990">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: one participant from the intradermal group.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Spain.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>healthy hospital personnel of 20 to 40 years of age with normal transaminase values and adequate weight for height (no more than 10% overweight).</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) Intradermal group (n = 33)<BR/>Male/female: 15/18.</P>
<P>(2) Intramuscular group (n = 36)<BR/>Male/female: 18/18.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 2 µg RV (yeast-derived) administered intradermally in the volar skin of the upper arm at 0, 1, and 6 months.</P>
<P>Intramuscular group:<BR/>Three injections of 20 µg RV (yeast-derived) administered intramuscularly in the deltoid or triceps muscle at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level.<BR/>Local adverse events.<BR/>Systematic adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: eight months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Halliday-1990">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: adequate (coded boxes).<BR/>Double blinding: adequate (placebo used).<BR/>Withdrawal: a total of 43 participants from the RV group and 12 participants from the PDV group.<BR/>Sample size calculation: it was calculated at the conventional 5% significance level, a 90% chance of detecting a difference as small as 5% between RV and PDV.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) healthy health-care workers who were negative for hepatitis B markers (HBs Ag, anti-HBs, anti-HBc); <BR/>(2) alanine aminotransferase level below 50 IU/liter; <BR/>(3) had not received immune globulin or HBIG within six months of the first injection;<BR/>(4) did not have any condition or medication that might influnence either the side effects or the antibody response.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) RV group (n = 200)<BR/>no detailed information.</P>
<P>(2) PDV group (n = 600)<BR/>no detailed information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RV group:<BR/>Three injections of 20 µg doses RV (mammalian cell-derived) administered intramuscularly in the upper arm at 0, 1, and 6 months.</P>
<P>PDV group:<BR/>Three injections of 20 µg doses PDV administered intramuscularly in the upper arm at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.<BR/>Adverse events after each injection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heijtink-1989">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>negative for anti-HBc and anti-HBs.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) Intradermal group (n = 82)<BR/>Mean age (years +/- standard deviation): 23.0 +/- 0.5.<BR/>Male/female: 40/42.</P>
<P>(2) Intramuscular group (n = 83)<BR/>Mean age (years +/- standard deviation): 23.2 +/- 0.4.<BR/>Male/female: 44/39.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Four injections of 2 µg RV (yeast-derived) in 0.1ml solution administered intradermally in the volar skin of the upper arm at 0, 1, 2, and 6 months.</P>
<P>Intramuscular group:<BR/>Four injections of 2 µg RV (yeast-derived) administered intramuscularly in the deltoid or triceps muscle at 0, 1, 2, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Henderson-2000">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: a total of 19 participants in the intradermal group and 20 participants in the intramuscular group.<BR/>Sample size calculation: not performed.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>full- or part-time hospital staff with patient contact and contact with blood or blood products.</P>
<P>Exclusion criteria:<BR/>(1) previous hepatitis B vaccination or with anti-HBs;<BR/>(2) underlying liver disease;<BR/>(3) routinely excluded from a standard intramuscular protocol of vaccination (e.g., history of allergies to vaccine components) or who developed symptoms of hypersensitivity during the vaccination series.</P>
<P>PARTICIPANT:<BR/>(1) Intradermal group (n = 91)<BR/>Male/female: 16/75.</P>
<P>(2) Intramuscular group (n = 89)<BR/>Male/female: 7/82.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 3 µg RV (yeast-derived) administered intradermally in the forearm at 0, 1, and 6 months.</P>
<P>Intramuscular group:<BR/>Three injections of 20 µg RV (yeast-derived) administered intramuscularly in the upper arm at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at two years follow-up.<BR/>Adverse events after each injection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: two years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Oliveira-1995">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Brazil.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) hospital personnel;<BR/>(2) seronegative for anti-HBc.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>PARTICIPANT:<BR/>(1) Group A (n = 103)<BR/>Median age (years): 27.<BR/>Male/female: 50/53.</P>
<P>(2) Group B (n = 97)<BR/>Median age (years): 27.<BR/>Male/female: 40/57.</P>
<P>(3) Group C (n = 100)<BR/>Median age (years): 26.<BR/>Male/female: 47/53.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A:<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route in the deltoid muscle at 0, 1, and 6 months.</P>
<P>Group B:<BR/>The first injection of 2 µg RV (yeast-derived) by the intradermal route at 0 month, and the second and the third injections of 20 µg by the intramuscular route in the deltoid muscle at 1 and 6 months.</P>
<P>Group C:<BR/>The first and the second injections of 2 µg RV (yeast-derived) by the intradermal route at 0 and 1 month, and the third injection of 20 µg by the intramuscular route in the deltoid muscle at 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: eight months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Parish-1991">
<CHAR_METHODS>
<P>Generation of allocation sequence: adequate (random number table).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: a total of 11 participants from the intradermal group and eight participants from the intramuscular group.<BR/>Sample size calculation: it was based on an 80% power of identifying a 10% decrease in overall response rate in any group, and a greater than 95% power of detecting such a response in both intradermal groups using a significance level of 0.05.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>healthy hospital employees and medical students who had no previous hepatitis B infection.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) Intradermal group (n = 47)<BR/>Mean age (years): 30.<BR/>Male/female: 14/33.</P>
<P>(2) Intramuscular group (n = 37)<BR/>Mean age (years): 30.<BR/>Male/female: 18/19.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 1 µg RV (yeast-derived) in 0.1ml solution administered intradermally at 0, 1, and 6 months.</P>
<P>Intramuscular group:<BR/>Three injections of 10 µg RV (yeast-derived) administered intramuscularly at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level one month at follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pennie-1992">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: adequate (performed).<BR/>Withdrawal: a total of 38 participants in the Korean PDV group and 34 participants in the American PDV group.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>healthy medical students.</P>
<P>Exclusion criteria:<BR/>(1) age less than 17 years;<BR/>(2) poor general health;<BR/>(3) current immunosuppression or pregnancy;<BR/>(4) past severe reaction to any vaccine;<BR/>(5) previous doses of hepatitis B vaccine or HBIG;<BR/>(6) previous known positive tests for hepatitis B virus.</P>
<P>Participants:<BR/>(1) Korean PDV group (n = 349)<BR/>Median age (years): 21.<BR/>Male/female: 82/267.<BR/>Program of study (%): Ambulance &amp; Emergency 3.7%, Dental Assistant 5.4%, Medicine 18.3%, Medical Technology 8.7%, Nursing 55.3%, Rehabilitation Therapy 8.6%.<BR/>Race (%): White 90.8%, Black 3.2%, Oriental 2.3%, West Asian 3.7%.</P>
<P>(2) American PDV group (n = 344)<BR/>Median age (years): 21.<BR/>Male/female: 88/256.<BR/>Program of study (%): Ambulance &amp; Emergency 3.5, Dental Assistant 4.4%, Medicine 17.4%, Medical Technology 9.5%, Nursing 57.0%, Rehabilitation Therapy 8.2%.<BR/>Race (%): White 85.2%, Black 6.1%, Oriental 3.2%, West Asian 5.5%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Korean PDV group:<BR/>Three injections of 20 µg Korean PDV injected intramuscularly in the deltoid muscle of at 0, 1, and 6 months.</P>
<P>American PDV group:<BR/>Three injections of 20 µg American PDV injected intramuscularly in the deltoid muscle of at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ricciardi-1990">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (no information).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy.<BR/>Publication language: Italian.</P>
<P>Inclusion criteria:<BR/>healthy health-care workers.</P>
<P>Exclusion criteria:<BR/>seropositive for anti-HBc or had abnormal results in liver function tests.</P>
<P>Participants:<BR/>(1) Rapid schedule group (n = 59)<BR/>Male/female: 18/41.</P>
<P>(2) Standard schedule group (n = 56)<BR/>Male/female: 17/39.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rapid scheduel group<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route at 0, 1, and 2 months. </P>
<P>Standard scheduel group:<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Soyletir-1992">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (not performed).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Turkey.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) seronegative for HBsAg, anti-HBs, and anti-HBc;<BR/>(2) medical students studying at Marmara University Medical School.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) RV group (n = 21)<BR/>no information.</P>
<P>(2) PDV group (n = 24)<BR/>no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>RV group:<BR/>Three injections of 2 µg RV (yeast-derived) administered intradermally in the upper arm at 0, 1, and 6 months.</P>
<P>PDV group:<BR/>Three injections of 2 µg PDV administered intradermally in the upper arm at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.<BR/>Adverse events after each injection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Szmuness-1982">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: adequate (coded vial).<BR/>Double blinding: adequate (performed).<BR/>Withdrawal: a total of 203 participants in the PDV group and 180 participants in the placebo group.<BR/>Sample size calculation: no reported.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) staff members from 43 hemodialysis units located throughout the eastern United States of America;<BR/>(2) serologically negative for HBsAg, anti-HBs, and anti-HBc;<BR/>(3) serum alanine aminotransferase level within the normal range (&lt;45 IU/liter).</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) PDV group (n = 441)<BR/>Male/female: 125/316.<BR/>Age: &lt;25 years 110, 25-34 years 216, &gt; 34 years 115.<BR/>Job category: Physician 47, Nurse 260, Technician 102, Other 32.<BR/>Time in dialysis units: &lt; one year 212, &gt; or = one year 226.</P>
<P>(2) Placebo group (n = 419)<BR/>Male/female: 89/330.<BR/>Age: &lt;25 years 110, 25-34 years 201, &gt; 34 years: 108.<BR/>Job category: Physician 39, Nurse 260, Technician 91, Other 29.<BR/>Time in dialysis units: &lt; one year 183, &gt; or = one year 232.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>PDV group:<BR/>Three intramuscular injections of 20 µg PDV at 0, 1, and 6 months.</P>
<P>Placebo group<BR/>Three intramuscular injections of placebo at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of hepatitis B events at maximum follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: two years.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Turchi-1997">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (single blinding of anti-HBs assessment).<BR/>Withdrawal: a total of 14 participants from the intradermal group and 21 participants from the intramuscular group.<BR/>Sample size calculation: 90 participants was needed to ensure that there would be at least 90% power to detect a difference of 15% with alpha level of 0.025 (one-sided).<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Brazil.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) seronegative for anti-HBc;<BR/>(2) healthy medical or nurse students;<BR/>(3) no previous hepatitis B vaccination.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants<BR/>(1) Intradermal group (n = 98)<BR/>Mean age (year +/- standard deviation): 20.1 +/- 1.8.<BR/>Male/female: 47/51.<BR/>Body mass index (mean +/- standard deviation): 21.4 +/- 2.5.<BR/>Current smokers (%): 1.0%.</P>
<P>(2) Intramuscular group (n = 114)<BR/>Mean age (year +/- standard deviation): 20.0 +/- 1.9.<BR/>Male/female: 46/68.<BR/>Body mass index (mean +/- standard deviation): 21.1 +/- 2.2.<BR/>Current smokers (%): 1.8%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intradermal group:<BR/>Three injections of 2 µg RV (yeast-derived) by the intradermal route at 0, 1, and 6 months.</P>
<P>Intramuscular group:<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route in the deltoid muscle at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.<BR/>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williams-2001">
<CHAR_METHODS>
<P>Generation of allocation sequence: adequate (computer-generated).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (single blinding of anti-HBs assessment).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: not reported.<BR/>Intention-to-treat: not stated and but used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United States of America.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>(1) previous administration, as an adult, of three doses of hepatitis B vaccine with at least a one-month interval between the first and last dose, and it had been at least three years since the last dose with no additional vaccine dose administered;<BR/>(2) post vaccination anti-HBs level above 10 IU/liter by radioimmunoassay or a positive test for anti-HBs by enzyme immunoassay within 12 months of the third vaccine dose;<BR/>(3) negative HBs antigen and anti-HBc.</P>
<P>Exclusion criteria: <BR/>health-care workers having an anti-HBs level above 50 IU/liter.</P>
<P>Participants:<BR/>(1) For the primary vaccine series, the mean time between first dose and third dose: 6.8 months.<BR/>The mean time from the first dose to post vaccination anti-HBs testing was 12 months.<BR/>(2) The mean age of participants at the time of booster dose was 46.7 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A:<BR/>One injection of 2.5 µg RV (yeast-derived) by the intramuscular route. </P>
<P>Group B:<BR/>One injection of 10 µg RV (yeast-derived) by the intramuscular route.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at the maximum follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: one year.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Winter-1994">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: inadequate (no information).<BR/>Withdrawal: six participants from the rapid schedule group and one participant from the standard schedule group.<BR/>Sample size calculation: not performed.<BR/>Intention-to-treat: not stated and not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United Kingdom.<BR/>Publication language: English.</P>
<P>Inclusion criteria:<BR/>healthy health-care workers.</P>
<P>Exclusion criteria:<BR/>no information.</P>
<P>Participants:<BR/>(1) Rapid schedule group (n = 59)<BR/>Male/female: 18/41.</P>
<P>(2) Standard schedule group (n = 56)<BR/>Male/female: 17/39.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rapid scheduel group:<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route at 0, 1, and 2 months. </P>
<P>Standard scheduel group:<BR/>Three injections of 20 µg RV (yeast-derived) by the intramuscular route at 0, 1, and 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of health-care workers without protective anti-HBs level at follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: seven months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zuckerman-1997">
<CHAR_METHODS>
<P>Generation of allocation sequence: inadequate (no information).<BR/>Allocation concealment: inadequate (no information).<BR/>Double blinding: adequate (performed).<BR/>Withdrawal: no dropouts.<BR/>Sample size calculation: a 5% placebo response was assumed. The calculated group size necessary to have 90% power to detect a 45% response in the active groups gave group size of 23, which were made up to 28 to allow for up to five participants dropping out in each treatment group.<BR/>Intention-to-treat: stated and used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: United Kingdom.<BR/>Publication language: English.</P>
<P>Inclusion criteria<BR/>health-care workers with anti-HBs level below 10 IU/liter after primay hepatitis B vaccination.</P>
<P>Exclusion criteria:<BR/>seropositive for anti-HBc or had abnormal results in liver function tests.</P>
<P>Participants:<BR/>(1) Group I (n = 25)<BR/>Mean age (year +/- standard deviation): 36 +/- 12.<BR/>Male/female: 8/17.<BR/>Mean weight (Kg +/- SD): 72 +/- 15.5.<BR/>Median number of previous inoculations: 5.<BR/>Ethnic group: White 23, Black 0, Chinese 1, Asian 1.</P>
<P>(2) Group II (n = 25)<BR/>Mean age (year +/- standard deviation): 39 +/- 11.5.<BR/>Male/female: 15/10.<BR/>Mean weight (Kg +/- standard deviation): 74.6 +/- 13.0.<BR/>Median number of previous inoculations: 5.<BR/>Ethnic group: White 23, Black 1, Chinese 1, Asian 0.</P>
<P>(3) Group III (n = 25)<BR/>Mean age (year +/- standard deviation): 37 +/- 11.8.<BR/>Male/female: 15/10.<BR/>Mean weight (Kg +/- SD): 77 +/- 14.8.<BR/>Median number of previous inoculations: 5.<BR/>Ethnic group: White 23, Black 1, Chinese 0, Asian 1.</P>
<P>(4) Group IV (n = 25)<BR/>Mean age (year +/- standard deviation): 40 +/- 11.9.<BR/>Male/female: 12/13.<BR/>Mean weight (Kg +/- standard deviation): 76.0 +/- 14.7.<BR/>Median number of previous inoculations: 6.<BR/>Ethnic group: White 23, Black 1, Chinese 0, Asian 1.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group I:<BR/>Two injections of 5 µg RV (mammalian cell-derived) by the intramuscular route in the deltoid two months apart.</P>
<P>Group II: <BR/>Two injections of 10 µg RV (mammalian cell-derived) by the intramuscular route in the deltoid two months apart.</P>
<P>Group III:<BR/>Two injections of 20 µg RV (mammalian cell-derived) by the intramuscular route in the deltoid two months apart.</P>
<P>Group IV:<BR/>Two injections of 40 µg RV (mammalian cell-derived) by the intramuscular route in the deltoid two months apart.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of non-responders without protective anti-HBs level after booster vaccination.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up time: six months.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>HBc: hepatitis B core.<BR/>HBs: hepatitis B surface.<BR/>HBIG: hepatitis B immune globulin.<BR/>PDV: plasma-derived vaccine.<BR/>RV: recombinant vaccine.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Levitz-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a case series. Twenty five health-care workers who had failed to respond to a three-dose primary series plus at least two further doses of intramuscular hepatitis B vaccine were recruited for the study. All health-care workers were immunised intradermally with 5 µg RV (yeast-derived) injected in the forearm every two to three weeks until they either developed hepatitis B antibodies or had received four additional doses of vaccine. Twenty-two of the 25 health-care workers were immunised successfully by this approach. Raised, pigmented papules were commonly present at the site of vaccination for more than six months after vaccination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Playford-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a case series. Eighteen health-care workers nonresponsive to previous intramuscular hepatitis B vaccination received intradermal 5 µg RV (yeast-derived) every second week for a maximum of four doses. After three doses vaccine, protective anti-HBs levels developed in 17 out of the 18 participants. The vaccine was well tolerated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trivello-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study evaluated 985 participants vaccinated during the mass campaign against HBV infection six years after primary immunisation. A total of 322 participants received RV (yeast-derived) at 0, 1, and 6 months during primary immunisation while the remaining 663 participants received PDV at 0, 1, 2, and 14 months. Six years after primary immunisation, before receiving the booster dose, 216 RV-vaccinated had detectable anti-HBs titres with a seroprotection rate of 67.2%. Six years after primary vaccination 620 PDV-vaccinated had detectable anti-HBs titres with seroprotection rate of 93.9%. A booster dose using a RV (yeast-derived) was administered to each participant. The response rate to booster dose were 97.4% and 99.2%, respectively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weissman-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a case series. RV (yeast-derived) was administered to 25 health-care workers who were non-responders to PDV. After three intramuscular injections of 10 µg vaccine, nine participants produced anti-HBs less than 2.1 IU/liter, five developed anti-HBs between 2.1 and 9.9 IU/liter, and in 11 vaccinees anti-HBs level of 10 IU/liter or greater were detected at least once. By the sixth and 12th months after the last vaccination, only four responders still maintained anti-HBs level as 10 IU/L or greater.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yagura-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a controlled study. This study enrolled medical staff to recieve 10 µg RV (Chinese hamster ovary cell derived) (n = 113) or 20 µg PDV (n = 112) at 0, 1, and 6 months by the intramuscular route. The anti-HBs seroconversion rate at 7 months was 96.9% in the RV group and 77.8% in the PDV group. The RV group maintained higher anti-HBs seroconversion rate for five years. The rate of non-responders was lower in the RV group (2.8%) than the PDV group (15.2%).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HBs: hepatitis B surface.<BR/>PDV: plasma-derived vaccine.<BR/>RV: recombinant vaccine.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE>Intradermal route versus intramuscular route: GMT (IU/litre) of anti-HBs at foll</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Trial</P>
</TD>
<TD>
<P>GMT (IU/litre) of anti-HBs in the intradermally vaccinated group</P>
</TD>
<TD>
<P>GMT (IU/litre) of anti-HBs in the intramuscularly vaccinated group</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gonzalez-1990" TYPE="STUDY">Gonzalez 1990</LINK>
</P>
</TD>
<TD>
<P>126</P>
</TD>
<TD>
<P>1649</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Heijtink-1989" TYPE="STUDY">Heijtink 1989</LINK>
</P>
</TD>
<TD>
<P>541</P>
</TD>
<TD>
<P>533</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Henderson-2000" TYPE="STUDY">Henderson 2000</LINK>
</P>
</TD>
<TD>
<P>685</P>
</TD>
<TD>
<P>7787</P>
</TD>
</TR>
<TR>
<TD>
<P>Patricia 1995</P>
</TD>
<TD>
<P>323</P>
</TD>
<TD>
<P>1278</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Parish-1991" TYPE="STUDY">Parish 1991</LINK>
</P>
</TD>
<TD>
<P>1237</P>
</TD>
<TD>
<P>1216</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Turchi-1997" TYPE="STUDY">Turchi 1997</LINK>
</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>4570</P>
</TD>
</TR>
<TR>
<TD>
<P>Median</P>
</TD>
<TD>
<P>432</P>
</TD>
<TD>
<P>1464</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-10-16 18:14:30 +0100" MODIFIED_BY="dimitrinka nikolova" NO="2">
<TITLE>GMT (IU/litre) of anti-HBs after booster vaccination in the Zuckerman 1997 trial</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Dose of vaccine (µg)</P>
</TD>
<TD>
<P>GMT (IU/litre) of anti-HBs with 95% CI</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>11.9 (5.7 to 25.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>28.6 (12.0 to 68.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>20</P>
</TD>
<TD>
<P>57.5 (16.8 to 197.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>40</P>
</TD>
<TD>
<P>61.8 (23.1 to 165.5)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Plasma-derived vaccine (PDV) versus placebo by intramuscular route</NAME>
<DICH_OUTCOME CHI2="3.6444838490374605" CI_END="0.7335753028276042" CI_START="0.3477489381886325" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5050742842787622" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="71" I2="17.68381685125794" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.1345552984206973" LOG_CI_START="-0.45873418740211797" LOG_EFFECT_SIZE="-0.29664474291140763" METHOD="MH" NO="1" P_CHI2="0.30250102709537185" P_Q="0.0" P_Z="3.3451876264237033E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1365" TOTAL_2="1332" WEIGHT="100.0" Z="3.5869887402990295">
<NAME>Hepatitis B events at maximum follow-up - Risk of infection</NAME>
<GROUP_LABEL_1>PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7734492911067083" CI_END="0.771432217452335" CI_START="0.360883025642484" DF="2.0" EFFECT_SIZE="0.5276331990239899" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="66" I2="27.88763052516722" ID="CMP-001.01.01" LOG_CI_END="-0.11270222757835935" LOG_CI_START="-0.44263354477111233" LOG_EFFECT_SIZE="-0.27766788617473587" NO="1" P_CHI2="0.24989270982559197" P_Z="9.703546636927133E-4" STUDIES="3" TAU2="0.0" TOTAL_1="699" TOTAL_2="668" WEIGHT="93.12718106086919" Z="3.298983929118223">
<NAME>High risk of infection</NAME>
<DICH_DATA CI_END="1.090073361992275" CI_START="0.43213264614390395" EFFECT_SIZE="0.6863354037267081" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="35" LOG_CI_END="0.037455726964741726" LOG_CI_START="-0.3643829229861821" LOG_EFFECT_SIZE="-0.1634635980107202" ORDER="631" O_E="0.0" SE="0.2360420121145702" STUDY_ID="STD-Crosnier-1981" TOTAL_1="184" TOTAL_2="170" VAR="0.05571583148309491" WEIGHT="49.937283705267326"/>
<DICH_DATA CI_END="1.6420410769316467" CI_START="0.07142500508444982" EFFECT_SIZE="0.3424657534246575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2153840171327591" LOG_CI_START="-1.1461497200295956" LOG_EFFECT_SIZE="-0.4653828514484183" ORDER="632" O_E="0.0" SE="0.7997716569098626" STUDY_ID="STD-Desmyter-1983" TOTAL_1="73" TOTAL_2="75" VAR="0.6396347031963471" WEIGHT="8.12371549549806"/>
<DICH_DATA CI_END="0.7294635184573759" CI_START="0.1627187579293809" EFFECT_SIZE="0.34452488687782806" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1369964229327373" LOG_CI_START="-0.7885623794807872" LOG_EFFECT_SIZE="-0.4627794012067623" ORDER="633" O_E="0.0" SE="0.38273306817982644" STUDY_ID="STD-Szmuness-1982" TOTAL_1="442" TOTAL_2="423" VAR="0.14648460147834366" WEIGHT="35.0661818601038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7021553951092325" CI_START="0.02335869016135844" DF="0.0" EFFECT_SIZE="0.1993993993993994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.23099920566502016" LOG_CI_START="-1.6315515139416248" LOG_EFFECT_SIZE="-0.7002761541383024" NO="2" P_CHI2="1.0" P_Z="0.140534749600294" STUDIES="1" TAU2="0.0" TOTAL_1="666" TOTAL_2="664" WEIGHT="6.872818939130812" Z="1.473802594361732">
<NAME>Low risk of infection</NAME>
<DICH_DATA CI_END="1.7021553951092325" CI_START="0.02335869016135844" EFFECT_SIZE="0.1993993993993994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23099920566502016" LOG_CI_START="-1.6315515139416248" LOG_EFFECT_SIZE="-0.7002761541383024" ORDER="634" O_E="0.0" SE="1.0940715124717" STUDY_ID="STD-Dienstag-1984" TOTAL_1="666" TOTAL_2="664" VAR="1.196992474402113" WEIGHT="6.872818939130812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.64448384903746" CI_END="0.7335753028276042" CI_START="0.3477489381886325" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5050742842787622" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="71" I2="17.68381685125793" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.1345552984206973" LOG_CI_START="-0.45873418740211797" LOG_EFFECT_SIZE="-0.29664474291140763" METHOD="MH" NO="2" P_CHI2="0.3025010270953715" P_Q="0.0" P_Z="3.3451876264237033E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1365" TOTAL_2="1332" WEIGHT="100.0" Z="3.5869887402990295">
<NAME>Hepatitis B events at maximum follow-up - Dose</NAME>
<GROUP_LABEL_1>PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22368105785110518" CI_END="0.6501959392524279" CI_START="0.1582224169669528" DF="1.0" EFFECT_SIZE="0.32074222205786557" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.18695574718343264" LOG_CI_START="-0.8007319855959393" LOG_EFFECT_SIZE="-0.493843866389686" NO="1" P_CHI2="0.6362493563682441" P_Z="0.0016106515516177598" STUDIES="2" TAU2="0.0" TOTAL_1="1108" TOTAL_2="1087" WEIGHT="41.939000799234606" Z="3.1539708823308277">
<NAME>High dose (20 µg)</NAME>
<DICH_DATA CI_END="1.7021553951092325" CI_START="0.02335869016135844" EFFECT_SIZE="0.1993993993993994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23099920566502016" LOG_CI_START="-1.6315515139416248" LOG_EFFECT_SIZE="-0.7002761541383024" ORDER="635" O_E="0.0" SE="1.0940715124717" STUDY_ID="STD-Dienstag-1984" TOTAL_1="666" TOTAL_2="664" VAR="1.196992474402113" WEIGHT="6.872818939130812"/>
<DICH_DATA CI_END="0.7294635184573759" CI_START="0.1627187579293809" EFFECT_SIZE="0.34452488687782806" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1369964229327373" LOG_CI_START="-0.7885623794807872" LOG_EFFECT_SIZE="-0.4627794012067623" ORDER="636" O_E="0.0" SE="0.38273306817982644" STUDY_ID="STD-Szmuness-1982" TOTAL_1="442" TOTAL_2="423" VAR="0.14648460147834366" WEIGHT="35.0661818601038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7006623519633818" CI_END="0.993753809175335" CI_START="0.4098878467411836" DF="1.0" EFFECT_SIZE="0.6382222254307093" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="41" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.0027211936304086448" LOG_CI_START="-0.38733495841316057" LOG_EFFECT_SIZE="-0.19502807602178462" NO="2" P_CHI2="0.4025616558680216" P_Z="0.04684510057187081" STUDIES="2" TAU2="0.0" TOTAL_1="257" TOTAL_2="245" WEIGHT="58.06099920076539" Z="1.9876979971985629">
<NAME>Low dose (3 or 5 µg)</NAME>
<DICH_DATA CI_END="1.090073361992275" CI_START="0.43213264614390395" EFFECT_SIZE="0.6863354037267081" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="35" LOG_CI_END="0.037455726964741726" LOG_CI_START="-0.3643829229861821" LOG_EFFECT_SIZE="-0.1634635980107202" ORDER="637" O_E="0.0" SE="0.2360420121145702" STUDY_ID="STD-Crosnier-1981" TOTAL_1="184" TOTAL_2="170" VAR="0.05571583148309491" WEIGHT="49.937283705267326"/>
<DICH_DATA CI_END="1.6420410769316467" CI_START="0.07142500508444982" EFFECT_SIZE="0.3424657534246575" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2153840171327591" LOG_CI_START="-1.1461497200295956" LOG_EFFECT_SIZE="-0.4653828514484183" ORDER="638" O_E="0.0" SE="0.7997716569098626" STUDY_ID="STD-Desmyter-1983" TOTAL_1="73" TOTAL_2="75" VAR="0.6396347031963471" WEIGHT="8.12371549549806"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.526911611532398" CI_END="1.190746089444224" CI_START="1.0247558407874353" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.104637501650549" ESTIMABLE="YES" EVENTS_1="1051" EVENTS_2="934" I2="37.23937083837295" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07581916390978102" LOG_CI_START="0.010620402338160377" LOG_EFFECT_SIZE="0.043219783123970706" METHOD="MH" NO="3" P_CHI2="0.09322726316753727" P_Q="0.0" P_Z="0.009363432582511242" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3931" TOTAL_2="3834" WEIGHT="300.0" Z="2.598491636978774">
<NAME>Adverse events after each injection of vaccine</NAME>
<GROUP_LABEL_1>PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.978798764490821" CI_END="1.243917313214489" CI_START="0.9843100470811883" DF="3.0" EFFECT_SIZE="1.1065262351771235" ESTIMABLE="YES" EVENTS_1="412" EVENTS_2="365" I2="24.600358611403184" ID="CMP-001.03.01" LOG_CI_END="0.09479151250256361" LOG_CI_START="-0.006868081927054112" LOG_EFFECT_SIZE="0.04396171528775472" NO="1" P_CHI2="0.2637626737104103" P_Z="0.09004977535834373" STUDIES="4" TAU2="0.0" TOTAL_1="1365" TOTAL_2="1330" WEIGHT="100.00000000000001" Z="1.6951352038347334">
<NAME>After the first injection of vaccine (0 month)</NAME>
<DICH_DATA CI_END="1.6536811917770684" CI_START="0.6961326822735121" EFFECT_SIZE="1.0729312762973353" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" LOG_CI_END="0.21845178695929224" LOG_CI_START="-0.15730797635578808" LOG_EFFECT_SIZE="0.030571905301752095" ORDER="639" O_E="0.0" SE="0.2207231450121049" STUDY_ID="STD-Crosnier-1981" TOTAL_1="184" TOTAL_2="170" VAR="0.04871870674403469" WEIGHT="8.740276758356577"/>
<DICH_DATA CI_END="1.8948083392407586" CI_START="1.1003092354942696" EFFECT_SIZE="1.4439096630877453" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="37" LOG_CI_END="0.27756528743351827" LOG_CI_START="0.041514758244578266" LOG_EFFECT_SIZE="0.15954002283904828" ORDER="640" O_E="0.0" SE="0.13865724931454765" STUDY_ID="STD-Desmyter-1983" TOTAL_1="73" TOTAL_2="75" VAR="0.019225832787476624" WEIGHT="9.899466689579713"/>
<DICH_DATA CI_END="1.274448288614376" CI_START="0.9108182172809051" EFFECT_SIZE="1.077399980625787" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="186" LOG_CI_END="0.10532221844393388" LOG_CI_START="-0.04056829164335595" LOG_EFFECT_SIZE="0.032376963400288956" ORDER="641" O_E="0.0" SE="0.08569680779494598" STUDY_ID="STD-Dienstag-1984" TOTAL_1="666" TOTAL_2="664" VAR="0.007343942866243914" WEIGHT="50.52245692196421"/>
<DICH_DATA CI_END="1.314057361451878" CI_START="0.8477535064058199" EFFECT_SIZE="1.055460437813379" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="111" LOG_CI_END="0.11861432353296322" LOG_CI_START="-0.07173040525432947" LOG_EFFECT_SIZE="0.023441959139316897" ORDER="642" O_E="0.0" SE="0.11180943591125919" STUDY_ID="STD-Szmuness-1982" TOTAL_1="442" TOTAL_2="421" VAR="0.012501349958793977" WEIGHT="30.837799630099514"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.487166338653571" CI_END="1.2201175950548326" CI_START="0.9383273308113901" DF="3.0" EFFECT_SIZE="1.0699858345996052" ESTIMABLE="YES" EVENTS_1="344" EVENTS_2="315" I2="68.37833455309942" ID="CMP-001.03.02" LOG_CI_END="0.0864016900372281" LOG_CI_START="-0.027645633724655002" LOG_EFFECT_SIZE="0.029378028156286554" NO="2" P_CHI2="0.023468354511255285" P_Z="0.31261312342482694" STUDIES="4" TAU2="0.0" TOTAL_1="1338" TOTAL_2="1302" WEIGHT="100.0" Z="1.0097541130091756">
<NAME>After the second injection of vaccine (1 month)</NAME>
<DICH_DATA CI_END="1.7064833850277514" CI_START="0.6839630355401719" EFFECT_SIZE="1.0803571428571428" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.2321020641787407" LOG_CI_START="-0.16496736888620384" LOG_EFFECT_SIZE="0.033567347646268446" ORDER="643" O_E="0.0" SE="0.2332405505077417" STUDY_ID="STD-Crosnier-1981" TOTAL_1="180" TOTAL_2="165" VAR="0.0544011544011544" WEIGHT="9.177474084779282"/>
<DICH_DATA CI_END="2.7511272595566543" CI_START="1.2895820990485407" EFFECT_SIZE="1.8835616438356164" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="24" LOG_CI_END="0.4395106801188472" LOG_CI_START="0.11044899597280393" LOG_EFFECT_SIZE="0.27497983804582554" ORDER="644" O_E="0.0" SE="0.19329246214899265" STUDY_ID="STD-Desmyter-1983" TOTAL_1="73" TOTAL_2="75" VAR="0.037361975923619756" WEIGHT="7.436765921015645"/>
<DICH_DATA CI_END="1.2020622548521172" CI_START="0.8430695070688256" EFFECT_SIZE="1.0066886473305514" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="177" LOG_CI_END="0.07992696037771242" LOG_CI_START="-0.07413661838588416" LOG_EFFECT_SIZE="0.0028951709959141197" ORDER="645" O_E="0.0" SE="0.090497708792751" STUDY_ID="STD-Dienstag-1984" TOTAL_1="658" TOTAL_2="655" VAR="0.008189835296737561" WEIGHT="55.72449730132691"/>
<DICH_DATA CI_END="1.2704595393844902" CI_START="0.7487566140174899" EFFECT_SIZE="0.9753281411687816" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="86" LOG_CI_END="0.10396083853093419" LOG_CI_START="-0.12565932831734009" LOG_EFFECT_SIZE="-0.010849244893202931" ORDER="646" O_E="0.0" SE="0.13488002264483365" STUDY_ID="STD-Szmuness-1982" TOTAL_1="427" TOTAL_2="407" VAR="0.018192620508670834" WEIGHT="27.661262692878164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.849985039906172" CI_END="1.3253972624529773" CI_START="0.9892376233520662" DF="3.0" EFFECT_SIZE="1.1450470898204659" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="254" I2="22.077619291915145" ID="CMP-001.03.03" LOG_CI_END="0.122346069240748" LOG_CI_START="-0.0046993746161694445" LOG_EFFECT_SIZE="0.05882334731228929" NO="3" P_CHI2="0.2781253723803787" P_Z="0.06952898549239292" STUDIES="4" TAU2="0.0" TOTAL_1="1228" TOTAL_2="1202" WEIGHT="100.0" Z="1.8149669705908238">
<NAME>After the third injection of vaccine (6 months)</NAME>
<DICH_DATA CI_END="2.574281068127929" CI_START="0.7539374951856317" EFFECT_SIZE="1.3931428571428572" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.41065596279873384" LOG_CI_START="-0.1226646576065965" LOG_EFFECT_SIZE="0.1439956525960687" ORDER="647" O_E="0.0" SE="0.3132751724057391" STUDY_ID="STD-Crosnier-1981" TOTAL_1="175" TOTAL_2="159" VAR="0.09814133364584554" WEIGHT="6.145733787474599"/>
<DICH_DATA CI_END="3.657310258885328" CI_START="1.0602497586754727" EFFECT_SIZE="1.9691780821917808" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5631618042008752" LOG_CI_START="0.025408182281549164" LOG_EFFECT_SIZE="0.2942849932412122" ORDER="648" O_E="0.0" SE="0.3158791394387716" STUDY_ID="STD-Desmyter-1983" TOTAL_1="73" TOTAL_2="75" VAR="0.09977963073257892" WEIGHT="4.628425674322956"/>
<DICH_DATA CI_END="1.2830915692113554" CI_START="0.9009108097098169" EFFECT_SIZE="1.075151647234027" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="171" LOG_CI_END="0.108257651374248" LOG_CI_START="-0.045318202104377994" LOG_EFFECT_SIZE="0.031469724634935" ORDER="649" O_E="0.0" SE="0.0902112165460802" STUDY_ID="STD-Dienstag-1984" TOTAL_1="644" TOTAL_2="640" VAR="0.008138063590723775" WEIGHT="67.06684203007235"/>
<DICH_DATA CI_END="1.5437336127378454" CI_START="0.8062703071582373" EFFECT_SIZE="1.1156462585034013" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="56" LOG_CI_END="0.1885723604432219" LOG_CI_START="-0.09351933384417842" LOG_EFFECT_SIZE="0.04752651329952175" ORDER="650" O_E="0.0" SE="0.16570205760082612" STUDY_ID="STD-Szmuness-1982" TOTAL_1="336" TOTAL_2="328" VAR="0.027457171893147503" WEIGHT="22.158998508130104"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4117844152367733" CI_END="1.1752340387351583" CI_START="0.9810388795635236" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0737552256383456" ESTIMABLE="YES" EVENTS_1="774" EVENTS_2="706" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07012436159497051" LOG_CI_START="-0.008313780749201008" LOG_EFFECT_SIZE="0.030905290422884747" METHOD="MH" NO="4" P_CHI2="0.9940776544525408" P_Q="0.0" P_Z="0.12247095009974057" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3712" TOTAL_2="3609" WEIGHT="300.0" Z="1.5444847200695033">
<NAME>Local adverse events after each injection of vaccine</NAME>
<GROUP_LABEL_1>PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1957470176357921" CI_END="1.2022775903660772" CI_START="0.8898966778711115" DF="2.0" EFFECT_SIZE="1.0343610750340797" ESTIMABLE="YES" EVENTS_1="273" EVENTS_2="258" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.08000475223056273" LOG_CI_START="-0.05066041451834131" LOG_EFFECT_SIZE="0.0146721688561107" NO="1" P_CHI2="0.9067636630855677" P_Z="0.659819759251628" STUDIES="3" TAU2="0.0" TOTAL_1="1292" TOTAL_2="1255" WEIGHT="100.0" Z="0.44016203015037153">
<NAME>After the first injection of vaccine (0 month)</NAME>
<DICH_DATA CI_END="1.6060995906845266" CI_START="0.5314834253493884" EFFECT_SIZE="0.9239130434782609" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.20577247141821658" LOG_CI_START="-0.27451027468074163" LOG_EFFECT_SIZE="-0.034368901631262536" ORDER="651" O_E="0.0" SE="0.28212046249646405" STUDY_ID="STD-Crosnier-1981" TOTAL_1="184" TOTAL_2="170" VAR="0.07959195535921879" WEIGHT="8.76458293786226"/>
<DICH_DATA CI_END="1.2689774240166032" CI_START="0.8733330492361582" EFFECT_SIZE="1.0527297483819222" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="161" LOG_CI_END="0.10345389576513206" LOG_CI_START="-0.05882010467685083" LOG_EFFECT_SIZE="0.022316895544140618" ORDER="652" O_E="0.0" SE="0.09532055112887793" STUDY_ID="STD-Dienstag-1984" TOTAL_1="666" TOTAL_2="664" VAR="0.00908600746751303" WEIGHT="61.79345489719371"/>
<DICH_DATA CI_END="1.3669592171287" CI_START="0.774125914828607" EFFECT_SIZE="1.02868778280543" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="75" LOG_CI_END="0.13575555769863995" LOG_CI_START="-0.11118839375158766" LOG_EFFECT_SIZE="0.012283581973526149" ORDER="653" O_E="0.0" SE="0.14505609947413783" STUDY_ID="STD-Szmuness-1982" TOTAL_1="442" TOTAL_2="421" VAR="0.021041271994650973" WEIGHT="29.441962164944023"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3655619020914948" CI_END="1.2795326610919524" CI_START="0.927321994521159" DF="2.0" EFFECT_SIZE="1.089283608312709" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="225" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.10705137607781198" LOG_CI_START="-0.03276943935874437" LOG_EFFECT_SIZE="0.037140968359533795" NO="2" P_CHI2="0.8329506370032513" P_Z="0.2977545841968914" STUDIES="3" TAU2="0.0" TOTAL_1="1265" TOTAL_2="1227" WEIGHT="100.00000000000001" Z="1.0412607036848334">
<NAME>After the second injection of vaccine (1 month)</NAME>
<DICH_DATA CI_END="1.8469335235884736" CI_START="0.6016823815899934" EFFECT_SIZE="1.0541666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.26645126422299215" LOG_CI_START="-0.22063270529456835" LOG_EFFECT_SIZE="0.02290927946421191" ORDER="654" O_E="0.0" SE="0.28611553479915" STUDY_ID="STD-Crosnier-1981" TOTAL_1="180" TOTAL_2="165" VAR="0.08186209925340361" WEIGHT="9.16955282914888"/>
<DICH_DATA CI_END="1.2872074282518322" CI_START="0.8669554930237753" EFFECT_SIZE="1.0563860802679734" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="147" LOG_CI_END="0.10964853733667886" LOG_CI_START="-0.0620031973684528" LOG_EFFECT_SIZE="0.023822669984113063" ORDER="655" O_E="0.0" SE="0.10082907865558477" STUDY_ID="STD-Dienstag-1984" TOTAL_1="658" TOTAL_2="655" VAR="0.0101665031025341" WEIGHT="64.73561132235929"/>
<DICH_DATA CI_END="1.6262786747423845" CI_START="0.8608888975301903" EFFECT_SIZE="1.1832350803520957" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="58" LOG_CI_END="0.21119496717001043" LOG_CI_START="-0.06505289303295568" LOG_EFFECT_SIZE="0.07307103706852737" ORDER="656" O_E="0.0" SE="0.16226936053218427" STUDY_ID="STD-Szmuness-1982" TOTAL_1="427" TOTAL_2="407" VAR="0.026331345367524" WEIGHT="26.094835848491844"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.524096027542523" CI_END="1.2932398420377471" CI_START="0.9420704451457736" DF="2.0" EFFECT_SIZE="1.103776713682958" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="223" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.11167907585801609" LOG_CI_START="-0.025916620780161582" LOG_EFFECT_SIZE="0.04288122753892726" NO="3" P_CHI2="0.7694740908600707" P_Z="0.2218467976320766" STUDIES="3" TAU2="0.0" TOTAL_1="1155" TOTAL_2="1127" WEIGHT="100.0" Z="1.2216321242977746">
<NAME>After the third injection of vaccine (6 months)</NAME>
<DICH_DATA CI_END="2.2510205820205016" CI_START="0.5555100827879638" EFFECT_SIZE="1.1182417582417583" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.35237946595434727" LOG_CI_START="-0.255308053987857" LOG_EFFECT_SIZE="0.04853570598324508" ORDER="657" O_E="0.0" SE="0.3569586573157886" STUDY_ID="STD-Crosnier-1981" TOTAL_1="175" TOTAL_2="159" VAR="0.12741948303269057" WEIGHT="6.063209296966438"/>
<DICH_DATA CI_END="1.2784913480352895" CI_START="0.8889330722564914" EFFECT_SIZE="1.0660643704121966" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="165" LOG_CI_END="0.106697793360989" LOG_CI_START="-0.051130935817038085" LOG_EFFECT_SIZE="0.027783428771975455" ORDER="658" O_E="0.0" SE="0.09270937678398262" STUDY_ID="STD-Dienstag-1984" TOTAL_1="644" TOTAL_2="640" VAR="0.008595028543674455" WEIGHT="73.66690323684513"/>
<DICH_DATA CI_END="1.7723603363427862" CI_START="0.8626642368910504" EFFECT_SIZE="1.2365079365079366" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="45" LOG_CI_END="0.2485520223908282" LOG_CI_START="-0.06415820595286267" LOG_EFFECT_SIZE="0.09219690821898277" ORDER="659" O_E="0.0" SE="0.18368753606967914" STUDY_ID="STD-Szmuness-1982" TOTAL_1="336" TOTAL_2="328" VAR="0.03374111090734967" WEIGHT="20.269887466188443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9812569776064636" CI_END="2.6627944703600828" CI_START="0.9143251157503969" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.560339662487466" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.4253376464114506" LOG_CI_START="-0.03889935036007817" LOG_EFFECT_SIZE="0.19321914802568618" METHOD="MH" NO="5" P_CHI2="0.6122415402277883" P_Q="0.0" P_Z="0.1027837325290457" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="539" TOTAL_2="483" WEIGHT="300.0" Z="1.6315053469994532">
<NAME>Systemic adverse events after each injection of vaccine</NAME>
<GROUP_LABEL_1>PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.20103190575212" CI_START="0.6479867103130723" DF="0.0" EFFECT_SIZE="1.440217391304348" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.5052900029235857" LOG_CI_START="-0.188433901069043" LOG_EFFECT_SIZE="0.15842805092727139" NO="1" P_CHI2="1.0" P_Z="0.3706764125378119" STUDIES="1" TAU2="0.0" TOTAL_1="184" TOTAL_2="159" WEIGHT="100.0" Z="0.89520707639225">
<NAME>After the first injection of vaccine (0 month)</NAME>
<DICH_DATA CI_END="3.20103190575212" CI_START="0.6479867103130723" EFFECT_SIZE="1.440217391304348" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5052900029235857" LOG_CI_START="-0.188433901069043" LOG_EFFECT_SIZE="0.15842805092727139" ORDER="660" O_E="0.0" SE="0.4074968551939775" STUDY_ID="STD-Crosnier-1981" TOTAL_1="184" TOTAL_2="159" VAR="0.16605368699298148" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0566577253067178" CI_START="0.5197344015518451" DF="0.0" EFFECT_SIZE="1.2604166666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.4852468105504788" LOG_CI_START="-0.2842185359967154" LOG_EFFECT_SIZE="0.10051413727688169" NO="2" P_CHI2="1.0" P_Z="0.6086128831946053" STUDIES="1" TAU2="0.0" TOTAL_1="180" TOTAL_2="165" WEIGHT="100.00000000000001" Z="0.5120544801239337">
<NAME>After the second injection of vaccine (1 month)</NAME>
<DICH_DATA CI_END="3.0566577253067178" CI_START="0.5197344015518451" EFFECT_SIZE="1.2604166666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4852468105504788" LOG_CI_START="-0.2842185359967154" LOG_EFFECT_SIZE="0.10051413727688169" ORDER="661" O_E="0.0" SE="0.45198775347671677" STUDY_ID="STD-Crosnier-1981" TOTAL_1="180" TOTAL_2="165" VAR="0.20429292929292928" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.890823804289463" CI_START="0.7511526354483128" DF="0.0" EFFECT_SIZE="2.7257142857142855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.9952324653845634" LOG_CI_START="-0.12427180467692457" LOG_EFFECT_SIZE="0.43548033035381944" NO="3" P_CHI2="1.0" P_Z="0.12730198852498023" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="159" WEIGHT="100.0" Z="1.5248280623748078">
<NAME>After the third injection of vaccine (6 months)</NAME>
<DICH_DATA CI_END="9.890823804289463" CI_START="0.7511526354483129" EFFECT_SIZE="2.7257142857142855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9952324653845634" LOG_CI_START="-0.12427180467692453" LOG_EFFECT_SIZE="0.43548033035381944" ORDER="662" O_E="0.0" SE="0.6576023498696291" STUDY_ID="STD-Crosnier-1981" TOTAL_1="175" TOTAL_2="159" VAR="0.43244085055405806" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Gluteal intramuscular injection versus deltoid intramuscular injection (20 µg plasma-derived vaccine)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="153.31751907309194" CI_START="2.911213373401992" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="21.12676056338028" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="2.1855917830478533" LOG_CI_START="0.4640740376253586" LOG_EFFECT_SIZE="1.3248329103366059" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.002555685332717774" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="3.0166692114531384">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at one year follow-up</NAME>
<GROUP_LABEL_1>Gluteal</GROUP_LABEL_1>
<GROUP_LABEL_2>Deltoid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours gluteal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours deltoid</GRAPH_LABEL_2>
<DICH_DATA CI_END="153.31751907309194" CI_START="2.911213373401992" EFFECT_SIZE="21.12676056338028" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="2.1855917830478533" LOG_CI_START="0.4640740376253586" LOG_EFFECT_SIZE="1.3248329103366059" ORDER="663" O_E="0.0" SE="1.0112280453114486" STUDY_ID="STD-de-Lalla-1988" TOTAL_1="71" TOTAL_2="75" VAR="1.0225821596244131" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-239.70185051859082" CI_START="-242.29814948140918" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-241.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="363.8651226524421">
<NAME>Geometric mean titre (IU/litre) of anti-HBs level at one year follow-up</NAME>
<GROUP_LABEL_1>Gluteal</GROUP_LABEL_1>
<GROUP_LABEL_2>Deltoid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours deltoid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours gluteal</GRAPH_LABEL_2>
<CONT_DATA CI_END="-239.70185051859082" CI_START="-242.29814948140918" EFFECT_SIZE="-241.0" ESTIMABLE="YES" MEAN_1="707.0" MEAN_2="948.0" ORDER="664" SD_1="4.0" SD_2="4.0" SE="0.6623333345147213" STUDY_ID="STD-de-Lalla-1988" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Different doses of plasma-derived vaccine (PDV) by intramuscular route</NAME>
<DICH_OUTCOME CHI2="6.232281594314783" CI_END="1.2419049846704067" CI_START="0.6654665946212213" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="66" I2="67.90902385051982" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.09408837022717166" LOG_CI_START="-0.17687374054362173" LOG_EFFECT_SIZE="-0.04139268515822506" METHOD="MH" NO="1" P_CHI2="0.044327946181514255" P_Q="0.0" P_Z="0.5492958483211305" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="300" TOTAL_2="300" WEIGHT="300.0" Z="0.5988156196653855">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at follow-up (12 months)</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4599960377512495" CI_START="0.8828246546038434" DF="0.0" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.39093440759762543" LOG_CI_START="-0.05412554681884501" LOG_EFFECT_SIZE="0.16840443038939024" NO="1" P_CHI2="1.0" P_Z="0.13800915934199615" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="1.483245639715873">
<NAME>2 µg versus 1 µg</NAME>
<DICH_DATA CI_END="2.4599960377512495" CI_START="0.8828246546038434" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" LOG_CI_END="0.39093440759762543" LOG_CI_START="-0.05412554681884501" LOG_EFFECT_SIZE="0.16840443038939024" ORDER="665" O_E="0.0" SE="0.26143042030653996" STUDY_ID="STD-Chan-1992" TOTAL_1="100" TOTAL_2="100" VAR="0.06834586466165414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.541366595685494" CI_START="0.4600730781523455" DF="0.0" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.1879059427733446" LOG_CI_START="-0.3371731793671531" LOG_EFFECT_SIZE="-0.07463361829690421" NO="2" P_CHI2="1.0" P_Z="0.5774111918429996" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="0.5571701396221247">
<NAME>5 µg versus 1 µg</NAME>
<DICH_DATA CI_END="1.541366595685494" CI_START="0.4600730781523455" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.1879059427733446" LOG_CI_START="-0.3371731793671531" LOG_EFFECT_SIZE="-0.07463361829690421" ORDER="666" O_E="0.0" SE="0.308434075528902" STUDY_ID="STD-Chan-1992" TOTAL_1="100" TOTAL_2="100" VAR="0.09513157894736843" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9885893552165578" CI_START="0.3302995430022296" DF="0.0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-0.0049840701807237" LOG_CI_START="-0.4810920271918654" LOG_EFFECT_SIZE="-0.24303804868629447" NO="3" P_CHI2="1.0" P_Z="0.04539247531301518" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.0" Z="2.0009992073578484">
<NAME>5 µg versus 2 µg</NAME>
<DICH_DATA CI_END="0.9885893552165579" CI_START="0.3302995430022296" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="-0.0049840701807236515" LOG_CI_START="-0.4810920271918654" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="667" O_E="0.0" SE="0.27966817072074135" STUDY_ID="STD-Chan-1992" TOTAL_1="100" TOTAL_2="100" VAR="0.07821428571428572" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Plasma-derived vaccines (PDV) produced in different countries: 20 µg by intramuscular route</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8204893599688323" CI_START="0.8865614554723223" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2704234320280166" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2601881450000768" LOG_CI_START="-0.052291154200189136" LOG_EFFECT_SIZE="0.10394849539994382" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.19223619204806594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="349" TOTAL_2="344" WEIGHT="100.0" Z="1.3039923460686254">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at follow-up (7 months)</NAME>
<GROUP_LABEL_1>Korean PDV</GROUP_LABEL_1>
<GROUP_LABEL_2>American PDV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Korean PDV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours American PDV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.820489359968832" CI_START="0.8865614554723223" EFFECT_SIZE="1.2704234320280166" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" LOG_CI_END="0.26018814500007675" LOG_CI_START="-0.052291154200189136" LOG_EFFECT_SIZE="0.10394849539994382" ORDER="668" O_E="0.0" SE="0.18355188714771367" STUDY_ID="STD-Pennie-1992" TOTAL_1="349" TOTAL_2="344" VAR="0.03369129527548702" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Recombinant vaccine (RV) versus plasma-derived vaccine (PDV)</NAME>
<DICH_OUTCOME CHI2="2.7748024404792035" CI_END="2.040352844149548" CI_START="0.7820058533557559" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="21" I2="63.96139828148264" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.30970527772804934" LOG_CI_START="-0.10678999621049524" LOG_EFFECT_SIZE="0.10145764075877703" METHOD="MH" NO="1" P_CHI2="0.09575855970433855" P_Q="0.0" P_Z="0.339633980826061" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="621" TOTAL_2="224" WEIGHT="100.0" Z="0.9548887312125783">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at maximum follow-up</NAME>
<GROUP_LABEL_1>RV</GROUP_LABEL_1>
<GROUP_LABEL_2>PDV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.397686650231949" CI_START="0.878073078573472" DF="0.0" EFFECT_SIZE="1.4509803921568627" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="17" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.3797924252318804" LOG_CI_START="-0.05646933796580079" LOG_EFFECT_SIZE="0.1616615436330398" NO="1" P_CHI2="1.0" P_Z="0.14634263479023835" STUDIES="1" TAU2="0.0" TOTAL_1="600" TOTAL_2="200" WEIGHT="85.82169709989259" Z="1.4525719645172546">
<NAME>20 µg vaccine by intramuscular route</NAME>
<DICH_DATA CI_END="2.397686650231949" CI_START="0.878073078573472" EFFECT_SIZE="1.4509803921568627" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="17" LOG_CI_END="0.3797924252318804" LOG_CI_START="-0.05646933796580079" LOG_EFFECT_SIZE="0.1616615436330398" ORDER="669" O_E="0.0" SE="0.25626231923287424" STUDY_ID="STD-Halliday-1990" TOTAL_1="600" TOTAL_2="200" VAR="0.06567037625861155" WEIGHT="85.82169709989259"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.215820497503464" CI_START="0.007194739288989136" DF="0.0" EFFECT_SIZE="0.12626262626262627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.34553457550527555" LOG_CI_START="-2.142984938684263" LOG_EFFECT_SIZE="-0.8987251815894934" NO="2" P_CHI2="1.0" P_Z="0.15687031486109054" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="24" WEIGHT="14.178302900107411" Z="1.415676250775396">
<NAME>2 µg vaccine by intradermal route</NAME>
<DICH_DATA CI_END="2.215820497503464" CI_START="0.007194739288989136" EFFECT_SIZE="0.12626262626262627" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.34553457550527555" LOG_CI_START="-2.142984938684263" LOG_EFFECT_SIZE="-0.8987251815894934" ORDER="670" O_E="0.0" SE="1.4617686810051982" STUDY_ID="STD-Soyletir-1992" TOTAL_1="21" TOTAL_2="24" VAR="2.136767676767677" WEIGHT="14.178302900107411"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="30.105306682280926" CI_END="0.9304101189427497" CI_START="0.7282574623011733" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.823151330024182" ESTIMABLE="YES" EVENTS_1="715" EVENTS_2="291" I2="66.78326480598287" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-0.03132557495942159" LOG_CI_START="-0.13771505655320587" LOG_EFFECT_SIZE="-0.08452031575631373" METHOD="MH" NO="2" P_CHI2="8.233148818427294E-4" P_Q="0.0" P_Z="0.0018447129696383983" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6534" TOTAL_2="2189" WEIGHT="1100.0" Z="3.114157008055324">
<NAME>Adverse events after the first injection of vaccine (20 µg by intramuscular route)</NAME>
<GROUP_LABEL_1>RV</GROUP_LABEL_1>
<GROUP_LABEL_2>PDV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.666817217406361E-32" CI_END="1.4611910040511722" CI_START="0.15055054930512193" DF="0.0" EFFECT_SIZE="0.46902356902356906" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="100.0" ID="CMP-005.02.01" LOG_CI_END="0.1647069897765599" LOG_CI_START="-0.8223176555630576" LOG_EFFECT_SIZE="-0.3288053328932488" NO="1" P_CHI2="0.0" P_Z="0.19160802249201686" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="1.3058369179297005">
<NAME>Fever</NAME>
<DICH_DATA CI_END="1.4611910040511722" CI_START="0.15055054930512193" EFFECT_SIZE="0.469023569023569" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.1647069897765599" LOG_CI_START="-0.8223176555630576" LOG_EFFECT_SIZE="-0.32880533289324887" ORDER="671" O_E="0.0" SE="0.5797831625232838" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.33614851554550046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7977119842190242" CI_START="0.44467436409878414" DF="0.0" EFFECT_SIZE="0.5955854844743733" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="54" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-0.09815388338929155" LOG_CI_START="-0.35195790732048254" LOG_EFFECT_SIZE="-0.22505589535488704" NO="2" P_CHI2="1.0" P_Z="5.09101017234861E-4" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="3.47592163884353">
<NAME>Pain</NAME>
<DICH_DATA CI_END="0.7977119842190242" CI_START="0.44467436409878414" EFFECT_SIZE="0.5955854844743733" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="54" LOG_CI_END="-0.09815388338929155" LOG_CI_START="-0.35195790732048254" LOG_EFFECT_SIZE="-0.22505589535488704" ORDER="672" O_E="0.0" SE="0.1490857400073622" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.022226557873542795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.992465810320616E-31" CI_END="0.763673120577194" CI_START="0.2880592525416379" DF="0.0" EFFECT_SIZE="0.46902356902356906" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" I2="100.0" ID="CMP-005.02.03" LOG_CI_END="-0.11709249523011013" LOG_CI_START="-0.5405181705563875" LOG_EFFECT_SIZE="-0.3288053328932488" NO="3" P_CHI2="0.0" P_Z="0.0023348177989251377" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="3.0439656730730005">
<NAME>Redness</NAME>
<DICH_DATA CI_END="0.763673120577194" CI_START="0.2880592525416379" EFFECT_SIZE="0.469023569023569" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="25" LOG_CI_END="-0.11709249523011013" LOG_CI_START="-0.5405181705563875" LOG_EFFECT_SIZE="-0.32880533289324887" ORDER="673" O_E="0.0" SE="0.24872233767755195" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.06186280125978618" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3891445708634504" CI_START="0.5342379646248814" DF="0.0" EFFECT_SIZE="0.8614718614718615" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="21" I2="0.0" ID="CMP-005.02.04" LOG_CI_END="0.14274744592550764" LOG_CI_START="-0.272265252890383" LOG_EFFECT_SIZE="-0.06475890348243764" NO="4" P_CHI2="1.0" P_Z="0.5407570432674178" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.6116686013031628">
<NAME>Swelling</NAME>
<DICH_DATA CI_END="1.3891445708634504" CI_START="0.5342379646248814" EFFECT_SIZE="0.8614718614718615" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="21" LOG_CI_END="0.14274744592550764" LOG_CI_START="-0.272265252890383" LOG_EFFECT_SIZE="-0.06475890348243764" ORDER="674" O_E="0.0" SE="0.24378051363044534" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.05942893882592374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7003257554913107" CI_START="0.616284859437736" DF="0.0" EFFECT_SIZE="1.0236625514403292" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="18" I2="0.0" ID="CMP-005.02.05" LOG_CI_END="0.23053213329556171" LOG_CI_START="-0.21021850165665992" LOG_EFFECT_SIZE="0.01015681581945089" NO="5" P_CHI2="1.0" P_Z="0.9280232113893809" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.09033222700127654">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.7003257554913107" CI_START="0.616284859437736" EFFECT_SIZE="1.0236625514403292" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="18" LOG_CI_END="0.23053213329556171" LOG_CI_START="-0.21021850165665992" LOG_EFFECT_SIZE="0.01015681581945089" ORDER="675" O_E="0.0" SE="0.2588991047217648" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.06702874642573135" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.94360696294732" CI_START="0.29031312348524985" DF="0.0" EFFECT_SIZE="2.345117845117845" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-005.02.06" LOG_CI_END="1.2774626745068298" LOG_CI_START="-0.5371333316212901" LOG_EFFECT_SIZE="0.37016467144276993" NO="6" P_CHI2="1.0" P_Z="0.4239209139287552" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.7996374090175381">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="18.94360696294732" CI_START="0.29031312348524985" EFFECT_SIZE="2.345117845117845" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2774626745068298" LOG_CI_START="-0.5371333316212901" LOG_EFFECT_SIZE="0.37016467144276993" ORDER="676" O_E="0.0" SE="1.0659026763947543" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="1.1361485155455004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7097642071470625" CI_START="0.33126637413604265" DF="0.0" EFFECT_SIZE="0.4848927875243665" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" I2="0.0" ID="CMP-005.02.07" LOG_CI_END="-0.14888590556671244" LOG_CI_START="-0.47982264582139383" LOG_EFFECT_SIZE="-0.3143542756940532" NO="7" P_CHI2="1.0" P_Z="1.9647241449557577E-4" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="3.723509564228891">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="0.7097642071470625" CI_START="0.33126637413604265" EFFECT_SIZE="0.4848927875243665" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="38" LOG_CI_END="-0.14888590556671244" LOG_CI_START="-0.47982264582139383" LOG_EFFECT_SIZE="-0.3143542756940532" ORDER="677" O_E="0.0" SE="0.19439387938888406" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.03778898034386" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9817485476109107" CI_START="0.17344461139255535" DF="0.0" EFFECT_SIZE="0.5862794612794613" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-005.02.08" LOG_CI_END="0.29704854857867113" LOG_CI_START="-0.7608391883490561" LOG_EFFECT_SIZE="-0.23189531988519244" NO="8" P_CHI2="1.0" P_Z="0.3901906654166116" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.8592716585945702">
<NAME>Rash</NAME>
<DICH_DATA CI_END="1.9817485476109107" CI_START="0.17344461139255535" EFFECT_SIZE="0.5862794612794613" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.29704854857867113" LOG_CI_START="-0.7608391883490561" LOG_EFFECT_SIZE="-0.23189531988519244" ORDER="678" O_E="0.0" SE="0.6214084933001001" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.38614851554550045" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.299309239499265" CI_START="0.8031320447900576" DF="0.0" EFFECT_SIZE="1.0215267428382182" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="61" I2="0.0" ID="CMP-005.02.09" LOG_CI_END="0.11371252676573586" LOG_CI_START="-0.09521304549441106" LOG_EFFECT_SIZE="0.009249740635662362" NO="9" P_CHI2="1.0" P_Z="0.8622218235347687" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.17354657274468113">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.299309239499265" CI_START="0.8031320447900576" EFFECT_SIZE="1.0215267428382182" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="61" LOG_CI_END="0.11371252676573586" LOG_CI_START="-0.09521304549441106" LOG_EFFECT_SIZE="0.009249740635662362" ORDER="679" O_E="0.0" SE="0.12272391534387231" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.015061159397329937" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7420794676344582" CI_START="0.9092670493272559" DF="0.0" EFFECT_SIZE="1.2585767585767587" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="37" I2="0.0" ID="CMP-005.02.10" LOG_CI_END="0.24106796213430576" LOG_CI_START="-0.04130854690307933" LOG_EFFECT_SIZE="0.09987970761561321" NO="10" P_CHI2="1.0" P_Z="0.1655875485285812" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="1.3865220614868872">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.7420794676344582" CI_START="0.9092670493272559" EFFECT_SIZE="1.2585767585767587" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="37" LOG_CI_END="0.24106796213430576" LOG_CI_START="-0.04130854690307933" LOG_EFFECT_SIZE="0.09987970761561321" ORDER="680" O_E="0.0" SE="0.1658693591948229" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.027512644319701185" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3840860997804683" CI_START="0.6091244986034339" DF="0.0" EFFECT_SIZE="0.9181942885646589" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="27" I2="0.0" ID="CMP-005.02.11" LOG_CI_END="0.14116310709796775" LOG_CI_START="-0.21529393309696385" LOG_EFFECT_SIZE="-0.03706541299949803" NO="11" P_CHI2="1.0" P_Z="0.6835635348248172" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="199" WEIGHT="100.0" Z="0.4076052166701005">
<NAME>Other</NAME>
<DICH_DATA CI_END="1.3840860997804683" CI_START="0.609124498603434" EFFECT_SIZE="0.9181942885646589" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="27" LOG_CI_END="0.14116310709796775" LOG_CI_START="-0.21529393309696376" LOG_EFFECT_SIZE="-0.03706541299949803" ORDER="681" O_E="0.0" SE="0.20938462990130904" STUDY_ID="STD-Halliday-1990" TOTAL_1="594" TOTAL_2="199" VAR="0.04384192323890816" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.881229080255318" CI_END="1.094722460166379" CI_START="0.8218823385204166" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9485425955603508" ESTIMABLE="YES" EVENTS_1="610" EVENTS_2="214" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.039304028494703255" LOG_CI_START="-0.08519035203280224" LOG_EFFECT_SIZE="-0.02294316176904947" METHOD="MH" NO="3" P_CHI2="0.8989694539407639" P_Q="0.0" P_Z="0.4700446376019911" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6479" TOTAL_2="2156" WEIGHT="1100.0" Z="0.7224064342225979">
<NAME>Adverse events after the second injection of vaccine (20 µg by intramuscular route)</NAME>
<GROUP_LABEL_1>RV</GROUP_LABEL_1>
<GROUP_LABEL_2>PDV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0778739359869634E-32" CI_END="7.52838565668131" CI_START="0.36772207593536904" DF="0.0" EFFECT_SIZE="1.6638370118845498" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="100.0" ID="CMP-005.03.01" LOG_CI_END="0.8767018585964799" LOG_CI_START="-0.4344802967856936" LOG_EFFECT_SIZE="0.22111078090539316" NO="1" P_CHI2="0.0" P_Z="0.5085893645720381" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.6610357918450807">
<NAME>Fever</NAME>
<DICH_DATA CI_END="7.52838565668131" CI_START="0.36772207593536904" EFFECT_SIZE="1.66383701188455" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.8767018585964799" LOG_CI_START="-0.4344802967856936" LOG_EFFECT_SIZE="0.2211107809053932" ORDER="682" O_E="0.0" SE="0.7701948885278346" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.5932001663144035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3122527648336533" CI_START="0.6666951367219045" DF="0.0" EFFECT_SIZE="0.9353462120864497" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="37" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.11801749647217215" LOG_CI_START="-0.17607271286985268" LOG_EFFECT_SIZE="-0.029027608198840246" NO="2" P_CHI2="1.0" P_Z="0.6988236180814194" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.38690894711765283">
<NAME>Pain</NAME>
<DICH_DATA CI_END="1.3122527648336533" CI_START="0.6666951367219045" EFFECT_SIZE="0.9353462120864497" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="37" LOG_CI_END="0.11801749647217215" LOG_CI_START="-0.17607271286985268" LOG_EFFECT_SIZE="-0.029027608198840246" ORDER="683" O_E="0.0" SE="0.17275004473752" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.029842577956815164" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3796660013085054" CI_START="0.46685010581994923" DF="0.0" EFFECT_SIZE="0.802556676320783" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="0.13977396223815408" LOG_CI_START="-0.3308225384164822" LOG_EFFECT_SIZE="-0.09552428808916402" NO="3" P_CHI2="1.0" P_Z="0.4262129902082442" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.7956887229001773">
<NAME>Redness</NAME>
<DICH_DATA CI_END="1.3796660013085056" CI_START="0.46685010581994923" EFFECT_SIZE="0.802556676320783" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.13977396223815416" LOG_CI_START="-0.3308225384164822" LOG_EFFECT_SIZE="-0.09552428808916402" ORDER="684" O_E="0.0" SE="0.27643071397478114" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.07641393962860725" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4718662244137606" CI_START="0.5039886126365142" DF="0.0" EFFECT_SIZE="0.8612803355637672" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" I2="0.0" ID="CMP-005.03.04" LOG_CI_END="0.167868339458644" LOG_CI_START="-0.2975792761040681" LOG_EFFECT_SIZE="-0.06485546832271206" NO="4" P_CHI2="1.0" P_Z="0.584926583423208" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.5462027427482534">
<NAME>Swelling</NAME>
<DICH_DATA CI_END="1.4718662244137604" CI_START="0.5039886126365142" EFFECT_SIZE="0.8612803355637672" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" LOG_CI_END="0.16786833945864393" LOG_CI_START="-0.2975792761040681" LOG_EFFECT_SIZE="-0.06485546832271206" ORDER="685" O_E="0.0" SE="0.27340623338439257" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.07475096845344094" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7863560694010077" CI_START="0.5829706204635002" DF="0.0" EFFECT_SIZE="1.020486700622524" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="15" I2="0.0" ID="CMP-005.03.05" LOG_CI_END="0.25196802989582495" LOG_CI_START="-0.23435333150529053" LOG_EFFECT_SIZE="0.00880734919526722" NO="5" P_CHI2="1.0" P_Z="0.9434053525866737" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.00000000000001" Z="0.07099045442815291">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.7863560694010074" CI_START="0.5829706204635003" EFFECT_SIZE="1.020486700622524" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="15" LOG_CI_END="0.25196802989582484" LOG_CI_START="-0.23435333150529042" LOG_EFFECT_SIZE="0.00880734919526722" ORDER="686" O_E="0.0" SE="0.28566757501657897" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.08160596341585279" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6056502981027796" CI_START="0.12284512909412477" DF="0.0" EFFECT_SIZE="0.66553480475382" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.03.06" LOG_CI_END="0.5569836034266125" LOG_CI_START="-0.9106420589599012" LOG_EFFECT_SIZE="-0.17682922776664442" NO="6" P_CHI2="1.0" P_Z="0.6367135300702578" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.47229879760085336">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="3.6056502981027796" CI_START="0.12284512909412472" EFFECT_SIZE="0.66553480475382" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.5569836034266125" LOG_CI_START="-0.9106420589599014" LOG_EFFECT_SIZE="-0.17682922776664442" ORDER="687" O_E="0.0" SE="0.8620905789500333" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.7432001663144036" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0356103824966434" CI_START="0.4277058088881617" DF="0.0" EFFECT_SIZE="0.66553480475382" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" I2="0.0" ID="CMP-005.03.07" LOG_CI_END="0.015196395797594717" LOG_CI_START="-0.36885485133088347" LOG_EFFECT_SIZE="-0.17682922776664442" NO="7" P_CHI2="1.0" P_Z="0.07109695858836686" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="1.8048576612001508">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="1.0356103824966434" CI_START="0.4277058088881617" EFFECT_SIZE="0.66553480475382" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="26" LOG_CI_END="0.015196395797594717" LOG_CI_START="-0.36885485133088347" LOG_EFFECT_SIZE="-0.17682922776664442" ORDER="688" O_E="0.0" SE="0.2255936036476017" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.050892474006711215" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.905820652408233" CI_START="0.20314792720212055" DF="0.0" EFFECT_SIZE="0.99830220713073" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-005.03.08" LOG_CI_END="0.6907116671697595" LOG_CI_START="-0.6921876045916857" LOG_EFFECT_SIZE="-7.37968710963159E-4" NO="8" P_CHI2="1.0" P_Z="0.9983309658140954" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.0020918256661787414">
<NAME>Rash</NAME>
<DICH_DATA CI_END="4.905820652408233" CI_START="0.20314792720212055" EFFECT_SIZE="0.99830220713073" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.6907116671697595" LOG_CI_START="-0.6921876045916857" LOG_EFFECT_SIZE="-7.37968710963159E-4" ORDER="689" O_E="0.0" SE="0.8123218776944704" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.6598668329810702" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4648112227701429" CI_START="0.809691398420149" DF="0.0" EFFECT_SIZE="1.0890569532335237" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="44" I2="0.0" ID="CMP-005.03.09" LOG_CI_END="0.16578165868882946" LOG_CI_START="-0.09168047433195618" LOG_EFFECT_SIZE="0.037050592178436634" NO="9" P_CHI2="1.0" P_Z="0.5726827415364548" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.5641049067961742">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.4648112227701429" CI_START="0.809691398420149" EFFECT_SIZE="1.0890569532335237" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="44" LOG_CI_END="0.16578165868882946" LOG_CI_START="-0.09168047433195618" LOG_EFFECT_SIZE="0.037050592178436634" ORDER="690" O_E="0.0" SE="0.15123453139452211" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.022871883486120695" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4652936784498976" CI_START="0.7445755356226116" DF="0.0" EFFECT_SIZE="1.0445199019053009" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="36" I2="0.0" ID="CMP-005.03.10" LOG_CI_END="0.16592467598577784" LOG_CI_START="-0.12809123741476414" LOG_EFFECT_SIZE="0.018916719285506856" NO="10" P_CHI2="1.0" P_Z="0.8008828935530053" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.252204638017252">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.4652936784498976" CI_START="0.7445755356226116" EFFECT_SIZE="1.0445199019053009" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="36" LOG_CI_END="0.16592467598577784" LOG_CI_START="-0.12809123741476414" LOG_EFFECT_SIZE="0.018916719285506856" ORDER="691" O_E="0.0" SE="0.17270640293372214" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.02982750161430519" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6506320938065304" CI_START="0.5545069147354061" DF="0.0" EFFECT_SIZE="0.9567062818336163" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="16" I2="0.0" ID="CMP-005.03.11" LOG_CI_END="0.2176502849921423" LOG_CI_START="-0.25609303380209497" LOG_EFFECT_SIZE="-0.019221374404976305" NO="11" P_CHI2="1.0" P_Z="0.8736335915046718" STUDIES="1" TAU2="0.0" TOTAL_1="589" TOTAL_2="196" WEIGHT="100.0" Z="0.15904478257550397">
<NAME>Other</NAME>
<DICH_DATA CI_END="1.6506320938065304" CI_START="0.5545069147354061" EFFECT_SIZE="0.9567062818336163" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="16" LOG_CI_END="0.2176502849921423" LOG_CI_START="-0.25609303380209497" LOG_EFFECT_SIZE="-0.019221374404976305" ORDER="692" O_E="0.0" SE="0.2782791705269838" STUDY_ID="STD-Halliday-1990" TOTAL_1="589" TOTAL_2="196" VAR="0.07743929674918612" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.342105418719044" CI_END="1.0647060973264433" CI_START="0.7979054753780848" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.921702134490965" ESTIMABLE="YES" EVENTS_1="575" EVENTS_2="211" I2="11.832947844974434" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.027229741178785554" LOG_CI_START="-0.09804855470592384" LOG_EFFECT_SIZE="-0.035409406763569164" METHOD="MH" NO="4" P_CHI2="0.33149340307572583" P_Q="0.0" P_Z="0.267882614162111" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6226" TOTAL_2="2112" WEIGHT="1100.0" Z="1.107951883930362">
<NAME>Adverse events after the third injection of vaccine (20 µg by intramuscular route)</NAME>
<GROUP_LABEL_1>RV</GROUP_LABEL_1>
<GROUP_LABEL_2>PDV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours RV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.334511439066473" CI_START="0.2906540995976582" DF="0.0" EFFECT_SIZE="1.3568904593639577" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.8017131247443764" LOG_CI_START="-0.5366235470578953" LOG_EFFECT_SIZE="0.13254478884324059" NO="1" P_CHI2="1.0" P_Z="0.6978549142413856" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.00000000000001" Z="0.38821773017903044">
<NAME>Fever</NAME>
<DICH_DATA CI_END="6.334511439066473" CI_START="0.2906540995976582" EFFECT_SIZE="1.3568904593639577" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.8017131247443764" LOG_CI_START="-0.5366235470578953" LOG_EFFECT_SIZE="0.13254478884324059" ORDER="693" O_E="0.0" SE="0.7861455858900245" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.6180248822143698" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.075632580923018" CI_START="0.6059817718221343" DF="0.0" EFFECT_SIZE="0.8073498233215548" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="50" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.03166394853525654" LOG_CI_START="-0.21754043939167622" LOG_EFFECT_SIZE="-0.09293824542820985" NO="2" P_CHI2="1.0" P_Z="0.1437693486157756" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="1.4618973232449188">
<NAME>Pain</NAME>
<DICH_DATA CI_END="1.075632580923018" CI_START="0.6059817718221343" EFFECT_SIZE="0.8073498233215548" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="50" LOG_CI_END="0.03166394853525654" LOG_CI_START="-0.21754043939167622" LOG_EFFECT_SIZE="-0.09293824542820985" ORDER="694" O_E="0.0" SE="0.14638389104989546" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.021428243558907666" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8507768478058007" CI_START="0.30432417279778345" DF="0.0" EFFECT_SIZE="0.508833922261484" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="-0.0701843370661999" LOG_CI_START="-0.5166635497918813" LOG_EFFECT_SIZE="-0.2934239434290406" NO="3" P_CHI2="1.0" P_Z="0.009990515961516892" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="2.5761573884335878">
<NAME>Redness</NAME>
<DICH_DATA CI_END="0.8507768478058007" CI_START="0.30432417279778345" EFFECT_SIZE="0.508833922261484" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="-0.0701843370661999" LOG_CI_START="-0.5166635497918813" LOG_EFFECT_SIZE="-0.2934239434290406" ORDER="695" O_E="0.0" SE="0.26226409966281244" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.06878245797194561" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.692917468788806" CI_START="0.6334066138861123" DF="0.0" EFFECT_SIZE="1.0355216663567044" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="19" I2="0.0" ID="CMP-005.04.04" LOG_CI_END="0.22863578638815713" LOG_CI_START="-0.19831740613738422" LOG_EFFECT_SIZE="0.015159190125386461" NO="4" P_CHI2="1.0" P_Z="0.889308674866255" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="0.13917903508251803">
<NAME>Swelling</NAME>
<DICH_DATA CI_END="1.692917468788806" CI_START="0.6334066138861123" EFFECT_SIZE="1.0355216663567044" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="19" LOG_CI_END="0.22863578638815713" LOG_CI_START="-0.19831740613738422" LOG_EFFECT_SIZE="0.015159190125386461" ORDER="696" O_E="0.0" SE="0.2507944187418913" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.0628978404720831" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9532948749209675" CI_START="0.5859799998213654" DF="0.0" EFFECT_SIZE="1.0698559391138895" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="0.0" ID="CMP-005.04.05" LOG_CI_END="0.2907678105608697" LOG_CI_START="-0.23211720670451597" LOG_EFFECT_SIZE="0.02932530192817686" NO="5" P_CHI2="1.0" P_Z="0.8259927440200733" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="0.21984388045992892">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.9532948749209678" CI_START="0.5859799998213653" EFFECT_SIZE="1.0698559391138895" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" LOG_CI_END="0.29076781056086975" LOG_CI_START="-0.23211720670451605" LOG_EFFECT_SIZE="0.02932530192817686" ORDER="697" O_E="0.0" SE="0.30714524746426697" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.0943382030398858" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="78.1851501182275" CI_START="0.25044417237768174" DF="0.0" EFFECT_SIZE="4.425044091710759" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-005.04.06" LOG_CI_END="1.8931242743625392" LOG_CI_START="-0.6012890695191313" LOG_EFFECT_SIZE="0.6459176024217039" NO="6" P_CHI2="1.0" P_Z="0.3100827320108812" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="1.0150484809040987">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="78.1851501182275" CI_START="0.25044417237768174" EFFECT_SIZE="4.425044091710759" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.8931242743625392" LOG_CI_START="-0.6012890695191313" LOG_EFFECT_SIZE="0.6459176024217039" ORDER="698" O_E="0.0" SE="1.465230745741284" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="2.1469011382655596" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.329455479452074" CI_START="0.5214803576277648" DF="0.0" EFFECT_SIZE="0.8326373273369739" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="22" I2="0.0" ID="CMP-005.04.07" LOG_CI_END="0.12367379834149651" LOG_CI_START="-0.2827620453094157" LOG_EFFECT_SIZE="-0.07954412348395958" NO="7" P_CHI2="1.0" P_Z="0.44297775017749963" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="0.7671745474509536">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="1.329455479452074" CI_START="0.5214803576277648" EFFECT_SIZE="0.8326373273369739" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="22" LOG_CI_END="0.12367379834149651" LOG_CI_START="-0.2827620453094157" LOG_EFFECT_SIZE="-0.07954412348395958" ORDER="699" O_E="0.0" SE="0.2387424264504192" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.05699794618743382" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.29479545333232" CI_START="0.0820687539469176" DF="0.0" EFFECT_SIZE="1.7019400352733687" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.04.08" LOG_CI_END="1.5477106693384748" LOG_CI_START="-1.0858221604367027" LOG_EFFECT_SIZE="0.23094425445088604" NO="8" P_CHI2="1.0" P_Z="0.7310320406803426" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="0.3437530119560594">
<NAME>Rash</NAME>
<DICH_DATA CI_END="35.29479545333232" CI_START="0.0820687539469176" EFFECT_SIZE="1.7019400352733687" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5477106693384748" LOG_CI_START="-1.0858221604367027" LOG_EFFECT_SIZE="0.23094425445088604" ORDER="700" O_E="0.0" SE="1.5469502204076917" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="2.393054984419406" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4780532434880134" CI_START="0.79479365995287" DF="0.0" EFFECT_SIZE="1.083857623028527" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="41" I2="0.0" ID="CMP-005.04.09" LOG_CI_END="0.1696900788061368" LOG_CI_START="-0.09974560590352294" LOG_EFFECT_SIZE="0.034972236451306926" NO="9" P_CHI2="1.0" P_Z="0.6108930160683176" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.0" Z="0.5087991516583478">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.4780532434880134" CI_START="0.79479365995287" EFFECT_SIZE="1.083857623028527" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="41" LOG_CI_END="0.1696900788061368" LOG_CI_START="-0.09974560590352294" LOG_EFFECT_SIZE="0.034972236451306926" ORDER="701" O_E="0.0" SE="0.1582678549266035" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.025048713903068415" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.643119725197772" CI_START="0.7781402431193148" DF="0.0" EFFECT_SIZE="1.1307420494699647" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="30" I2="0.0" ID="CMP-005.04.10" LOG_CI_END="0.21566920926486" LOG_CI_START="-0.10894212367362846" LOG_EFFECT_SIZE="0.053363542795615754" NO="10" P_CHI2="1.0" P_Z="0.5193126913502882" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="99.99999999999999" Z="0.6444052400763711">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.643119725197772" CI_START="0.7781402431193148" EFFECT_SIZE="1.1307420494699647" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="30" LOG_CI_END="0.21566920926486" LOG_CI_START="-0.10894212367362846" LOG_EFFECT_SIZE="0.053363542795615754" ORDER="702" O_E="0.0" SE="0.19067830382008116" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.03635821554770318" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2814311513420942" CI_START="0.32988874412123487" DF="0.0" EFFECT_SIZE="0.6501766784452296" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" ID="CMP-005.04.11" LOG_CI_END="0.10769527739857011" LOG_CI_START="-0.48163250242807776" LOG_EFFECT_SIZE="-0.1869686125147538" NO="11" P_CHI2="1.0" P_Z="0.21363717647037106" STUDIES="1" TAU2="0.0" TOTAL_1="566" TOTAL_2="192" WEIGHT="100.00000000000001" Z="1.2436262443835076">
<NAME>Other</NAME>
<DICH_DATA CI_END="1.2814311513420942" CI_START="0.32988874412123487" EFFECT_SIZE="0.6501766784452296" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.10769527739857011" LOG_CI_START="-0.48163250242807776" LOG_EFFECT_SIZE="-0.1869686125147538" ORDER="703" O_E="0.0" SE="0.3461740550897314" STUDY_ID="STD-Halliday-1990" TOTAL_1="566" TOTAL_2="192" VAR="0.1198364764172684" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Different brands of RV (10 µg Recombinvax-HB versus 20 µg Engerix-B by intramuscular route)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6753911041617926" CI_START="1.021007013321289" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3078937523381968" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="96" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.22411620513544683" LOG_CI_START="0.00902872527620955" LOG_EFFECT_SIZE="0.1165724652058282" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.033627456697787605" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="891" TOTAL_2="874" WEIGHT="100.0" Z="2.124510766893525">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at follow-up (7 months)</NAME>
<GROUP_LABEL_1>Recombivax HB</GROUP_LABEL_1>
<GROUP_LABEL_2>Engerix-B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Recombinvax</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Engerix-B</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6753911041617926" CI_START="1.021007013321289" EFFECT_SIZE="1.3078937523381968" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="96" LOG_CI_END="0.22411620513544683" LOG_CI_START="0.00902872527620955" LOG_EFFECT_SIZE="0.1165724652058282" ORDER="704" O_E="0.0" SE="0.12634345036951253" STUDY_ID="STD-Averhoff-1998" TOTAL_1="891" TOTAL_2="874" VAR="0.015962667451273473" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Intradermal route versus intramuscular route</NAME>
<DICH_OUTCOME CHI2="25.78860561851541" CI_END="1.8641242197829888" CI_START="1.2592550133193199" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5321252459285744" ESTIMABLE="YES" EVENTS_1="180" EVENTS_2="120" I2="72.85622920622656" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.27047484909563857" LOG_CI_START="0.10011368853716007" LOG_EFFECT_SIZE="0.18529426881639932" METHOD="MH" NO="1" P_CHI2="5.493978905987129E-4" P_Q="0.0" P_Z="2.0122105295179814E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="750" TOTAL_2="774" WEIGHT="300.0" Z="4.263531572939284">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) at maximum follow-up</NAME>
<GROUP_LABEL_1>Intradermal</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8533359320087164" CI_START="0.2159406323768942" DF="0.0" EFFECT_SIZE="0.6326219512195121" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.26795414581361154" LOG_CI_START="-0.6656656311407467" LOG_EFFECT_SIZE="-0.1988557426635676" NO="1" P_CHI2="1.0" P_Z="0.40376133591949215" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="100.0" Z="0.8349225313349619">
<NAME>Plasma-derived vaccine (2 µg by intradermal route versus 2 µg by intramuscular route)</NAME>
<DICH_DATA CI_END="1.853335932008716" CI_START="0.21594063237689426" EFFECT_SIZE="0.6326219512195121" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.26795414581361143" LOG_CI_START="-0.6656656311407466" LOG_EFFECT_SIZE="-0.1988557426635676" ORDER="705" O_E="0.0" SE="0.5484128784754203" STUDY_ID="STD-Heijtink-1989" TOTAL_1="82" TOTAL_2="83" VAR="0.30075668527769617" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5300549452244432" CI_END="3.680853439541495" CI_START="1.4737765605355004" DF="1.0" EFFECT_SIZE="2.329110457226692" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="23" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.5659485254973158" LOG_CI_START="0.16843164506841124" LOG_EFFECT_SIZE="0.36719008528286357" NO="2" P_CHI2="0.46658383609771203" P_Z="2.936090638254348E-4" STUDIES="2" TAU2="0.0" TOTAL_1="285" TOTAL_2="291" WEIGHT="100.00000000000001" Z="3.620874373224597">
<NAME>Plasma-derived vaccine (2 µg vaccine by intradermal route versus 20 µg vaccine by intramuscular route)</NAME>
<DICH_DATA CI_END="3.5299473263749848" CI_START="1.381010750557825" EFFECT_SIZE="2.207916485428447" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" LOG_CI_END="0.5477682249245475" LOG_CI_START="0.14019705938222873" LOG_EFFECT_SIZE="0.34398264215338814" ORDER="706" O_E="0.0" SE="0.23940932014936547" STUDY_ID="STD-Coleman-1991" TOTAL_1="209" TOTAL_2="216" VAR="0.05731682257438137" WEIGHT="95.55462580408975"/>
<DICH_DATA CI_END="41.239412961249926" CI_START="0.5903680913421911" EFFECT_SIZE="4.934210526315789" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.615312474518744" LOG_CI_START="-0.22887712362488905" LOG_EFFECT_SIZE="0.6932176754469275" ORDER="707" O_E="0.0" SE="1.0832860988353097" STUDY_ID="STD-de-Lalla-1988" TOTAL_1="76" TOTAL_2="75" VAR="1.1735087719298245" WEIGHT="4.445374195910256"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.28953531903929" CI_END="1.7579999868501575" CI_START="1.129587836751785" DF="4.0" EFFECT_SIZE="1.409189626046025" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="89" I2="76.86461824341116" ID="CMP-007.01.03" LOG_CI_END="0.2450188674892297" LOG_CI_START="0.052920007308983934" LOG_EFFECT_SIZE="0.1489694373991068" NO="3" P_CHI2="0.0016979218470495328" P_Z="0.0023670523114442993" STUDIES="5" TAU2="0.0" TOTAL_1="383" TOTAL_2="400" WEIGHT="100.0" Z="3.039838256463204">
<NAME>Recombinant vaccine (1 or 2 µg by intradermal route versus 10 or 20 µg by intramuscular route)</NAME>
<DICH_DATA CI_END="66.08452572824892" CI_START="1.152543479988087" EFFECT_SIZE="8.727272727272727" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8200997775251135" LOG_CI_START="0.061657318237572714" LOG_EFFECT_SIZE="0.9408785478813433" ORDER="708" O_E="0.0" SE="1.0329178050160583" STUDY_ID="STD-Gonzalez-1990" TOTAL_1="33" TOTAL_2="36" VAR="1.066919191919192" WEIGHT="1.0793342366958607"/>
<DICH_DATA CI_END="1.246280414078735" CI_START="0.7035756011210668" EFFECT_SIZE="0.9364040215104045" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" LOG_CI_END="0.09561576991982773" LOG_CI_START="-0.15268922959293701" LOG_EFFECT_SIZE="-0.028536729836554607" ORDER="709" O_E="0.0" SE="0.14585558584336875" STUDY_ID="STD-Henderson-2000" TOTAL_1="91" TOTAL_2="89" VAR="0.021273851921712307" WEIGHT="53.62383242323662"/>
<DICH_DATA CI_END="6.062578957236031" CI_START="1.323373486199966" EFFECT_SIZE="2.8325" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7826574077700921" LOG_CI_START="0.12168242930077768" LOG_EFFECT_SIZE="0.45216991853543487" ORDER="710" O_E="0.0" SE="0.3882599742317869" STUDY_ID="STD-Oliveira-1995" TOTAL_1="100" TOTAL_2="103" VAR="0.1507458075904678" WEIGHT="8.893752778864235"/>
<DICH_DATA CI_END="1.8320595922944043" CI_START="0.4724648137509415" EFFECT_SIZE="0.9303675048355899" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.2629395960696611" LOG_CI_START="-0.3256305295098825" LOG_EFFECT_SIZE="-0.03134546672011074" ORDER="711" O_E="0.0" SE="0.3457290052345333" STUDY_ID="STD-Parish-1991" TOTAL_1="47" TOTAL_2="37" VAR="0.11952854506045996" WEIGHT="13.890003688907445"/>
<DICH_DATA CI_END="3.0704993458566197" CI_START="1.1976039217627248" EFFECT_SIZE="1.9176136363636365" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.48720900919550636" LOG_CI_START="0.0783132095102815" LOG_EFFECT_SIZE="0.28276110935289395" ORDER="712" O_E="0.0" SE="0.2401874168019532" STUDY_ID="STD-Turchi-1997" TOTAL_1="112" TOTAL_2="135" VAR="0.057689995189995194" WEIGHT="22.513076872295844"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="46.09249362714117" CI_END="1.6298534713789252" CI_START="1.236038768847227" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4193526968884744" ESTIMABLE="YES" EVENTS_1="298" EVENTS_2="207" I2="86.98269603607007" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.2121485618076109" LOG_CI_START="0.09203209278545604" LOG_EFFECT_SIZE="0.15209032729653346" METHOD="MH" NO="2" P_CHI2="2.8376627936310683E-8" P_Q="0.0" P_Z="6.927849131024282E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1014" TOTAL_2="1004" WEIGHT="300.0" Z="4.963375402637471">
<NAME>Sensitivity analysis: number of health-care workers without protective anti-HBs level - follow-up</NAME>
<GROUP_LABEL_1>Intradermal (2 µg)</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular (20 µg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.54138287582203" CI_END="1.8881968043241" CI_START="1.1718314627431425" DF="2.0" EFFECT_SIZE="1.4874973691264255" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="77" I2="87.13113230669175" ID="CMP-007.02.01" LOG_CI_END="0.2760472582764298" LOG_CI_START="0.0688651542896032" LOG_EFFECT_SIZE="0.17245620628301647" NO="1" P_CHI2="4.219257050502856E-4" P_Z="0.0011027575936257464" STUDIES="3" TAU2="0.0" TOTAL_1="400" TOTAL_2="408" WEIGHT="100.0" Z="3.262906850744352">
<NAME>Seven or eight months after the first injection of vaccine</NAME>
<DICH_DATA CI_END="3.5299473263749848" CI_START="1.381010750557825" EFFECT_SIZE="2.207916485428447" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" LOG_CI_END="0.5477682249245475" LOG_CI_START="0.14019705938222873" LOG_EFFECT_SIZE="0.34398264215338814" ORDER="713" O_E="0.0" SE="0.23940932014936547" STUDY_ID="STD-Coleman-1991" TOTAL_1="209" TOTAL_2="216" VAR="0.05731682257438137" WEIGHT="28.0856512220029"/>
<DICH_DATA CI_END="1.246280414078735" CI_START="0.7035756011210668" EFFECT_SIZE="0.9364040215104045" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" LOG_CI_END="0.09561576991982773" LOG_CI_START="-0.15268922959293701" LOG_EFFECT_SIZE="-0.028536729836554607" ORDER="714" O_E="0.0" SE="0.14585558584336875" STUDY_ID="STD-Henderson-2000" TOTAL_1="91" TOTAL_2="89" VAR="0.021273851921712307" WEIGHT="61.683812246284894"/>
<DICH_DATA CI_END="6.062578957236031" CI_START="1.323373486199966" EFFECT_SIZE="2.8325" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" LOG_CI_END="0.7826574077700921" LOG_CI_START="0.12168242930077768" LOG_EFFECT_SIZE="0.45216991853543487" ORDER="715" O_E="0.0" SE="0.3882599742317869" STUDY_ID="STD-Oliveira-1995" TOTAL_1="100" TOTAL_2="103" VAR="0.1507458075904678" WEIGHT="10.230536531712211"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.329194789727396" CI_END="2.0009084472774625" CI_START="1.0685574610582966" DF="1.0" EFFECT_SIZE="1.462219426157683" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="46" I2="94.22939142796876" ID="CMP-007.02.02" LOG_CI_END="0.3012272176957679" LOG_CI_START="0.028797881062146834" LOG_EFFECT_SIZE="0.16501254937895735" NO="2" P_CHI2="3.14325197843246E-5" P_Z="0.01758080180182963" STUDIES="2" TAU2="0.0" TOTAL_1="307" TOTAL_2="298" WEIGHT="100.00000000000001" Z="2.3743305899162106">
<NAME>One year after the first injection of vaccine</NAME>
<DICH_DATA CI_END="12.436286856025813" CI_START="2.2772972303858605" EFFECT_SIZE="5.3217592592592595" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="6" LOG_CI_END="1.0946907309453193" LOG_CI_START="0.35741971796341476" LOG_EFFECT_SIZE="0.726055224454367" ORDER="716" O_E="0.0" SE="0.4330766425759441" STUDY_ID="STD-Coleman-1991" TOTAL_1="216" TOTAL_2="209" VAR="0.18755537834485203" WEIGHT="13.103556743882985"/>
<DICH_DATA CI_END="1.2398687899752632" CI_START="0.6248942369987522" EFFECT_SIZE="0.8802197802197802" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="40" LOG_CI_END="0.09337572806160369" LOG_CI_START="-0.2041934805353155" LOG_EFFECT_SIZE="-0.05540887623685595" ORDER="717" O_E="0.0" SE="0.174793626121169" STUDY_ID="STD-Henderson-2000" TOTAL_1="91" TOTAL_2="89" VAR="0.03055281173258701" WEIGHT="86.89644325611702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.556986747853497" CI_END="1.6216854410915733" CI_START="1.0976158867703047" DF="1.0" EFFECT_SIZE="1.3341617980913034" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="84" I2="91.34722551978582" ID="CMP-007.02.03" LOG_CI_END="0.20996661778724063" LOG_CI_START="0.040450384338211104" LOG_EFFECT_SIZE="0.12520850106272585" NO="3" P_CHI2="6.749574461577534E-4" P_Z="0.0037873969920062295" STUDIES="2" TAU2="0.0" TOTAL_1="307" TOTAL_2="298" WEIGHT="100.0" Z="2.8953469251660358">
<NAME>Two years after the first injection of vaccine</NAME>
<DICH_DATA CI_END="3.5607156633750257" CI_START="1.3736992470518383" EFFECT_SIZE="2.2116402116402116" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" LOG_CI_END="0.5515372950004251" LOG_CI_START="0.137891660203157" LOG_EFFECT_SIZE="0.3447144776017911" ORDER="718" O_E="0.0" SE="0.24297749345883046" STUDY_ID="STD-Coleman-1991" TOTAL_1="216" TOTAL_2="209" VAR="0.059038062327536" WEIGHT="25.099254381717827"/>
<DICH_DATA CI_END="1.2470905406207375" CI_START="0.8674965376197562" EFFECT_SIZE="1.040118611547183" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="63" LOG_CI_END="0.09589798504594264" LOG_CI_START="-0.061732249903814804" LOG_EFFECT_SIZE="0.01708286757106392" ORDER="719" O_E="0.0" SE="0.09259278029173476" STUDY_ID="STD-Henderson-2000" TOTAL_1="91" TOTAL_2="89" VAR="0.008573422962153465" WEIGHT="74.90074561828217"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-344.72397516173896" CI_START="-347.27602483826104" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-346.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="75" UNITS="" WEIGHT="99.99999999999999" Z="531.4532431633795">
<NAME>Geometric mean titre (IU/litre) of anti-HBs level at follow-up</NAME>
<GROUP_LABEL_1>Intradermal</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<CONT_DATA CI_END="-344.72397516173896" CI_START="-347.27602483826104" EFFECT_SIZE="-346.0" ESTIMABLE="YES" MEAN_1="602.0" MEAN_2="948.0" ORDER="720" SD_1="4.0" SD_2="4.0" SE="0.6510450438508898" STUDY_ID="STD-de-Lalla-1988" TOTAL_1="76" TOTAL_2="75" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6197181115852937" CI_START="0.5329727449756285" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9291208791208792" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.20943943847143476" LOG_CI_START="-0.2732949992461008" LOG_EFFECT_SIZE="-0.03192778038733303" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.7954332512455079" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="89" WEIGHT="100.0" Z="0.25926180017881034">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Intradermal-2 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular-20 µg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6197181115852937" CI_START="0.5329727449756285" EFFECT_SIZE="0.9291208791208792" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.20943943847143476" LOG_CI_START="-0.2732949992461008" LOG_EFFECT_SIZE="-0.03192778038733303" ORDER="721" O_E="0.0" SE="0.2835605982892857" STUDY_ID="STD-Henderson-2000" TOTAL_1="91" TOTAL_2="89" VAR="0.08040661290217765" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.73899976893108" CI_END="10.172597942103405" CI_START="4.6301246223808175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.862972840199312" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="19" I2="96.52040778022807" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="1.0074318799468305" LOG_CI_START="0.6655926804529275" LOG_EFFECT_SIZE="0.836512280199879" METHOD="MH" NO="5" P_CHI2="8.282027263994962E-8" P_Q="0.0" P_Z="8.603616449036213E-22" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="242" WEIGHT="100.0" Z="9.592427926607543">
<NAME>Local adverse events</NAME>
<GROUP_LABEL_1>Intradermal-2 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular-20 µg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.713823990933521" CI_START="1.4865693094476098" EFFECT_SIZE="2.3496503496503496" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5698213173957754" LOG_CI_START="0.17218516245378918" LOG_EFFECT_SIZE="0.37100323992478224" ORDER="722" O_E="0.0" SE="0.23357344574363448" STUDY_ID="STD-Gonzalez-1990" TOTAL_1="33" TOTAL_2="36" VAR="0.05455655455655456" WEIGHT="76.27201908905889"/>
<DICH_DATA CI_END="47.7210800014439" CI_START="9.570380277626958" EFFECT_SIZE="21.37074829931973" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="6" LOG_CI_END="1.678710263861673" LOG_CI_START="0.9809291947458907" LOG_EFFECT_SIZE="1.329819729303782" ORDER="723" O_E="0.0" SE="0.40988005407060923" STUDY_ID="STD-Turchi-1997" TOTAL_1="98" TOTAL_2="206" VAR="0.16800165872492556" WEIGHT="23.727980910941117"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.855425174668871" CI_END="0.815646699080254" CI_START="0.11539878944981347" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30679739518548327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" I2="79.4044812961576" I2_Q="0.0" ID="CMP-007.06" LOG_CI_END="-0.08849791706228398" LOG_CI_START="-0.9377987469690533" LOG_EFFECT_SIZE="-0.5131483320156687" METHOD="MH" NO="6" P_CHI2="0.027559440524977052" P_Q="0.0" P_Z="0.017864048463227162" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="242" WEIGHT="100.0" Z="2.3684240355397215">
<NAME>Systemic adverse events</NAME>
<GROUP_LABEL_1>Intradermal-2 µg</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular-20 µg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intradermal</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intramuscula</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.855425174668871" CI_END="0.815646699080254" CI_START="0.11539878944981347" DF="1.0" EFFECT_SIZE="0.30679739518548327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" I2="79.4044812961576" ID="CMP-007.06.01" LOG_CI_END="-0.08849791706228398" LOG_CI_START="-0.9377987469690533" LOG_EFFECT_SIZE="-0.5131483320156687" NO="1" P_CHI2="0.027559440524977052" P_Z="0.017864048463227162" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="242" WEIGHT="100.0" Z="2.3684240355397215">
<NAME>Fever</NAME>
<DICH_DATA CI_END="0.5885229866403765" CI_START="0.03594936013317805" EFFECT_SIZE="0.14545454545454545" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.23023656973454465" LOG_CI_START="-1.444308835270056" LOG_EFFECT_SIZE="-0.8372727025023002" ORDER="724" O_E="0.0" SE="0.7131520585301977" STUDY_ID="STD-Gonzalez-1990" TOTAL_1="33" TOTAL_2="36" VAR="0.5085858585858586" WEIGHT="91.75385966195947"/>
<DICH_DATA CI_END="14.703119579843685" CI_START="0.30051959854560883" EFFECT_SIZE="2.1020408163265305" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.1674094893451312" LOG_CI_START="-0.5221271999918145" LOG_EFFECT_SIZE="0.3226411446766585" ORDER="725" O_E="0.0" SE="0.9924422146580163" STUDY_ID="STD-Turchi-1997" TOTAL_1="98" TOTAL_2="206" VAR="0.9849415494353081" WEIGHT="8.246140338040536"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Rapid schedule (0, 1, and 2 months) versus standard schedule (0, 1, and 6 months)</NAME>
<DICH_OUTCOME CHI2="2.610225249916754" CI_END="8.07414779980482" CI_START="1.4739899198792494" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4498133961893536" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="6" I2="23.37826016878105" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.9070966950435995" LOG_CI_START="0.16849451353945885" LOG_EFFECT_SIZE="0.5377956042915291" METHOD="MH" NO="1" P_CHI2="0.27114213843028023" P_Q="0.0" P_Z="0.004314505009910773" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="121" WEIGHT="100.0" Z="2.8542022806073795">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) by recombinant vaccine</NAME>
<GROUP_LABEL_1>Rapid schedule</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard schedule</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rapid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours standard</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.252580249730855" CI_START="0.9031828490819673" DF="0.0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="1.734420398033416" LOG_CI_START="-0.04422431800490269" LOG_EFFECT_SIZE="0.8450980400142568" NO="1" P_CHI2="1.0" P_Z="0.06253283071300227" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="16.7157729326262" Z="1.862498684417027">
<NAME>Non-smoker (20 µg by intramuscular route)</NAME>
<DICH_DATA CI_END="54.252580249730855" CI_START="0.9031828490819673" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.734420398033416" LOG_CI_START="-0.04422431800490269" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="726" O_E="0.0" SE="1.0447847106342492" STUDY_ID="STD-Winter-1994" TOTAL_1="39" TOTAL_2="39" VAR="1.0915750915750917" WEIGHT="16.7157729326262"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.079992572534579" CI_START="0.3950683816537772" DF="0.0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.7058630773017135" LOG_CI_START="-0.4033277266404153" LOG_EFFECT_SIZE="0.1512676753306491" NO="2" P_CHI2="1.0" P_Z="0.5929358469913295" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="54.21331761932822" Z="0.53458646541148">
<NAME>Smoker (20 µg by intramuscular route)</NAME>
<DICH_DATA CI_END="5.0799925725345805" CI_START="0.3950683816537771" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7058630773017136" LOG_CI_START="-0.4033277266404154" LOG_EFFECT_SIZE="0.1512676753306491" ORDER="727" O_E="0.0" SE="0.6515441688186371" STUDY_ID="STD-Winter-1994" TOTAL_1="20" TOTAL_2="17" VAR="0.4245098039215686" WEIGHT="54.21331761932822"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.421273777498655" CI_START="1.1545059528734058" DF="0.0" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="1.3696105106977314" LOG_CI_START="0.06239617657186681" LOG_EFFECT_SIZE="0.7160033436347992" NO="3" P_CHI2="1.0" P_Z="0.03178765732632323" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="65" WEIGHT="29.070909448045565" Z="2.147070651995073">
<NAME>Common participants (20 µg by intramuscular route)</NAME>
<DICH_DATA CI_END="23.421273777498655" CI_START="1.1545059528734058" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.3696105106977314" LOG_CI_START="0.06239617657186681" LOG_EFFECT_SIZE="0.7160033436347992" ORDER="728" O_E="0.0" SE="0.7678641706808468" STUDY_ID="STD-Ricciardi-1990" TOTAL_1="50" TOTAL_2="65" VAR="0.5896153846153847" WEIGHT="29.070909448045565"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Booster vaccination with recombinant vaccine in non-responders</NAME>
<DICH_OUTCOME CHI2="7.199947577844183" CI_END="1.4505297036425895" CI_START="0.8847844251808268" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1328751431844215" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="63" I2="30.55504993694543" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.16152662662092013" LOG_CI_START="-0.05316253083770078" LOG_EFFECT_SIZE="0.054182047891609665" METHOD="MH" NO="1" P_CHI2="0.20618972239241973" P_Q="0.0" P_Z="0.3225215426207789" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="140" WEIGHT="500.0" Z="0.9892894800395056">
<NAME>Number of health-care workers without protective anti-HBs level (&lt; 10 IU/litre) after booster vaccination</NAME>
<GROUP_LABEL_1>Low dose</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6324466375638952" CI_END="2.1582464988312275" CI_START="0.8878641381622474" DF="1.0" EFFECT_SIZE="1.3842794759825328" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="0.33410104505892263" LOG_CI_START="-0.051653485303195544" LOG_EFFECT_SIZE="0.1412237798778635" NO="1" P_CHI2="0.42645951756322487" P_Z="0.15126545932100144" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="40" WEIGHT="100.0" Z="1.435075938376622">
<NAME>2.5 or 5 µg versus 10 µg</NAME>
<DICH_DATA CI_END="1.9991134699867645" CI_START="0.6659756770856915" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3008374454390445" LOG_CI_START="-0.17654163194135566" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="729" O_E="0.0" SE="0.2804148331177911" STUDY_ID="STD-Williams-2001" TOTAL_1="13" TOTAL_2="15" VAR="0.07863247863247862" WEIGHT="51.091703056768566"/>
<DICH_DATA CI_END="3.221599415222369" CI_START="0.8196627388007309" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5080715377672044" LOG_CI_START="-0.086364807137418" LOG_EFFECT_SIZE="0.21085336531489315" ORDER="730" O_E="0.0" SE="0.3491748515043386" STUDY_ID="STD-Zuckerman-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.12192307692307691" WEIGHT="48.90829694323144"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.550082129088543" CI_START="0.5562575567955155" DF="0.0" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-009.01.02" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" NO="2" P_CHI2="1.0" P_Z="0.7768249154530719" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.28345911931358597">
<NAME>5 µg versus 20 µg</NAME>
<DICH_DATA CI_END="1.550082129088543" CI_START="0.5562575567955155" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.19035470930901688" LOG_CI_START="-0.25472407605181935" LOG_EFFECT_SIZE="-0.03218468337140124" ORDER="731" O_E="0.0" SE="0.26144148169647513" STUDY_ID="STD-Zuckerman-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.06835164835164834" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7509233313544885" CI_START="0.7584434394466082" DF="0.0" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="0.4394784867060524" LOG_CI_START="-0.12007680097102859" LOG_EFFECT_SIZE="0.15970084286751188" NO="3" P_CHI2="1.0" P_Z="0.263236665917981" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.1187738091813024">
<NAME>5 µg versus 40 µg</NAME>
<DICH_DATA CI_END="2.7509233313544885" CI_START="0.7584434394466082" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4394784867060524" LOG_CI_START="-0.12007680097102859" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="732" O_E="0.0" SE="0.32868554582486287" STUDY_ID="STD-Zuckerman-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.10803418803418802" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1153362111261702" CI_START="0.2927642884607821" DF="0.0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" I2="0.0" ID="CMP-009.01.04" LOG_CI_END="0.0474058024756942" LOG_CI_START="-0.5334818998482832" LOG_EFFECT_SIZE="-0.24303804868629447" NO="4" P_CHI2="1.0" P_Z="0.10099234881140441" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.640061651821157">
<NAME>10 µg versus 20 µg</NAME>
<DICH_DATA CI_END="1.1153362111261702" CI_START="0.2927642884607821" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.0474058024756942" LOG_CI_START="-0.5334818998482832" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="733" O_E="0.0" SE="0.3412163117856053" STUDY_ID="STD-Zuckerman-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.11642857142857141" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9137731355635283" CI_START="0.830453495807857" DF="0.0" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-009.01.05" LOG_CI_END="0.4644557348710394" LOG_CI_START="-0.08068468239321319" LOG_EFFECT_SIZE="0.19188552623891314" NO="5" P_CHI2="1.0" P_Z="0.1676523605966116" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.3797865968924452">
<NAME>20 µg versus 40 µg</NAME>
<DICH_DATA CI_END="2.9137731355635283" CI_START="0.830453495807857" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.4644557348710394" LOG_CI_START="-0.08068468239321319" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="734" O_E="0.0" SE="0.32021817958960813" STUDY_ID="STD-Zuckerman-1997" TOTAL_1="25" TOTAL_2="25" VAR="0.10253968253968251" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-16 18:11:12 +0100" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2008-10-16 18:11:12 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2008-10-16 18:10:50 +0100" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-16 18:11:12 +0100" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="4" ROWS="5">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search result</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1: 'vaccine' and 'anaesthesiologists'<BR/>#2: 'vaccine' and 'dental'<BR/>#3: 'vaccine' and 'doctor'<BR/>#4: 'vaccine' and 'emergency'<BR/>#5: 'vaccine' and 'employee'<BR/>#6: 'vaccine' and 'haemodialysis'<BR/>#7: 'vaccine' and 'hospital'<BR/>#8: 'vaccine' and 'nurse'<BR/>#9: 'vaccine' and 'obstetrical'<BR/>#10: 'vaccine' and 'occupational'<BR/>#11: 'vaccine' and 'periodontal'<BR/>#12: 'vaccine' and 'personnel'<BR/>#13: 'vaccine' and 'physician'<BR/>#14: 'vaccine' and 'professional'<BR/>#15: 'vaccine' and 'staff'<BR/>#16: 'vaccine' and 'student'<BR/>#17: 'vaccine' and 'surgeon'<BR/>#18: 'vaccine' and 'worker'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Feburary 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15 citations</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1: 'vaccine' and 'anaesthesiologists'<BR/>#2: 'vaccine' and 'dental'<BR/>#3: 'vaccine' and 'doctor'<BR/>#4: 'vaccine' and 'emergency'<BR/>#5: 'vaccine' and 'employee'<BR/>#6: 'vaccine' and 'haemodialysis'<BR/>#7: 'vaccine' and 'hospital'<BR/>#8: 'vaccine' and 'nurse'<BR/>#9: 'vaccine' and 'obstetrical'<BR/>#10: 'vaccine' and 'occupational'<BR/>#11: 'vaccine' and 'periodontal'<BR/>#12: 'vaccine' and 'personnel'<BR/>#13: 'vaccine' and 'physician'<BR/>#14: 'vaccine' and 'professional'<BR/>#15: 'vaccine' and 'staff'<BR/>#16: 'vaccine' and 'student'<BR/>#17: 'vaccine' and 'surgeon'<BR/>#18: 'vaccine' and 'worker'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 1, 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15 citations</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1: 'vaccine' and 'anaesthesiologists'<BR/>#2: 'vaccine' and 'dental'<BR/>#3: 'vaccine' and 'doctor'<BR/>#4: 'vaccine' and 'emergency'<BR/>#5: 'vaccine' and 'employee'<BR/>#6: 'vaccine' and 'haemodialysis'<BR/>#7: 'vaccine' and 'hospital'<BR/>#8: 'vaccine' and 'nurse'<BR/>#9: 'vaccine' and 'obstetrical'<BR/>#10: 'vaccine' and 'occupational'<BR/>#11: 'vaccine' and 'periodontal'<BR/>#12: 'vaccine' and 'personnel'<BR/>#13: 'vaccine' and 'physician'<BR/>#14: 'vaccine' and 'professional'<BR/>#15: 'vaccine' and 'staff'<BR/>#16: 'vaccine' and 'student'<BR/>#17: 'vaccine' and 'surgeon'<BR/>#18: 'vaccine' and 'worker'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1966 to Feburary 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 citations</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1: 'vaccine' and 'anaesthesiologists'<BR/>#2: 'vaccine' and 'dental'<BR/>#3: 'vaccine' and 'doctor'<BR/>#4: 'vaccine' and 'emergency'<BR/>#5: 'vaccine' and 'employee'<BR/>#6: 'vaccine' and 'haemodialysis'<BR/>#7: 'vaccine' and 'hospital'<BR/>#8: 'vaccine' and 'nurse'<BR/>#9: 'vaccine' and 'obstetrical'<BR/>#10: 'vaccine' and 'occupational'<BR/>#11: 'vaccine' and 'periodontal'<BR/>#12: 'vaccine' and 'personnel'<BR/>#13: 'vaccine' and 'physician'<BR/>#14: 'vaccine' and 'professional'<BR/>#15: 'vaccine' and 'staff'<BR/>#16: 'vaccine' and 'student'<BR/>#17: 'vaccine' and 'surgeon'<BR/>#18: 'vaccine' and 'worker'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1980 to Feburary 2003</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 citations</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>